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Thymidine phosphorylase (TP) is an enzyme that promotes tumour growth and 
metastasis thus is an attractive druggable target. Currently, the most potent TP 
inhibitors are pyrimidine derivatives; although some purine based inhibitors 
have also been reported but their potency against TP is still weak. The goal of 
this project was to develop new TP inhibitors that are analogues of purine. It 
was hypothesized that the pyrazolo[1,5-a][1,3,5]triazine scaffold equipped 
with a homophthalimide moiety would exhibit TP inhibitory activity through 
proper structural modifications. In addition, it was also hypothesized that 
compounds consisting of both pyrimidine moiety and purine related moiety 
could inhibit TP through dual site interaction. 
In particular, to test the first hypothesis, a total of 59 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones as well as their isosteric 
2- thioxo analogues were synthesized and subjected to an in vitro enzyme 
bioassay. All target compounds were obtained in good yields (32%-94%) via a 
synthetic approach that required annulation of the 1,3,5-triazine ring onto 
substituted 3-amino pyrazoles. Results of the subsequent enzyme test showed  
that although 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones  were not 
active against TP, most of their isosteric 2- thioxo analogues exhibited TP 
inhibitory activity with IC50 values ranging from 87.3µM to 40nM. The best 
compound 17r showed an IC50 value of 40nM which is around 800 times more 
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potent than the lead compound 7DX. Therefore, the first hypothesis was 
proven to be partially true. Further enzyme inhibitory kinetic studies revealed 
that 17r was a non-competitive inhibitor, suggesting that it might bind to an 
allosteric site.  
To test the second hypothesis, 31 compounds consisting of both pyrimidine 
moiety and purine moiety designed as 
3H-2-(5-chlorouracil-6-methylthio)-pyrazolo[1,5-a][1,3,5]triazin-4-ones were 
synthesized and evaluated by the in vitro enzyme assay. A multiple-step 
convergent synthetic scheme was devised to generate the target compounds in 
good yields (40%-96%). The intermediate 5-chloro-6-chloromethyluracil was 
synthesized by a 4-step reaction and then coupled with  
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones to yield the target 
compounds.  Subsequent enzyme tests showed that this type of compounds 
was active against TP with IC50 values ranging from 67.8µM to 0.36µM, and 
the second hypothesis in this study was proven to be true. The best compound 
in this series, 24r, was subjected to enzyme inhibitory kinetic studies. Results 
revealed that 24r demonstrated a mixed-type of enzyme inhibition kinetics, 
thus suggesting that it might potentially bind at two different sites on the 
enzyme.  
In addition, a total of 26 compounds with IC50 values less than 10µM were 
selected from the two series of compounds synthesized to explore their 
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potential antiangiogenic properties. They were subjected to a gelatin 
zymography assay that evaluated their potential suppressive effect on the 
secretion of the angiogenic factor MMP-9 in cancer cells. Based on the results 
obtained, 9 compounds among them did suppress the secretion of MMP-9 thus 
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1.1 A brief overview of enzyme inhibitors as drugs 
Enzyme inhibitors refer to a group of molecules which block the catalytic 
activity of enzymes. According to interacting mechanisms with their targets, 
enzyme inhibitors can be categorized into either reversible inhibitors which 
bind non-covalently with the enzymes or irreversible inhibitors which interact 
with enzymes via covalent bond formation. Based on their binding sites, 
reversible inhibitors can be further divided into subcategories such as 
competitive inhibitors, mixed type inhibitors, non-competitive inhibitors and 
uncompetitive inhibitors. In particular, a competitive inhibitor can bind to the 
corresponding substrate binding site; a mixed type inhibitor can bind to an 
allosteric siteat the same time affecting the binding of the substrate; a 
non-competitive inhibitor can bind to allosteric site but do not affect the 
binding of the substrate; an uncompetitive inhibitor can only bind to the 
corresponding substrate-enzyme complex. The inhibitory effect of a 
competitive inhibitor can be completely overcome once the substrate 
accumulated to a certain concentration level. Butthe inhibitory effect of other 
types of inhibitors can not be completely overcome, thus they possess an 
advantage over competitive inhibitors from this aspect. The approach to 
design an enzyme inhibitor is to mimic the structure of the substrate, therefore 
most enzyme inhibitors are competitive inhibitors. 
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Many enzyme inhibitors are antimetabolites, and they act by interfering with 
the essential metabolic pathways which may lead to disruption of normal 
cellular functions. As antimetabolites often appear structurally similar to 
essential metabolites, they are mistakenly recognized by the enzymes, leading 
to either blockage of the enzymes or the generation of non-functional products. 
One such example is theantifolate-methotrexate. It is structurally similar to 
dihydrofolate, and hence it can inhibit the enzyme dihydrofolate reductase. 
Since many disease processes are found to be associated with the metabolite 
imbalance, designing enzyme inhibitors as antimetabolites has been 
considered as an efficient strategy for the drug development in some cases. 
Many different types of enzymes involved in the regulation of metabolism 
have been targeted for the development of inhibitors to be used as drugs. Some 
representatives, sorted by enzyme categories, are described below. 
1.1.1 Oxidoreductases (EC 1) as targets for developing enzyme 
inhibitors as drugs 
Oxidoreductase is an enzyme which catalyzes the transfer of electrons from an 
electron donor (reductant) to an electron acceptor (oxidant). Some examples of 
which oxidoreductases are used as targets to develop drugs are provided 
below. 
Aldose reductase, which is involved in the sorbitol pathway, plays an 
important role in sorbitol accumulation thus is responsible for retinopathy and 
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neuropathy in people with diabetes. Ranirestat is an aldose reductase inhibitor 
used in the treatment of diabetic neuropathy.1 
 
5-Alpha-reductase, which catalyzes the conversion of testosterone to 
dihydrotestosterone, is involved in several diseases including prostatic 
hyperplasia, lower urinary tract symptoms, androgenic alopecia as well as 
prostate cancer. A representative 5-alpha-reductase inhibitor namely 
finasteride has been clinically used for the treatment of benign prostatic 











Monoamine oxidase, which deaminates monoamine neurotransmitters such as 
dopamine, is considered as a druggable target in the treatment of several 
diseases including panic disorder, atypical depression as well as post-traumatic 




















Dihydrofolate reductase, which catalyzes the reduction of dihydrofolic acid to 
tetrahydrofolic acid, is closely associated with cell proliferation thus served as 
an important target in the cancer treatment. Dihydrofolate reductase inhibitor 
such as methotrexate, developed in the 1960s, has been widely applied 
clinically as antitumor agents even today.5  
 
5-Lipoxygenase, which transforms essential fatty acids into leukotrienes, is an 
established target for pharmaceutical intervention in asthma. Zileuton is an 
orally active 5-lipoxygenase inhibitor which is used for the maintenance 








Aromatase is an enzyme that synthesizes estrogen. As estrogen is essential for 












inhibitors possess therapeutic value in breast cancer or ovarian cancer 






Ribonucleotide reductase, which plays a key role in the formation of 
deoxyribonucleotides, is closely related to the growth of tumors. Triapine, a 









1.1.2 Transferases (EC 2) as targets for developing enzyme inhibitors as 
drugs 
The function of transferase is to catalyze the transfer of a functional group 
from one donor molecule to an acceptor molecule. Several examples of using 
transferases as targets for the drug design are listed below. 
Catechol-O-methyl transferase is an enzyme that degrades dopamine, and it 
serves as a target for drugs used in the treatment of Parkinson’s disease. A 
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catechol-O-methyl transferase inhibitor namely entacapone has served as the 








Dihydropteroate synthase, which is not expressed in the human body, 
produces dihydropteroate in bacteria, thus is an ideal target for sulfonamide 








Reverse transcriptase, which belongs to the nucleotidyltransferase family, can 
add free nucleotides to the 3’end of the newly forming DNA strand. This 
enzyme transcribes the single-stranded viral RNA genome into the 
corresponding double-stranded viral DNA, thus it is crucial for the 
proliferation of virus, eg. HIV. Therefore, a reverse-transcriptase inhibitor 












Tyrosine kinases that catalyze the transfer of a phosphate group from ATP to a 
protein thus activating a particular signal pathway are considered as important 
targets in cancer chemotherapy. Imatinib, which inhibits a receptor tyrosine 









1.1.3 Hydrolase (EC 3) as targets for developing enzyme inhibitors as 
drugs 
Hydrolases are a type of enzymes which catalyze the hydrolysis of their 
corresponding substrates. A few examples of drugs which are enzyme 
inhibitors of hydrolases are provided below. 
Acetylcholinesterase which hydrolyzes the neurotransmitter acetylcholine is 
an established target in the treatment of a range of central nervous diseases. 
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For example, Donepezil, an inhibitor of acetylcholinesterase, is indicated for 





Viral neuraminidase which cleaves sialic acid groups from glycoproteins plays 
an important role in the replication of the influenza virus. A neuraminidase 
inhibitor namely zanamivir has been used clinically in the prophylaxis or 










1.1.4 Lyases (EC 4) as targets for developing enzyme inhibitors as drugs 
Lyases refer to those enzymes which catalyze the breakage of various bonds in 
their corresponding substrates via means other than hydrolysis and oxidation. 
Aromatic-L-amino-acid decarboxylase is a lyase involved in the biosynthesis 
of dopamine. Inhibiting this enzyme in the body periphery would cause the 
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accumulation of dopamine-precursor known as levodopa which could cross 
the blood brain barrier and enter the dopamine-deficient brains of Parkinson’s 
disease patients. Carbidopa, which inhibits aromatic-L-amino-acid 








In summary, all of these examples mentioned above show that developing 
inhibitors against some enzymes associated with disease processes is a good 
approach for the drug development. However, there are several major 
challenges in the design of enzyme inhibitors as drugs. Selectivity is one 
challenge that refers to how specific inhibitors are able to act against different 
isoforms of the enzyme which share the same substrates. Low selectivity may 
lead to unwanted interactions with other isoforms, causing some potential side 
effects. In particular, these isoenzymes are often distributed unequally in 
different tissues and involved in various biological processes. Therefore, from 
clinical standpoint, selective inhibition of isoenzymes is important for 
corresponding treatments. Another challenge encountered by enzyme 
inhibitors that serve as therapeutic agents is related to their physicochemical 
properties. For inhibitors targeting those enzymes located in the brain, their 
therapeutic effects largely depend on whether they can easily penetrate the 
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blood brain barrier or not. In addition, subcellular localization of intended 
targets should also be considered. For inhibitors of enzymes located in the 
nucleus, their capability to pass through the nuclear membrane is crucial for 
their activity. All these issues of accessibility  are closely related to their 
physicochemical properties. The third challenge faced by enzyme inhibitors 
applied clinically is drug resistance. Drug resistance can be caused by 
mutation of the targets, thus the structures of the inhibitor binding sites may 
change, leading to decrease in their binding affinity. There are several 
approaches to deal with the drug resistance problem. In addition to inhibiting 
alternative targets, inhibiting multiple targets, and developing new inhibitors 
specifically targeting the mutant target, another potential solution to solve this 
problem could be increasing the structure diversity of the enzyme inhibitors. 
Therefore, for a specific enzyme which is validated as a target in the disease 
treatment, it is worthy to develop several inhibitors with different scaffolds.  
The target in this project, namely thymidine phosphorylase, is an enzyme that 
has been proven to be involved in the growth of tumor. However, currently all 
of its potent inhibitors are restricted to only one chemical scaffold. Therefore, 
it is worthy to develop new inhibitors based on a different chemical scaffold to 
increase the structure diversity of its inhibitors. 
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1.2 Thymidine phosphorylase as a target for developing enzyme inhibitors 
possessing therapeutic values 
Thymidine phosphorylase (TP) occurs widely in many normal tissues and cells. 
Within the cell, TP is found in both the cytoplasm and the nucleus.19 TP 
catalyses the reverse phosphorolysis of pyrimidine nucleosides (Figure 1). The 
active site of TP includes a thymidine binding site and a phosphate binding 
site (Figure 2).20 It has been proposed that the products and substrates are 
generated by moving the sugar anomeric carbon towards either the phosphate 
oxygen or the thymine nitrogen. Its main metabolic function appears to be 
catabolic in nature, and it plays a key role in maintaining the balance of the 
nucleotide pool as well as controlling nucleic acid homoestasis by ensuring the 
correct supply of deoxyribonucleoside triphosphates (dNTPs) for DNA 



























Figure 2. The active site of TP. 
1.2.1 Physiological functions of thymidine phosphorylase 
TP is involved in a few physiological processes in the human body. One of the 
richest sources of TP is found in blood platelets which suggests that TP may 
play a role in the wound healing process. TP activity can also be detected in 
plasma and serum which is probably due to cell turnover or blood platelet 
damage.22 TP is also found to participate in the female reproductive cycle. 
Large amounts of TP are detectable in the placenta.23, 24 Furthermore, large 
quantities of TP are also found in the endometrium which undergoes extensive 
angiogenesis during each menstrual cycle. As the cycle progresses, expression 
of TP moves from the stroma to the epithelium.25 It has been also reported that 
the human chorionic gonadotropin26 as well as a combination of progesterone 
and transforming growth factor beta one could elevate endometrial TP 
expression.25, 26 Besides, over expression of TP has been found in decidualized 
endometrium (decidualized tissues are characterized by the intensive 
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outgrowth of the microvasculature).27 TP is also detected together with 
vascular endothelial growth factor (VEGF) in the trophoblast during the first 
trimester of pregnancy. Therefore, both of them play an important role in 
gestation.23 
1.2.2 Pathological functions of thymidine phosphorylase 
1.2.2.1 Thymidine phosphorylase in cancers 
Over expression of TP has been found in tumor tissues of breast,28 bladder,29, 
30 gastric,31-33 colorectal,34, 35 lung,35, 36 esophageal,35, 37 and cervical35, 38 
cancers. The occurrence of TP in the various types of cancers is an indication 
that TP plays a role in tumor development. It has been discovered in several 
studies that TP is involved in tumor angiogenesis as well as metastasis. 
Besides, TP can also protect cancer cells from apoptosis. 
Thymidine phosphorylase induces tumor angiogenesis. 
Angiogenesis, which involves the formation of new capillaries from existing 
blood vessels, is of fundamental importance in some physiological processes 
such as embryonic development, wound repair, as well as reproduction and 
some pathological processes such as tumor development. It is a multistep 
process consisting of degradation of the surrounding extracellular matrix 
(ECM) by protease, migration as well as proliferation of endothelial cells, and 
differentiation of endothelial cells into mature blood vessels. A lot of proteins 
including enzymes such as TP, cytokines, growth factors as well as their 
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receptors, adhesion molecules and components of the ECM are involved in 
this well-coordinated process.39-42 The rate of new blood vessel formation is 
determined by the equilibrium between angiostatic and angiogenic proteins.42 
Alteration of this equilibrium by the uncontrolled release of angiogenic 
regulators could cause some pathological conditions such as inflammation and 
tumor growth.40, 42 It has been proposed as early as 1970s that tumor can not 
grow beyond a certain size, generally 1-2 mm3 without sufficient supply of 
oxygen and other essential nutrients.43 Therefore, antiangiogenesis, which 
prevents the formation of new blood vessels surrounding the tumor tissues, is 
widely considered as a significant therapeutic strategy in the cancer treatment. 
In 2004, after a series of clinical trials, avastin, a monoclonal antibody 
targeting against VEGF-A,44 was approved by the FDA for clinical use in 
combination with standard chemotherapy for metastatic colon cancer. This 
became the first ever commercially available antiangiogenesis drug to be used 
clinically. Some other angiogenesis inhibitors applicable to cancer treatment 
include itraconazole, suramin, tetrathiomolybdate, and tasquinimod. In 
summary, angiogenesis inhibitors have been thought to possess potential as a 
“silver bullet” in the cancer treatment. 
In 1992, the angiogenic protein platelet-derived endothelial cell growth factor 
(PD-ECGF), isolated from platelets, was shown to be identical to TP,45 and TP 
has already been proven to play an important role in the tumor angiogenesis 
process in various studies reported earlier. It was reported in some in vitro28, 46, 
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47 studies that TP could induce tube formation and the migration of endothelial 
cells. TP was also shown to stimulate angiogenesis in several in vivo models 
such as chorio-allantoic membrane (CAM),46-48 the freeze-injured skin graft,28 
rat corneal,49 and mouse dorsal air sac49 assays. In 2009, TP was identified as 
a key regulator of the angiogenic potential of endothelial progenitor cells 
(EPC, a type of bone marrow-derived cells which can differentiate into 
endothelial cells).50 All these evidence suggested that TP is closely associated 
with the tumor angiogenesis process. In addition, it has been supported by 
multiple experimental data that the enzymatic activity of TP is indispensable 
for its angiogenic property. First, TP mutants without catalytic activity did not 
stimulate the formation of new blood vessels in the gelatine sponge assay.28, 51 
Second, TP-directed neutralizing antibodies28 or a specific TP inhibitor such 
as 5-amino-6-chlorouracil51 could abolish the angiogenic activities of TP. 
Third, migration of endothelial cells as well as angiogenesis could be induced 
by 2-deoxy-D–ribose (2DDR), which is a degradation product of the 
TP-metabolite 2DDR-1P.52-54 
However, unlike most other angiogenic factors which are released into the 
extracellular space to activate endothelial cells, TP is mainly found inside the 
cell due to the lack of an amino-terminal hydrophobic leader sequence 
required for cell secretion.46 Furthermore, while angiogenic factors usually 
bind to a specific receptor located at the cell surface and stimulate relative 
biological response of the cell via a signal transduction cascade, there is still 
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no receptor found in mammalian cells for either TP or 2DDR. Therefore, they 
probably induce angiogenesis by a non-receptor-mediated mechanism. 
Numerous studies have been carried out to investigate this mechanism, and it 
was found that TP could induce the expression and/or secretion of other 
angiogenic factors. In the presence of thymidine, human bladder carcinoma 
cells transfected with TP were reported to over-express heme oxygenase-1 
(HO-1),55 which has some proangiogenic properties including promoting 
endothelial cell proliferation, protecting endothelial cells from apoptosis as 
well as inducing the secretion of several angiogenic factors such as VEGF 
(belonging to the platelet-derived growth factor family) and interleukin-8. 56-59 
Besides, it has also been reported that over-expression of TP would 
up-regulate the secretion of MMPs (matrix metalloproteinase, which are 
known to digest the ECM surrounding tumor as well as the endothelial cells 
thus facilitating cell invasion, migration and metastasis60). Human epidermoid 
carcinoma cells transfected with TP would express more MMP-9.61 TP over 
expressed PC-3 prostate as well as KK47 bladder cancer cells also showed 
higher levels of MMP-7 and MMP-9 secretion compared with the 
mock-transfected control cells.62 Moreover, clinical data supported a 
relationship between over-expression of TP and up-regulation of MMPs 
secretion: in breast cancer, higher levels of TP was correlated with higher 
levels of MMP-9,63 and in human bladder cancers, over-expression of TP was 
associated with over-expression of MMP-1 as well as MMP-9.62 In addition to 
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inducing the expression and/or secretion of other angiogenic factors, TP and 
2DDR could also directly stimulate the migration of endothelial cells via the 
activation of integrins and their downstream signaling pathways. It was 
reported that in human umbilical vein endothelial cells (HUVEC), both TP and 
2DDR induced the formation of focal adhesions as well as the phosphorylation 
of tyrosine397 of focal adhesion kinase (FAK), which was a nonreceptor 
protein-tyrosine kinase and played an important role in the attachment and 
migration of endothelial cells.64 
Thymidine phosphorylase promotes tumor metastasis. 
It has been found that high TP expression was associated with metastasis, and 
TP was able to increase the metastatic potential of tumors in various studies. 
TP over-expressing human epidermoid carcinoma cells exhibited more 
basement membrane invasion than their mock-transfected counterparts.65 
Intrasplenic injection of human epidermoid carcinoma cells transfectd with TP 
in nude mice led to obviously more metastatic nodules in the livers. The 
stimulation of metastasis by TP over-expressing cells could be significantly 
inhibited by the TP inhibitor TPI as well as 2-deoxy-L-ribose (2DLR), which 
is a stereoisomer of 2DDR.65, 66 Finally, metastasis accompanied with lung 
colonization was inhibited by treating with neutralizing antibodies against TP 




Thymidine phosphorylase protects cancer cells from apoptosis. 
It was reported by Moghaddam et al.28 in 1995 that TP over-expressing breast 
carcinomas grew faster without an increase in micro vessel density than breast 
cancers which did not express TP. A clinical study conducted subsequently 
also showed that TP was serving as a prognostic factor independent of 
angiogenesis in human colon carcinomas.68 Therefore, TP was supposed to 
promote tumor growth via another mechanism besides angiogenesis.  
A relationship between TP expression and apoptosis was first found in vitro by 
using human epidermoid carcinoma cells transfected with TP. This type of 
cells exhibited resistance to apoptosis induced by hypoxia. The fact that the 
generated resistance could be abrogated by treating the cells with TPI 
suggested that the enzymatic activity of TP was necessary for its protection 
against the hypoxia-induced apoptosis.69 Potential molecular mechanism 
revealed that the products of the TP activity such as 2DDR and thymine are 
believed to be involved in this protection. It was found in human leukemia 
cells that 2DDR could inhibit various pro-apoptotic events induced by hypoxia 
including release of mitochondrial cytochrome c, loss of mitochondrial 
transmembrane potential, phosphorylation of p38 mitogen-activated protein 
kinase and down-regulation of the antiapoptotic proteins.70, 71 
Besides hypoxia-induced apoptosis, TP also inhibits apoptosis stimulated by 
microtubule-interfering, DNA damage-inducing agents as well as Fas, which 
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is a tumor necrosis factor receptor and forms the death-inducing signaling 
complex (DISC) upon ligand binding.72-76 Further mechanism studies 
suggested that TP could protect cells against apoptosis induced by Fas through 
inhibiting the cleavage of caspase-8, phosphorylation of Bcl-2 and release of 
cytochrome c.75 However, unlike the case in inhibiting hypoxia-induced 
apoptosis, TP exerted its protective effects against apoptosis stimulated via 
other mechanisms independent of its enzymatic activity.39, 49, 57 
Finally, the antiapoptotic effect of TP was supported by numerous clinical 
studies. It was found that expression of TP was associated with the decrease in 
apoptotic cells in colon,77 gastric,78 esophageal,79, 80 ovarian81 as well as oral 
squamous cell82 carcinomas. 
1.2.2.2 Thymidine phosphorylase in other diseases 
Many studies had suggested that TP was involved in various chronic 
inflammatory diseases. It was found that inflammatory cells contained large 
amount of TP, and inflammatory cytokines were demonstrated to induce TP 
expression.83-89 TP levels increase in psoriasis.90 In inflammatory bowel 
disease, over expression of TP was found in macrophages and fibroblasts of 
the inflamed colonic mucosa.91, 92 Furthermore, up-regulation of TP in chronic 
glomerulonephritis indicated that it played an important role in the progression 
of interstitial fibrosis.93 TP was also reported to be involved in reumatoid 
arthritis (RA). It has been reported that TP levels in the synovial fluid or sera 
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of patients with RA were higher than that of patients with osteoarthritis or 
normal healthy individuals, and serum TP could be used as an efficient clinical 
marker for RA.83-85 However, some in vivo studies revealed that it was enzyme 
itself instead of its enzymatic activity that was implicated in the pathology of 
RA.86 Extracellular secretion of MMP-1 and MMP-3, which are main triggers 
of cartilage degeneration, was also induced by TP. 83, 88Besides, TP was found 
to upregulate VEGF expression, suggesting that both factors have synergistic 
effects on angiogenesis in RA.22 
TP is also involved in mitochondrial neurogastrointestinal encephalopathy 
(MNGIE), which is an autosomal recessive human disorder associated with 
multiple deletions of skeletal muscle mitochondrial DNA. It has been reported 
that loss-of-function mutations of the TP gene are possible reasons of this 
disease.94, 95 Severely reduced TP activity would increase levels of thymidine 
as well as 2’-deoxyuridine in the plasma and tissue, and this might lead to an 
imbalance in mitochondrial nucleoside and nucleotide pools thus this would 
interfere with mitochondrial DNA replication and repair.95-97 However, some 
other studies indicated that functional mutations of the TP gene might not be 
the primary cause of this mitochondrial disease because TP mutations were 
also detected in unrelated healthy individuals.98 It has been revealed that exon 
10 of TP gene overlapped with the SCO2 (synthesis of cytochrome c oxidase 2) 
gene, and mutations in SCO2 was reported to cause mitochondrial disorders 
characterized by hypertrophic cardiomyopathy and encephalopathy.99, 100 
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Therefore, the exact role of TP deficiency in MNGIE development still 
remains unsolved. 
Table 1. Various roles of TP in diseases. 




Elevating the expression of 
some angiogenic factors 
such as MMPs, VEGF 
Promoting metastasis Generating 2DDR 
Preventing apoptosis Generating 2DDR 
Reumatoid arthritis Inducing angiogenesis 
Elevating the expression of 
some angiogenic factors 
such as MMPs, VEGF 
 
1.2.3 Thymidine phosphorylase inhibitors and their potential 
therapeutic values 
Due to the involvement in various physiological and pathological processes, 
TP was recognized as a good target in the disease treatment. Substantial 
efforts have been put in to developing potent TP inhibitors with potential 
therapeutic value since 1960s. 
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1.2.3.1 Pyrimidine derivatives as inhibitors of thymidine phosphorylase 
For more than 30 years, TP inhibitors had been analogues of pyrimidine. For 
example, 6-aminothymine (6AT), 6-amino-5-chlorouracil (6A5CU), and 
6-amino-5-bromouracil (6A5BU) are TP inhibitors which exhibit IC50 values 
of about 30µM.101 Based on pioneering work conducted in the late nineteen 
sixties and early nineteen seventies, it was proposed that the homophthalimide 
moiety was important for TP inhibitory activity.102 X-ray crystallographic 
structure of E. coli TP was solved in 1990103 which revealed that the 
interaction between this moiety and amino acids in the thymine/thymidine 
binding sites was essential. Moreover, existence of a hydrophobic pocket 
located close to C-5 of the pyrimidine ring was also found in this structure, 
and it explained the general observation that hydrophobic groups such as CH3, 





















Besides position C-5, it was also proposed that there was another hydrophobic 
cavity that surrounded position C-6 of the pyrimidine ring. Many compounds 
were designed to target this hydrophobic cavity. One example was 
6-(2-aminoethylamino)-5-chlorouracil (AEAC), which was found to be 65 
times more potent against human TP than 6A5BU.104 However, the 
corresponding 6-aminoethanol derivative was inactive, thus the basic 
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substituent at position 6 was believed to be crucial for the inhibitory activity. 
Another inhibitor developed by the same group was 
5-chloro-6-(1-imidazolylmethyl)uracil (CIMU), which showed similar activity 
to AEAC against TP.104 In other studies, a series of 
6-(phenylalkylamino)uracil derivatives was synthesized and investigated for 
TP inhibitory activity, the most potent compound 
6-(4-phenylbutylamino)uracil (PBAU) was slightly more potent than 6AT. 
However, in this series of compounds, the corresponding 5-chloro and 
5-methyl analogues were less active compared with those unsubstituted 
compounds, which contradicted with the general observation from most 
studies of TP inhibitors.105 Moreover, besides studies that aimed at improving 
the inhibitory activity of TP inhibitors, there were also some work conducted 
for attempts to improve solubility. Several water soluble uracil derivatives 
with the pyridinium substituent were synthesized and evaluated. It was found 
that 6-methylenepyridinium substituted compounds such as CMPU possessed 
TP inhibitory activity similar to 6A5BU, while the corresponding compounds 








































In the year 2000, a very potent TP inhibitor 
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracil hydrochloride (TPI) was 
developed by Taiho Pharmaceutical Co., Ltd. 107 Details on the discovery 
process of TPI was disclosed later in 2004.108, 109 During the discovery process, 
several series of 6-methyleneamino uracil derivatives were synthesized and 
tested. The final candidates, besides showing good in vitro inhibitory activity 
against TP, also possessed good pharmacokinetic profiles. During the first 
stage of study, a potent inhibitor namely 5-bromo-6-(pyrrolidinylmethyl)uracil 
(BPMU) with an IC50 value of 0.51µM against human TP was identified. 
108However, this compound revealed toxic effects in further in vivo studies, 
and this promoted new series of 6-methylene bridged uracil derivatives were 
to be designed for reducing toxicity.109 It was found that a compound with an 
N-methylguanidine substituent at position 6 of the uracil ring was more active 
against TP than the corresponding lead compound substituted with a 
pyrrolidine moiety at the same position. Further work in this series generated 
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two very potent TP inhibitors namely 
5-chloro-6-[(2-iminoimidazolidinyl)methyl]uracil (CIIMU) hydrobromide   
and TPI, with IC50 values as low as 13 and 35nM, against human TP 
respectively.109 Subsequent in vivo studies revealed that both compounds 
possessed good pharmacokinetics profiles. However, the synthesis of CIIMU 
involved a highly toxic reagent namely cyanogen bromide; considering the 
safety of workers, the development of CIIMU was discontinued by the 
company and TPI was finally chosen as the drug candidate for further 
investigations.109 Neither significant body weight loss nor death was observed 
after administration of TPI at high dose (2000mg/kg) in in vivo studies thus it 





























Besides 5-halouracils with various substituents at position 6, some work 
focusing on 6-halouracils with various substituent at position 5 was also 
conducted. 110 Results showed that compounds with certain hydrophobic 
groups at position 5 possessed significant inhibitory activity against TP. The 
most potent compounds were 6-chlorouracils with a five-, six-membered ring 
containing a conjugated-electron system at position 5. The representative of 
this group of compounds was 6-chloro-5-cyclopent-1-en-1-yluracil (CCEU), 
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which possessed a Ki value as low as 0.20µM and 0.29µM for TP expressed in 







Some multi-substrate inhibitors designed for interacting with both the 
thymidine and phosphate binding sites were also developed. In the open 
conformation of E. coli TP, the distance between the thymidine binding site 
and the phosphate binding site was approximately 8-10 Å.103 Therefore, 
several series of compounds bearing a thymine moiety, a spacer of 6-9 atoms 
and a phosphonate moiety were prepared and evaluated.111 One example was 
the compound TP-64 with an IC50 value against E. coli TP ranging between 
20µM and 100µM. Further kinetic studies proved that TP-64 was able to 












In addition, pro-drug strategy has been taken into account for developing 
pro-drugs of TP inhibitors that could be converted into the corresponding TP 
inhibitors only at the tumor site thus reducing potential side effects. It has been 
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proposed that hypoxic conditions at the tumor environment could reduce the 
nitro groups to amino groups. Therefore, some nitroimidazolylmethyluracil 
prodrug derivatives were synthesized and tested against E. coli TP. Among 
them, 5-chloro-6-[(2-nitro-imidazolyl)methyl]uracil (CNIMU) and 
5-bromo-6-[(2-nitro-imidazolyl)methyl]uracil (BNIMU) inhibited E. coli TP 
at IC50 values around 20µM which were 1000-fold less active than their 



















CNIMU BNIMU  
Another activation approach of pro-drugs relied on xanthine oxidase (XO) 
which is widely found in hypoxic tissues such as breast and brain tumors. Two 
pro-drugs namely 6-amino-5-bromo-3H-pyrimidin-4-one (6A5BP) and 
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]-3H-pyrimidin-4-one 
hydrochloride (CIPMP) were readily oxidized to the active forms 6A5BU and 



















1.2.3.2 Purine derivatives as inhibitors of thymidine phosphorylase 
Besides pyrimidine derivatives, some purine derivatives were also found to be 
active against TP. In 1998, 7-deazaxanthine (7DX) was identified as the first 
purine like TP inhibitor with an IC50 value of 40µM against E. coli TP.113 Its 
derivative namely 7-(2-aminoethyl)-deazaxanthine (7AEDX) showed an IC50 
















Another example of TP inhibitor that contains the purine moiety is 
5’-O-tritylinosine (KIN 59), which shows an IC50 value of 67 and 44µM 
against human and E. coli TP respectively. Further kinetic studies found that 
KIN59 was a non-competitive TP inhibitor, thus it was believed to bind to TP 
at another site different from the substrate binding site.115 Subsequent work 
carried out by the same research group derived a more potent analogue namely 
1-(cyclopropyl) methyl-5’-O-tritylinosine (CPMOT) which exhibited an IC50 
value as low as 2.3µM. It was also found in the structure activity relationship 
(SAR) studies that the trityl group at the position 5’ of the ribose was crucial 
























In addition, a multi-substrate inhibitor TP65 consisting of 7-deazaxanthine, a 
spacer of 8 carbon atoms as well as a phosphonate moiety was developed in 














Lastly, a prodrug of 7DX, namely 7H-pyrrolo[2,3-d]pyrimidin-2(1H)-one 
(7HPPO), was reported. 7HPPO itself did not demonstrate TP inhibitory 










1.2.3.3 Thymidine phosphorylase inhibitors based on other structures 
Using the active site in a homology model of human TP generated based on 
the E. coli structure in the open-cleft conformation, a computational screening 
of the National Cancer Institute database of anticancer compounds was carried 
out. A total of thirteen compounds were finally selected for further enzyme 
assay. It was found that hydrazine carboxamide 
2-[(1-methyl-2,5-dioxo-4-pentyl-4-imidazolidinyl)methylene] (HCMM) 
possessed inhibitory activity against E. coli TP and human TP, exhibiting IC50 
value of 20 and 77µM respectively.117 Later in 2011, another 
non-nucleobase-derived TP inhibitor, namely 
3-(2,4,5-trioxo-3-phenylethyl-imidazolodin-1-yl)propionamide (TPIPA), was 



















Besides, some 3-substituted isocoumarins and 3-formylchromones have been 
found to possess TP inhibitory activity. The best compound among 
3-substituted isocoumarins was 3-(2-methylphenyl) isocoumarin (MPIC) with 
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an IC50 value of 61µM against E. coli TP.119 The most potent inhibitor derived 
from the 3-formylchromone scaffold was 3-[(3-methoxy-4-methylphenyl) 










1.2.3.4 Therapeutic potential of inhibitors of thymidine phosphorylase 
It was known that besides pyrimidine nucleosides, TP can also induce the 
phosphorolysis of several nucleoside analogues that are being used as clinical 
antiviral and/ or antitumor agents thus reduce their activity.121 Therefore, it is 
proposed that a combination of nucleoside analogue therapeutic agents and a 
TP inhibitor might be able to improve the biological efficacy of these agents. 
In addition, since TP was found to be involved in the tumor angiogenesis as 
well as metastasis in 1990s, the clinical implication of TP inhibitors has 
already broadened to include controlling the development of tumor. 
Some in vivo studies have been performed to investigate the antiangiogenesis 
properties of TPI. In the mouse dorsal air sac assay model, TPI completely 
inhibited the angiogenesis induced by the human epidermoid carcinoma cells 
transfected with TP cDNA at the dose of 50mg/kg/day.122 Moreover, it also 
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significantly decreased the growth rate of the same type of cells xenografted 
into nude mice and increased the apoptotic index of these cells at the dose of 
50mg/kg/day.122 Further studies revealed that TPI suppressed chemotactic 
motility as well as the basement membrane invasion of human epidermoid 
carcinoma cells transfected with TP cDNA.123 Based on the results of these in 
vivo studies, TPI was believed to possess antiangiogenesis and antimetastasis 
properties thus might be considered as a novel potential agent for suppressing 
the growth of tumors.  
Besides, TPI was also applied to prevent the degradation of some nucleoside 
antitumor agents. It was reported in some in vivo studies that after combined 
oral administration, TPI increased the plasma concentration of thymidylate 
synthase (TS) inhibitor trifluorothymidine (TFT) and enhanced its antitumor 
activity.109 Promising results from these preliminary studies led to the 
generation of a formulation consisting of TFT and TPI in a 2:1 ratio on the 
molar basis. This formulation, namely TAS-102, has already entered the phase 
Ⅲ clinical trials for treating the metastatic colorectal cancer.124 
In another study, another pyrimidine based TP inhibitor CIMU was found to 
inhibit TP transfected carcinoma cells and human monocyte cells induced 
migration of HUVEC in a co-culture assay.52 
For purine based TP inhibitors, multisubstrate inhibitor TP65 significantly 
inhibited the angiogenesis stimulated by TP in the CAM assay at a dose of 
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250nmol, and it also completely suppressed the TP induced formation of 
microvascular sprouts from endothelial cell aggregates in a three-dimensional 
fibrin gel.48 Besides, it has also been reported that 7DX as well as KIN59 
could significantly prevent neovascularisation in the chicken chorioallantoic 
membrane during development in the CAM assay. 113, 115 
In summary, TP inhibitors have been proven to possess potential therapeutic 
value by various in vivo or in vitro studies. It is very encouraging that the 
pyrimidine based TP inhibitor, TPI, has now entered clinical trials as a major 
component of TAS-102. However, for purine based TP inhibitors, there is still 
room for further improvement. In this project, a fused bicyclic scaffold namely 
pyrazolo[1,5-a][1,3,5]triazine, which is an analogue of purine, served as a 
template for generating new potent purine based TP inhibitors so as to increase 
the structural diversity of TP inhibitors. 
1.3 Synthesis of pyrazolo[1,5-a][1,3,5]triazines 
Pyrazolo[1,5-a][1,3,5]triazine, the heterocyclic system is an analogue of 
purine, and this scaffold has been investigated particularly in the area of 













Purine Pyrazolo[1,5-a][1,3,5]triazine  
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Pyrazolo[1,5-a][1,3,5]triazine was synthesized for the first time by Checchi 
and Ridi,125 in 1957. Since that time, several approaches have been developed 
for the preparation of compounds with the pyrazolo[1,5-a][1,3,5] triazine 
scaffold. Common approaches to the synthesis of pyrazolo[1,5-a][1,3,5] 
triazines can be categorized into: annulation of the 1,3,5-triazine ring onto a 
pyrazole scaffold; annulation of the pyrazole ring onto a 1,3,5-triazine scaffold; 
concurrent formation of both the 1,3,5-triazine and pyrazole ring; ring 
transformation reactions. 
1.3.1 Synthesis of pyrazolo[1,5-a][1,3,5] triazines from pyrazole scaffold 
Among these four common synthetic approaches, the most frequently utilized 
approach to construct the pyrazolo[1,5-a][1,3,5]triazine heterocyclic system is 
the 1,3,5-triazine ring annulation method. Suitable pyrazoles can be cyclized 
to form pyrazolo[1,5-a][1,3,5] triazines according to the following methods: 
i. Four-bond formation through cyclization of 3-aminopyrazoles with two 
carbon and one nitrogen atoms. 
It has been reported that1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazines 
could be prepared by the condensation of 3-phenylaminopyrozoles with 
two equivalents of formaldehyde and one equivalent of primary amines  
(Scheme 1).126 In particular, 5-phenyl-3-phenylaminopyrazole provided 
two of the three triazine nitrogens while the third nitrogen was derived 
from appropriately selected amine as a reagent. The remaining two 
carbons of the triazine came from two moles of formaldehyde. The 
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reaction could be carried out at room temperature in methanol with the 












Scheme 1. Synthesis of 1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazines 
through four-bond cyclization. 
ii. Three-bond formation through cyclization of 3-aminopyrazoles with 
reagents introducing a C-N fragment and one carbon atom. 
4-Aryloxy-2,2-dimethyl-2,3-dihydropyrazolo[1,5-a][1,3,5]triazines could 
be synthesized by the reaction between 3-aminopyrazole and aryl cyanates 
in acetone (Scheme 2).127 In this synthetic scheme, 3-amino pyrazole 
provided two of the three triazine nitrogens, and the third nitrogen as well 
as one carbon were derived from appropriately selected cyanate. The 
remaining one carbon of the triazine came from acetone which also served 
as the solvent of the reaction mixture. Reactions could be run without 












Scheme 2. Synthesis of 
4-aryloxy-2,2-dimethyl-2,3-dihydropyrazolo[1,5-a][1,3,5]triazines   
through three-bond cyclization. 
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iii. Two-bond formation through cyclization of 3-aminopyrazoles with 
reagents introducing a C-N-C fragment. 
2,4-Diarylpyrazolo[1,5-a][1,3,5]triazines could be generated by the 
reaction between 3-aminopyrazole and ethyl N-benzoylimidates (Scheme 
3).128 In this type of reaction, 3-amino pyrazole provided two of the three 
triazine nitrogens, and the third nitrogen as well as two carbons were 
derived from appropriately selected ethyl N-benzoylimidates. Although the 
nucleophilicity of exocyclic nitrogen atom of 3-aminopyrazole was higher, 
the major product turned out to be the one formed by the nucleophilic 

















Scheme 3. Synthesis of 2,4-diarylpyrazolo[1,5-a][1,3,5]triazines   
through two-bond cyclization. 
iv. Two-bond formation through cyclization of N-acylpyrazolidindiones with 
reagents introducing an N-C-N fragment. 
Refluxing a mixture of N- acetylpyrazolidindiones and urea in ethanol 
containing small amounts of acetic acid could afford target 
pyrazolo[1,5-a][1,3,5]triazines with yields around 50% (Scheme 4).129 
Appropriately selected N-acylpyrazolidindiones would provide one of the 
three triazine nitrogens and two carbons. The other two nitrogens as well 
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as one carbon were derived from urea. The cyclization was fulfilled by the 














Scheme 4. Synthesis of pyrazolo[1,5-a][1,3,5]triazines           
through two-bond cyclization. 
v. Two-bond formation through cyclization of 5-aminopyrazoles having 
carbon atom at N1 with reagents introducing a C-N fragment. 
2-Amino-4-thioxopyrazolo[1,5-a][1,3,5]triazines could be prepared via 
refluxing cyanamide and methyl 5-amino-3-arylpyrazole-1-carbodithioates 
in ethanol in the presence of sodium ethoxide (Scheme 5), giving yields 
around 60%.130 In this case, 5-amino-3-phenylpyrazole-1-carbodithioate 
provided two of the three triazine nitrogens and two of the three triazine 
carbons. The remaining one carbon and one nitrogen of the triazine were 













Scheme 5. Synthesis of 2-amino-4-thioxopyrazolo[1,5-a][1,3,5]triazines 
through two-bond cyclization. 
vi. Two-bond formation through cyclization of pyrazoles having N-C 
appendage at C3 with reagents introducing a C-N fragment. 
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It has been discovered that the formation of fused tricyclic 
benzopyrazolo[1,5-a][1,3,5]triazine ring system could be achieved by 
refluxing of phenyl isocyanate and 3-azomethine substituted indazole in 
toluene, giving a yield of 47% (Scheme 6).131 In this synthetic scheme, 
3-azomethine substituted indazole provided two of the three triazine 
nitrogens and two of the three triazine carbons. The remaining one carbon 
and one nitrogen of the triazine were derived from phenyl isocyanate. The 
carbon atom in the isocyanate moiety served as a good electrophilic center 
which could be easily attacked by the nitrogen atom located on the 
indazole to form the product. 
NHN








Scheme 6. Synthesis of fused tricyclic benzopyrazolo[1,5-a][1,3,5]triazine 
ring system through two-bond cyclization. 
vii. Two-bond formation through cyclization of 5-aminopyrazoles having a 
C-N appendage at N1 with one carbon atom. 
2,4-Dioxo-7-phenylpyrazolo[1,5-a][1,3,5]triazine could be obtained by the 
reaction between 5-amino-1-carbamoyl-3-phenylpyrazole and ethyl 
chloroformate in the presence of pyridine with a yield of 34% (Scheme 
7).130 In particular, 5-amino-1-carbamoyl-3-phenylpyrazole provided all 
the three triazine nitrogens and two of the three triazine carbons. The 
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remaining one carbon was derived from ethyl chloroformate. The 
cyclization was fulfilled via the nucleophilic attack of two amino groups 













Scheme 7. Synthesis of 2,4-dioxo-7-phenylpyrazolo[1,5-a][1,3,5]triazine 
through two-bond cyclization. 
viii. Two-bond formation through cyclization of pyrazoles having an N-C-N 
appendage at C3(5) with one carbon atom. 
Synthesis of 4-amino-2-methyl-7-phenylpyrazolo[1,5-a][1,3,5]triazine by 
refluxing acetamidine and cyanogen bromide in methanol has been 
reported , giving a yield of 42% (Scheme 8).132 In this reaction, 
acetamidine provided three triazine nitrogens and two of the three triazine 











Scheme 8. Synthesis of 
4-amino-2-methyl-7-phenylpyrazolo[1,5-a][1,3,5]triazine        
through two-bond cyclization. 
ix. One-bond formation through intramolecular cyclization of 
5-aminopyrazoles having a C-N-C appendage at N1. 
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4-Amino-7-methyl-2-oxopyrazolo[1,5-a][1,3,5]triazine could be prepared 
by a thermal intramolecular ring closure reaction conducted at 200oC using 
[(5-amino-3-methyl-pyrazol-1-yl)-imino-methyl]-carbamic acid ethyl ester 
as the starting material with a yield of 96% (Scheme 9).133 In this example, 
all three triazine nitrogens and three triazine carbons came from 
[(5-amino-3-methyl-pyrazol-1-yl)-imino-methyl]-carbamic acid ethyl ester. 
The nitrogen atom of the primary amino group attacked the electrophilic 














Scheme 9. Synthesis of 
4-amino-7-methyl-2-oxopyrazolo[1,5-a][1,3,5]triazine           
through one-bond intramolecular cyclization. 
x. One-bond formation through intramolecular cyclization of pyrazoles 
having an N-C-N-C appendage at C3(5). 
It has been reported that 5-aza-9-deazahypoxanthine could be generated by 
refluxing N-carbethoxy-N′-(3(5)-pyrazolyl)formamidine in xylene, giving 
a yield around 80% (Scheme 10).134 In this synthetic scheme, 
[(2H-pyrazol-3-ylimino)-methyl]-carbamic acid ethyl ester provided all 
three triazine nitrogens as well as three triazine carbons. The product was 
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formed by the nucleophilic attack of the nitrogen of the secondary amine 












Scheme 10. Synthesis of 5-aza-9-deazahypoxanthine            
through one-bond intramolecular cyclization. 
1.3.2 Synthesis of pyrazolo[1,5-a][1,3,5] triazines from      
1,3,5-triazine scaffold 
Annulation of the pyrazole ring onto a 1,3,5-triazine scaffold is an alternative 
approach to generate pyrazolo[1,5-a][1,3,5]triazine scaffold. However, unlike 
using pyrazoles as starting materials, in this case only one type of cyclization 
was reported which was a one-bond formation through intramolecular 
cyclization of 1,3,5-triazines possessing C-C-N fragment.135-137 
In the literature, there are reports that described 
2,4-diamino-1,3,5-triazino[1,2-b]indazoles could be prepared by the 
decomposition of relative azides in the refluxing acetic acid with yields 
ranging from 80% to 90% (Scheme 11).136 In this type of reaction, the starting 
azides provided all atoms of the pyrazole ring in the target compounds. Target 




Scheme 11. Synthesis of 2,4-diamino-1,3,5-triazino[1,2-b]indazoles. 
1.3.3 Synthesis of pyrazolo[1,5-a][1,3,5] triazines by concurrent 
formation of both the 1,3,5-triazine and pyrazole rings 
Another approach for synthesizing pyrazolo[1,5-a][1,3,5]triazines is by 
forming both the 1,3,5-triazine ring as well as the pyrazole ring at the same 
time, which could be fulfilled via a two-bond formation through 
intramolecular cyclization of open-chain structures consisting of five carbon 
and four nitrogen atoms. 
One example was the synthesis of 
7-oxo-4-thioxopyrazolo[1,5-a][1,3,5]triazines, which could be generated by 
refluxing N-acyl-2-cyanoacetylthiosemicarbaside in potassium hydroxide 
solution, giving yields in the range of 55%-92% (Scheme 12).138-140 Both rings 
of the pyrazolo[1,5-a][1,3,5]triazine scaffold were constructed at the same 
time through two intramolecular nucleophilic reactions involving nitrogen 
atoms and carbon atoms, resulting in target compounds with different 



































1.3.4 Synthesis of pyrazolo[1,5-a][1,3,5] triazines by ring transformation 
reactions 
This approach is represented by a category of reactions in which the fused 
bicyclic ring system has already presented in the starting materials and will be 
later converted into the pyrazolo[1,5-a][1,3,5] triazine scaffold. 
According to literature, a target pyrazolo[1,5-a][1,3,5] triazine was 
successfully prepared by the transformation of the 1,3,5-thiadiazine ring of the 
starting material into the 1,3,5-triazine ring, giving a yield of 63% (Scheme 
13).141 The transformation was fulfilled by the nucleophilic attack of one 
nitrogen atom in the hydrazine molecule and the subsequent release of one 















Scheme 13. Pyrazolo[1,5-a][1,3,5] triazine scaffold generated by 
transformation of the 1,3,5-thiadiazine ring. 
Besides, transformation of the 1,2,3-triazine ring into the pyrazole ring could 
also result in the formation of pyrazolo[1,5-a][1,3,5] triazine with reported 
yields around 70%-80% (Scheme 14).136 During the reaction process, an azide 
intermediate would be formed first via the cleavage of N-N single bond in the 
middle ring, target compound was then generated by the subsequent evolution 


















Scheme 14. Pyrazolo[1,5-a][1,3,5] triazine scaffold generated by 
transformation of the 1,2,3-triazine ring. 
In summary, plenty of methods have been developed for the synthesis of 
differently substituted pyrazolo[1,5-a][1,3,5] triazines. This scaffold, with 
various substituents, is considered as a good template for developing new 
chemical entities with different biological activities and physicochemical 
properties. Generally, most substitutions were made at position 2, 4, 7 and 8. 
In particular, since many fused bicyclic ring systems were formed by 
nucleophilic reactions between amino groups and electrophilic carbon atoms 
attaching to oxygen, sulfur, or nitrogen, the substituents at position 2 or 4 were 
usually OH, SH, or NH2. However, substituents at position 7 and 8 could vary, 
which are usually determined by the corresponding starting materials. 
Eventually, the selection of a specific method for preparing target compounds 
should depend on the position of substituents to be introduced on the target 
compounds as well as the availability of the starting materials. The utility of 
previously described synthetic methods for introducing substituents to 
different positions of the pyrazolo[1,5-a][1,3,5] triazine scaffold has been 




Table 2. Selection of synthetic methods for introducing substituents to     











Synthetic methods Position of substitution 
Synthesis from pyrazole scaffold (methodⅰ) 1, 3, 7, 8 
Synthesis from pyrazole scaffold (methodⅱ) 2, 4, 7, 8 
Synthesis from pyrazole scaffold (methodⅲ) 2, 4, 7, 8 
Synthesis from pyrazole scaffold (methodⅳ) 2, 4, 6, 7, 8 
Synthesis from pyrazole scaffold (methodⅴ) 2, 4, 7, 8 
Synthesis from pyrazole scaffold (methodⅵ) 2, 3, 4, 7, 8 
Synthesis from pyrazole scaffold (methodⅶ) 2, 4, 7, 8 
Synthesis from pyrazole scaffold (methodⅷ) 2, 4, 7, 8 
Synthesis from pyrazole scaffold (methodⅸ) 2, 4, 7, 8 
Synthesis from pyrazole scaffold (methodⅹ) 4, 7, 8 
Synthesis from 1,3,5-triazine scaffold 7, 8 
Synthesis by the concurrent ring formation 2, 4, 7 





1.4 Biological activity of pyrazolo[1,5-a][1,3,5]triazines 
Due to the structural similarity between the pyrazolo[1,5-a][1,3,5]triazine 
scaffold and the purine system, modifications of this scaffold have given rise 
to a lot of bioactive agents which could interact with targets of biogenic 
purines. In particular, many enzyme inhibitors are found to contain the 
pyrazolo[1,5-a][1,3,5]triazine scaffold, and some of them are drugs. 
1.4.1 Enzyme inhibitors containing the pyrazolo[1,5-a][1,3,5]triazine 
scaffold 
Xanthine oxidase (XO), which oxidizes hypoxanthine to xanthine and 
eventually to uric acid, is a good target in the treatment of gout. In 1985, 
Robins et al.142 developed a compound possessing 
pyrazolo[1,5-a][1,3,5]triazine scaffold namely 
8-phenyl-5-aza-9-deazahypoxanthine as a potent inhibitor of XO. 
Later, another very potent XO inhibitor BOF 4272 was identified by Japanese 
researchers.143, 144  Some in vitro as well as in vivo studies145, 146 including 
experimental data on healthy human volunteers147 showed promising results. 
Mechanism studies showed that stereochemistry was crucial to the activity of 
BOF 4272: although both enantiomers were demonstrated mixed type 

















Cyclin-dependent kinase 2 (CDK2), which is involved in the regulation of the 
cell cycle, is considered as a good target in the cancer treatment. Some 
substituted 2,4-diaminopyrazolo[1,5-a][1,3,5]triazines have been reported to 
possess CDK2 inhibitory activity. 148, 149 These inhibitors of CDK2 possess a 
wide range of substituents attached to two amino groups while position 7 of 
the pyrazole ring should be kept unsubstituted for maintaining the activity.148 
Some of such compounds showed strong antiproliferative activity against 
human colon cancer cells.148 Further developed macrocyclic derivatives 
showed even better anticancer activity in in vitro experiments.150 
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Cyclic nucleotide phosphodiesterases (PDE), which hydrolyze second 
messengers such as cAMP and cGMP, are another group of enzymes that can 
be inhibited by pyrazolo[1,5-a][1,3,5]triazines. Since specific PDE are 
expressed at different levels in different tissues, selectivity in the inhibition of 
enzyme isoforms is very important for PDE inhibitors. Several potent and 
rather selective inhibitors against cAMP PDE from brain and lung, which 
possessed pyrazolo[1,5-a][1,3,5]triazine scaffold, have been developed, and it 
was found that bromination in position 7 improved PDE inhibitory activity as 
well as selectivity (the activity of the compounds was expressed in relation to 
the inhibitory activity of reference drug theophylline, activity α = 
IC50[theophylline] / IC50[compound]).151-154 
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PDE: αbrain = 146; αlung = 143; αheart = 57 PDE: αbrain = 250; αlung = 185; αheart = 40
PDE: αbrain = 18; αlung = 160; αheart = 12.5 PDE: αbrain = 97; αlung = 14; αheart = 0.5





















DNA gyrase, which is present in bacteria but not in human, is therefore a good 
target for antibacterial therapy. It can also be inhibited by some 
pyrazolo[1,5-a][1,3,5]triazines. For some inhibitors, value of maximal 
non-effective concentration (MNEC) against DNA grase is similar to the value 
of minimal inhibitory concentration (MIC) against Staphylococcus 
pyogenes.155 
MNEC (gyrase) = 0.5 μg/mL
















1.4.2 Other biological activities  
Besides those enzyme inhibitors mentioned above, some other 
pyrazolo[1,5-a][1,3,5]triazines were reported to  possess miscellaneous 
biological activities. 
Some pyrazolo[1,5-a][1,3,5]triazines with various substituents have been 
identified as ligands of a number of G-protein coupled receptors including 
adenosine, corticotropin-releasing factor and cannabinoid receptors. 
It has been claimed that pyrazolo[1,5-a][1,3,5]triazine scaffold could serve as 
a good template for developing adenosine receptor antagonists.34, 156, 157 LUF 










                   LUF 5441  
Corticotropin-releasing factor (CRF), which is a hormone and 
neurotransmitter, is released in the brain in response to stress and coordinates 
endocrine, immune, autonomic and behavioral reactions. Therefore, CRF 
receptor is believed to be a good target for treatment of anxiety and mood 
disorders. Some potent CRF receptor antagonists with 
pyrazolo[1,5-a][1,3,5]triazine scaffold were reported. One reported 
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noncompetitive antagonist with high affinity and selectivity for CRF1 was 
DMP 696.158 This compound possessed good anxiolytic and antidepressant 
activities as well as high oral bioavailability and desirable pharmacokinetic 
properties. DMP 696 is widely used as an effective tool for investigating the 
role of CRF and its receptors in the behavior, and mechanisms of its action, 
side effects, pharmacokinetics as well as its advantages over other CRF1 
blocking agents were also studied.159, 160 Another representative of CRF1 
antagonists possessing pyrazolo[1,5-a][1,3,5]triazine scaffold was MJL 
1-109-2, and its systemic effects were investigated via a series of behavior 
tests.161 In addition, a radiolabeled [76Br] MJL 1-109-2 was developed for the 













      DMP 696      MJL 1-109-2  
Cannabinoid (CB) receptor antagonists were claimed to be potential 
therapeutic agents for treatment of central nervous system (CNS) disorders. A 
potent and selective CB1 receptor antagonist with 
pyrazolo[1,5-a][1,3,5]triazine scaffold was reported to enhance 
antiparkinsonian action of L-DOPA in animal studies and suggested to be used 










Selective CB1 receptor antagonist possessing 
pyrazolo[1,5-a][1,3,5]triazine scaffold.  
Among other pyrazolo[1,5-a][1,3,5]triazines showing biological activities, 
2,4-diamino-7-methylpyrazolo[1,5-a][1,3,5]triazine, namely dametralast, 
exhibited bronchodilator activity164, antiallergic activity164, antiinflammatory 
activity165 as well as low toxicity. This compound and its derivatives were 
further investigated as antiasthmatic agents via various animal studies and 
even clinical trials.166 However, mechanism regarding to the biological 







In summary, the pyrazolo[1,5-a][1,3,5]triazine scaffold has been proved to be 
a good template for generating biologically active agents. In this project, a 
systemic lead optimization approach was adopted to investigate whether 





1.5 Hypothesis and objectives 
1.5.1 Hypothesis 
The reported purine like TP inhibitor 7DX (IC50=40µM against E. coli TP) is 
intrinsically a deazapurine that also contains the homophthalimide moiety 
which is believed to be important for the interaction with the enzyme. Since 
pyrazolo[1,5-a][1,3,5]triazine is the analogue of purine, it is hypothesized that 
a pyrazolo[1,5-a][1,3,5]triazine possessing the homophthalimide moiety 
namely 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-dione (Figure 3) may  
possess TP inhibitory activity comparable to 7DX, and modifications with 
various substituents at positions 7 or 8 of the pyrazolo[1,5-a][1,3,5]triazine 
scaffold may lead to the enhancement of the inhibitory activity. In addition, 
isosetric replacement of the oxygen atom at position 2 with a sulfur atom may 
also generate new chemical entities possessing TP inhibitory activity 






























IC50 = 40μM against E. coli TP
Figure 3. 7DX and proposed substituted pyrazolo[1,5-a][1,3,5]triazines. 
Since TP inhibitors containing only the pyrimidine moiety (such as TPI) are 
competitive inhibitors while KIN59 containing a purine moiety without the 
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homophthalimide structure is a non-competitive inhibitor, it can be inferred 
that the pyrimidine moiety is a competitive fragment while the purine moiety 
without the homophthalimide structure is a non-competitive fragment, and 
these two fragments bind to TP at different sites. Henceforth, the second 
hypothesis to be tested is that compounds consisting of both the pyrimidine 
moiety and the purine moiety without the homophthalimide structure, would 
possess TP inhibitory activiey. In the design of this study, 
5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines was used as the model to 


























IC50 = 35nM against human TP IC50 = 67μM against human TP










Figure 4. Proposed TP inhibitors possessing both the pyrimidine moiety  













To test the hypotheses mentioned above, the following objectives need to be 
accomplished: 
I. To synthesize a series of 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones with various 
substitutents at position 7 or 8 of the pyrazolo[1,5-a][1,3,5]triazine 
scaffold.  Since many substituted 3-amino pyrazoles are commercial 
available, this objective could be fulfilled by reacting various substituted 
3-amino pyrazoles with a reagent namely ethoxycarbonyl isocyanate 
which provides two carbon atoms and one nitrogen atom of the formed 









II. To synthesize a series of 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones with various 
substitutents at position 7 or 8 of the pyrazolo[1,5-a][1,3,5]triazine 
scaffold. Similar to the first objective, this work could be done by reacting 
various substituted 3-amino pyrazoles with a reagent namely 
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ethoxycarbonyl isothiocyanate which provides two carbon atoms and one 









III. To synthesize a series of 
5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines  
with various substitutents at position 7 or 8 of the 
pyrazolo[1,5-a][1,3,5]triazine scaffold. Target compounds could be 
generated via coupling reactions between 5-chloro-6-chloromethyluracil 














IV. To evaluate the TP inhibitory activity of synthesized compounds by in 




V. To investigate the inhibition type of the most potent compounds via 
enzyme kinetic studies and compare them with their lead compounds 7DX, 
TPI or KIN59. 
VI. To evaluate cytotoxic effects of selected potent TP inhibitors against the 
TP over-expressed breast cancer cell line MDA-MB-23128, 167 by MTT 
assay. 
VII. To use gelatin zymography for exploring the antiangiogenic potential of 
selected potent TP inhibitors by evaluating their capability to suppress 




















2. Fused bicyclic pyrazolo[1,5-a][1,3,5]triazine 











As mentioned in the introduction, currently most potent TP inhibitors are 
pyrimidine derivatives thus it is worthy to explore developing new inhibitors 
based on other heterocyclic structures. Using 7DX as the lead compound, it is 
hypothesized that fused bicyclic pyrazolo[1,5-a][1,3,5]triazines which possess 
the homophthalimide moiety namely 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones may possess TP 
inhibitory activity. In addition, isosteric replacement of the oxygen atom at 
position 2 (part of the homophthalimide moiety) with sulfur atom may also 
generate compounds which can be active against TP. To test this hypothesis, a 
series of 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones as well as a 
series of 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones were 
synthesized and evaluated for inhibition against TP. In order to derive a clear 
structure activity relationship, substituents with different Hansch-Fujita 
constants and sigma constants were introduced to positions 7 and 8 separately. 
The enzyme inhibition kinetic behaviors of the best compounds in each library 
were determined to elucidate the nature of inhibition. Finally, antiangiogenic 
potential of selected potent inhibitors was evaluated based on investigating 







As mentioned in the introduction, common approaches to the synthesis of 
pyrazolo[1,5-a][1,3,5] triazines can be categorized according to how the fused 
bicyclic ring system is formed, and the most frequently utilized approach is 
through the annulation of the 1,3,5-triazine ring onto a pyrazole scaffold. 
Based on the dissection analysis for retrosynthesis, the target structure could 
be dissected into a pyrazole scaffold and another fragment in 10 ways as 































































R= O or S
A B C D
F H I
Figure 5. Dissection analysis of 
fused bicyclic pyrazolo[1,5-a][1,3,5] triazines. 
In the selection of the specific method to be adopted for synthesis, practicality 
as well as commercial availability of the starting materials were important 
consideration factors. Since carbonyl group (C=O) or thio-carbonyl group 
(C=S) are good electrophilic centers, the formation of an amide bond or a 
thio-amide bond would be easier than the formation of a normal N-C bond. 
Therefore, approaches A-D were discarded as they involved the formation of a 
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normal N-C bond. In addition, since many 4- and 5-substituted 3-amino 
pyrazoles are either commercially available or can be easily synthesized, plan 
E was eventually adopted as the best approach for synthesizing target 
compounds in this study while approaches F-J were discarded due to 
unavailability of corresponding starting materials. Detailed retrosynthesis plan 
for generating target compounds was then constructed (Figure 6). According 
to this plan, both the 2,4-dione series and the 2-thioxo-4-one series can be 
readily generated through reacting substituted 3-amino pyrazoles with either 
ethoxycarbonyl isocyanate or ethoxycarbonyl isothiocyanate respectively, 
































1,3-Dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones Ethoxycarbonyl isothiocyanate 3-Amino pyrazoles  
 
Figure 6. Retrosynthesis of  
fused bicyclic pyrazolo[1,5-a][1,3,5] triazines. 
For the required aryl substituted 3-amino pyrazoles which are unavailable 




3-amino pyrazoles with an aryl substituent located at position 4 was prepared 
via a three step synthetic scheme169, 170 (Scheme 15). In the first step, 
4-substituted aryl acetonitriles (2) were synthesized by treating 
correspondingly substituted benzylbromide (1) with potassium cyanide (Yield 
56% for 2a; 69% for 2b). Reactions of this step involved a nucleophilic attack 
of the anion CN- towards the carbon atom attached to the highly electron 
withdrawing bromo atom. (Mechanism 1) It was reported by Stacey et al.169 
that this type of reactions would take four hours to complete in refluxing 
methanol. However, in this study, the reactions took only one hour to 
complete in refluxing ethanol, and the yield was comparable to the reported 
result. Therefore, the higher temperature of refluxing ethanol might have sped 
up the reaction rate. In the second step, the synthesized acetonitriles (2) were 
subsequently reacted with dimethoxymethyldimethylamine to give 
3-dimethylamino-2-aryl-acrylonitriles (3) (Yield 80% for 3a, 85% for 3b). 
This step involved a double bond formation between the carbon atom beside 
the CN group in 2 and another carbon atom linked with two leaving OMe 
groups in dimethoxymethyldimethylamine. Electron withdrawing substituents 
on the phenyl ring in 2 would facilitate the deprotonation of the methylene 
adjacent to the CN group in 2 thus improved the nucleophilicity of its carbon 
atom and facilitate the double bond formation. (Mechanism 2) Therefore, 
intermediates with electron withdrawing substituents such as iodo and 
pentafluorosulfur on the phenyl ring were obtained in yields (80%, 85%) 
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slightly higher than the one without any substituent on the phenyl ring 
(reported yield 75% by Velankar et al.170). Finally, the target 4-aryl-3-amino 
pyrazoles (4) were obtained via a nucleophilic reaction between hydrazine and 
the corresponding acrylonitriles (Yield 29% for 4a, 19% for 4b). (Mechanism 
3) According to TLC results, in this step, a byproduct which was more 
hydrophobic than 3 was formed together with the target amine thus this might 
have led to the lower yields. As target amines were not acquired in large 
amounts, no further efforts were put in for optimization of the reaction 





















Scheme 15. Synthesis of 4-aryl-1H-pyrazol-3-ylamines. Reagents and 
conditions: (a) KCN, ethanol, reflux, yields 56% (2a) and 69% (2b); (b) 
dimethoxymethyldimethylamine, DMF, reflux, yields 80% (3a) and 85% (3b); 



































Mechanism 3. Synthesis of 4-aryl-3-amino pyrazoles. 
5-Phenyl-1H-pyrazol-3-ylamine (7) was prepared by a two-step synthetic 
scheme171, 172 (Scheme 16). 3-Oxo-3-phenylpropionitrile (6) was first 
synthesized by treating 2-bromo-1-phenylethanone (5) with potassium cyanide 
(Yield 76%). In this step, the anion CN- acted as a nucleophilic agent which 
attacked the highly electrophilic alfa carbon atom adjacent to Br in 5, and 6 
was formed as Br left the molecule. (Mechanism 4) Based on the TLC results, 
this reaction went smoothly and was complete within 1h shorter than the time 
3h as reported by Lida et al.171) with a yield comparable to the reported yield 
in the literature. Target amine 7 was then generated by a nucleophilic reaction 
between the hydrazine and the synthesized 3-Oxo-3-phenylpropionitrile with a 
yield of 16%. (Mechanism 5) According to TLC, this reaction was completed 
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after 1h, which was indeed much shorter than the time 6-8h reported by 
Krishna et al.172 under similar reaction conditions. Albeit the yield was low, 
the amount obtained was enough for further synthesis of target compounds. 
Therefore, no further optimization of the reaction conditions was conducted. 









Scheme 16. Synthesis of 5-Phenyl-1H-pyrazol-3-ylamine. Reagents and 

























 Mechanism 5. Synthesis of 5-Phenyl-1H-pyrazol-3-ylamine. 
Target compounds 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones (10) 
and (13) were synthesized via a two-step synthetic scheme168 as presented in 
scheme 17. In the first step, the corresponding amines 7, 8, and 11 were 
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reacted separately with ethoxycarbonyl isocyanate at room temperature in 
anhydrous DMF to give N-ethoxycarbonyl-N’-(pyrazol-3-yl) ureas (9) and (12) 
in good yields (Yields 41%-94% for 9a-m, Yields 40%-85% for 12a-o). This 
type of nucleophilic reactions were originally reported by Capuano et al.168, 
the strongly electrophilic isocyanate moiety ensured high yields of this type of 
reactions. (Mechanism 6) Theoretically, the endocyclic nitrogen could also 
perform a nucleophilic attack towards the isocyanate moiety. However, there 
was no peak of the corresponding aromatic amine group on 1HNMR spectrum 
of intermediates, thus the isocyanate moiety should be attacked by exocyclic 
nitrogen exclusively. However, the solvent system they chose was diethyl 
ether, which was not good for dissolving amines and might have affected the 
rates of reactions. In this study, anhydrous DMF was selected instead as the 
solvent system for this step, in which different amines could readily dissolve. 
It was found that all the intermediates were generated in good yields by 
changing the solvent. Target compounds were then generated in a second step 
reaction which was intrinsically an intramolecular ring annulation reaction 
(Yields 41%-91% for 10a-10m, Yields 49%-92% for 13a-13o, Table 3 and 
Table 4). (Mechanism 7) The original ring annulation reaction reported by 
Capuano et al.168 was carried out through refluxing intermediates in pyridine, 
which required a high temperature (115oC). In this study, it was found that 
ring annulation could be fullfilled at a lower temperature by refluxing 
intermediates in ethanol instead. The use of catalytic sodium ethoxide was 
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indispensable, and it took less than 1h for completing the reaction that 


























































































































Scheme 17. Synthesis of 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones. 
Reagents and conditions: (a) ethoxycarbonyl isocyanate, DMF, rt, yields 
41%-94% (9a-m) and 40%-85% (12a-o); (b) EtONa, ethanol, reflux, yields 





































































X = O or S
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10b Me 55 10i  83 
10c 
 






73 10k OMe  78 
10e F 80 10l OEt  
55 
10f Cl 64 10m  89 






















Cpd R Yield (%) Cpd R Yield (%) 
13a Cl 53 13i Cl 57 
13b Br 66 13j Br  49 






13d COOEt 54 13l  87 
13e CH3 51 13m  
74 
13f CN 75 13n OMe
 
75 
13g  54 13o 
OEt
 92 










Target compounds1,3-dihydropyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones 15 
and 17 were synthesized similarly by a two-step synthetic scheme as 
illustrated in scheme 18.168 The corresponding amines 4, 7, 8, and 11 were 
reacted with ethoxycarbonyl isothiocyanate instead at room temperature in 
anhydrous DMF to give N-ethoxycarbonyl-N’-(pyrazol-3-yl)thioureas 14 and 
16 in good yields (Yields 82%-98% for 14a-m, Yields 64%-95% 16a-r). 
Compared to the similar reaction between amines and ethoxycarbonyl 
isocyanate, it was found that the reactions between amines and ethoxycarbonyl 
isothiocyanate took shorter time to complete and gave higher yields. This 
could be attributed to the presence of a stronger electrophilic center 
isothiocyanate in the reactant. Subsequently, intramolecular ring annulation 
reactions similar to the second step in the synthesis of 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones were carried out under 
the same conditions to produce the eventual target compounds of 15 and 17 
(Yields 32%-89% for 15a-m, Yields 43%-94% for 17a-r, Table 5 and Table 
6). Unlike the first step, yields in the second step were similar between 
syntheses of these two series, since both involved the nucleophilic attack of 
the ester carbonyl group in the intermediates by the nitrogen atom located at 












































































4a   R=4-iodo-phenyl























































Scheme 18. Synthesis of 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4 
-ones. Reagents and conditions: (a) ethoxycarbonyl isothiocyanate, DMF, rt, 
yields 82%-98% (14a-m) and 64%-95% (16a-r); (b) EtONa, ethanol, reflux, 
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15b Me 79 15i  81 
15c 
 






32 15k OMe  58 
15e F 89 15l 
OEt
 75 
15f Cl 80 15m  69 


















Cpd R Yield (%) Cpd R Yield (%) 
17a Cl 45 17j Br  81 






17c I 60 17l  94 
17d COOEt 87 17m 
 
94 
17e CH3 47 17n OMe  
85 
17f CN 70 17o OEt
 
91 
17g  60 17p 
NO2  
81 




17i Cl 90 17r 
SF5  
43 
Among the 59 target compounds synthesized; compounds 10a168, 10f173, 10i173, 
10k173, 10m174, 13g143, 15a168, 15m174, 17e148 and 17g175 have been previously 
reported; however, full characterization of these compounds were not 
disclosed and their TP inhibitory activities were never investigated. The rest of 
the 49 target compounds, which have not hitherto been reported in literature, 
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were synthesized and fully characterized by 1H, 13C NMR and mass 
spectrometry. Their purity was also determined by reverse phase HPLC and 
was found to be >95% pure. Thus the target compounds were pure enough for 
biological evaluation. 
2.2 Thymidine phosphorylase inhibitory activity 
All the 1,3-dihydropyrazolo[1,5-a][1,3,5]triazin-2,4-diones (10 and 13) and 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones (15 and 17) were 
evaluated for inhibitory activity using a modified TP bioassay which was a 
continuous UV spectrophotometric enzyme assay32. Since human TP is not 
commercially available, the bioassay used commercially available (Sigma, 
T-2807) recombinant E.coli TP (Enzyme Commission (EC) Number 2.4.2.4, 
expressed in Escherichia coli) as the enzyme and thymidine as the substrate.  
It has been reported that KIN59 showed comparable IC50 values against 
human TP (67µM) and E.coli TP (44µM),115 thus there should be a significant 
homology between human TP and E.coli. TP. In the bioassay, the rate of 
decrease in absorbance monitored at 290nm was taken to be the rate of the 
enzymatic activity. A comparison of the rate of enzymatic reaction in the 
absence and presence of an inhibitor or test compound would give the relative 
extent of enzyme inhibition. Triplicate experiments were conducted to obtain 
the IC50 values of the target compounds. 
First, compounds 10a-m, 13a-o, 15a-m and 17a-o were screened at 
concentration of 50µM for their inhibitory effects against the enzymatic 
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activity. The screening results, expressed as percent inhibition, showed that 
none of the 1,3-dihydropyrazolo[1,5-a][1,3,5]triazin-2,4-diones (10 and 13) 
exhibited more than 50% inhibition at the concentration of 50µM , thus these 
two series were considered not active against TP. However, 23 out of the 28 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones (15 and 17) were 
found to exhibit a range of 50%-100% inhibition at the concentration of 50µM. 
Therefore, this screening experiment suggested that the isosteric replacement 
of the oxygen atom with a sulfur atom at position 2 of the 
pyrazolo[1,5-a][1,3,5]triazine scaffold was very important for the TP 
inhibitory activity. This result was indeed unexpected as it was reported that 
the homophthalimide moiety was supposed to be the essential pharmacophoric 
element. 
To further investigate the structure and TP inhibitory activity relationship of 
the 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones (15 and 17), the 
IC50 values for TP inhibition of  all the compounds in this series were 
subsequently determined. The two libraries of 28 compounds (15a-m, 17a-o) 
exhibited IC50 values ranging from above 100µM to 0.24µM, with 9 out of the 
28 compounds having IC50 values below 10µM (Table 7 and Table 8).  
Depending on the substituents at position 7 and position 8, the inhibitory 
activity of the pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-2ones can vary 
significantly. In comparison, compound 15a, which did not possess any 
substituent at either position 7 or position 8, was found to be about half as 
79 
 
active as the reference compound 7DX. However, with the introduction of 
certain substituents on 15a at either 7 or 8 position, the inhibitory activity was 
found to be better than 7DX with respect to IC50 values.  
In particular, placing a phenyl ring at either position 7 or 8 appeared to 
enhance the TP inhibition. For instance, based on a comparison between 
compounds 15a & 15m, 15b & 15i, 15c & 15j and 15d & 15h, the results 
showed that the inclusion of a phenyl ring had improved the TP inhibition by 
1.5, 4.1, 4.4 and 3.3 times respectively. A similar phenyl effect was also 
observed for compounds 17a & 17i, 17b & 17j and 17e & 17l. The changes in 
TP inhibition in these cases were even greater; registering an enhancement in 
TP inhibition of 51.1, 70.5 and 51.3 times respectively. Therefore, it is very 
clear from the results that the presence of the phenyl ring is important for the 
inhibitory activity of this type of compounds, and it seems to suggest that there 
is a potential hydrophobic interaction site close to positions 7 and 8. Based on 
the comparison above, it is hypothesized that position 8 was possibly closer to 
the hydrophobic site.  
In addition to the requirement of a phenyl ring at position 8, the substituents 
on the para position of this phenyl ring also appeared to be an important 
contributory factor to the inhibitory activity. The fact that inhibitory activity of 
17n < 17o < 17l suggested that increasing the hydrophobicity of substituents 
on the phenyl ring would improve the potency. This is consistent with the 
Craig plot (Figure 7) where the methoxy group (OCH3), the ethoxy group 
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(OCH2CH3), and the methyl group (CH3) are known to possess similar 
electron donating properties while the hydrophobicity of methoxy group < 
ethoxy group < methyl group. However, such requirement for increase in 
hydrophobicity appeared to have a limit. The fact that 17m was about 3.3 
times less active than 17l demonstrated that when the bulkiness got too large, 
the inhibitory activity would not increase accordingly. Besides hydrophobic 
properties, the effects of electron withdrawing properties on the activity were 
also investigated by synthesizing compound 17p and comparing it with 
compound 17h. The fact that 17p was 18.1 times more potent than 17h 
suggested that greater electron withdrawing effect would lead to more active 
compounds since the nitro group (NO2) and the fluoro group (F) possess 
similar hydrophobicity constant while the electron withdrawing property of 
the nitro group was much stronger than that of the fluoro group (Figure 7, 
πΝΟ2 = 0.24 and πF = 0.15, σΝΟ2 = 0.778 and σF = 0.062176).Therefore, it could 
be deduced that the more hydrophobic and electron withdrawing groups 
inserted on the para position of the phenyl ring, the compounds would become 
more potent. This conclusion was consistent with the observation that potency 
of 17k > 17i, 17j > 17h > 17g.  
Since the above SAR results appeared to suggest that substituents located in 
the top right hand quadrant of the Craig plot (+σ, +π) (Figure 7) would give 
good TP inhibitory activity, two more compounds bearing the iodo group (I) 
and the pentafluorosulfur group (SF5) at the para position of the phenyl ring 
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(17q and 17r respectively) were synthesized as per the method described 
above to develop more potent TP inhibitors and validate the structural 
requirements for TP inhibition. It was found that 17q inhibited TP at an IC50 
value of 0.21µM while 17r exhibited 50% inhibition at a concentration of 
0.04µM. Therefore, 17r was found to be around 800 times more potent than 
7DX under the evaluating conditions used for the bioassay. The Ki value of 
17r was also calculated as 69nM by a reported method.177 
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15b Me 79.4±8.2 15i  19.3±2.3 
15c 
 






32.6±5.7 15k OMe  28.4±2.0 
15e F 41.7±0.5 15l 
OEt
 6.1±0.7 
15f Cl 33.5±3.8 15m  46.2±1.8 
15g Br  34.9±6.3 7DX  32.2±5.1 
aValues are mean, n=3. 
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Cpd R IC50a(µM) Cpd R IC50a(µM) 
17a Cl 27.6±1.3 17j Br  0.63±0.12 






17c I 20.8±2.7 17l  1.7±0.1 
17d COOEt >100 17m 
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17e CH3 87.3±6.0 17n OMe  
39.7±9.9 
17f CN >100 17o OEt
 
15.5±0.3 
17g  26.3±2.0 17p 
NO2  
0.58±0.02 




17i Cl 0.54±0.04 17r 
SF5  
0.040±0.005 
7DX  32.2±5.1    




Figure 7. Craig plot for para-substituents.176 
2.3 Enzyme inhibition kinetic studies 
With the identification of 15l and 17r as the most active compounds in the 
respective libraries, it was of interest to determine whether 15l and 17r would 
inhibit TP in any way that would be different from 7DX. Further investigation 
was thus carried out to determine the enzyme inhibition kinetics of 15l and 
17r using a similar method as reported in the literature.104   TPI and 7DX 
were found to be competitive inhibitors in this method, and it was consistent 
with reported results.20, 116 
Four different concentrations of 15l (0, 1µM, 5µM, 10µM) and 17r (0, 
0.01µM, 0.1µM, and 0.2µM) were chosen for performing the enzyme 
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inhibition kinetic study. For 15l, it was demonstrated on the Lineweaver-Burk 
plot that the lines generated at different concentrations had different gradients 
and they converged at a point on the negative side of the x axis (Figure 8a). 
This observation pointed to the fact that 15l exhibited non-competitive 
inhibition kinetics on TP with respect to thymidine being the substrate. This 
was further supported by the fact that the Vmax values decreased from 7.8µM 
/min to 2.7µM /min while the Km values did not change significantly as the 
inhibitor concentration increased from 0 to 10µM. (Km and Vmax values were 
calculated from the Eadie-Hofstee plots) This charateristic Vmax and Km values 
of the enzyme is typical in the presence of an inhibitor that exhibits 
non-competitive inhibition kinetics. For 17r, a similar Lineweaver-Burk plot 
was generated which demonstrated that 17r was also a non-competitive 
inhibitor of TP (Figure 8b). In this case, the Vmax values decreased from 
9.9µM /min to 2.6µM /min while the Km values did not change significantly as 
concentrations of 17r increased from 0 to 0.2µM. 
In summary, both 15l and 17r were found to be non-competitive inhibitors, 
and they might interact with TP in a way different from 7DX, which was 







Figure 8. Lineweaver-Burk plots of thymidine phosphorylase inhibition by 
15l (a) and 17r (b) prepared at different concentrations. All data points are 
means of three experiments. 
2.4 Antiangiogenic potential studies 
As mentioned in the introduction, TP inhibitors were proven to possess 
antiangiogenesis properties, thus it was of interest to investigate the 
antiangiogenic potential of newly synthesized TP inhibitors in this project. 















































factor MMP-9, it was hypothesized that the enzymatic activity of TP may play 
a role in this process and TP inhibitors would be able to suppress the MMP-9 
secretion via inhibiting TP. Therefore, a total of 11 compounds in this series 
with IC50 values less than 10µM against TP were selected for further 
biological investigation of their effects on the MMP-9 secretion in cancer cells 
by the gelatin zymography assay so as to evaluate their antiangiogenic 
potential. As described previously in the introduction, TP was correlated with 
higher levels of MMP-9 in the breast cancer. Therefore, a TP over-expressed 
breast cancer cell line MDA-MB-231 was chosen for conducting the gelatin 
zymography assay. In order to ensure the potential suppressive effects on 
MMP-9 secretion by the selected compounds were not the consequence of 
their severe cytotoxic effects, the antiproliferative activity of these compounds 
against the MDA-MB-231 cell line was evaluated first by the MTT assay.  
2.4.1 Cytotoxicity study of selected TP inhibitors against MDA-MB-231 
Although in the gelatin zymography assay, the total protein amount in each 
sample could be adjusted to the same level via performing the protein 
quantification thus eliminating the relative errors caused by the difference of 
cell number; severe cytotoxic effects would still impair the reliability of this 
assay. Therefore, cytotoxic effects of these compounds against the 
MDA-MB-231 cell line were evaluated first by the MTT assay to ensure that 
the concentration used in the following gelatin zymography assay would not 
cause severe antiproliferative effects. All selected compounds were screened 
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at the concentration of 100µM. As shown in Table 9, all selected compounds, 
except 15j which exhibited cell viability slightly lower than 50% (48%), 
exhibited cell viability above 50% at the concentration of 100µM. Therefore, 
from these observations, these selected compounds could be considered not to 
cause severe antiproliferative effects at the concentration of 100µM. 100µM is 
deem to be a relatively high concentration, and if cell viability was not 
adversely affected at the concentration of 100µM, it would mean that at 



























































17r H SF5  
64±4 







2.4.2 Inhibition of MMP-9 secretion in MDA-MB-231 by selected TP 
inhibitors  
The gelatin zymography assay was conducted to evaluate suppressive effects 
of selected compounds on MMP-9 secretion. An initial screen at 100µM was 
carried out for eleven selected 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones together with two 
reference compounds TPI and 7DX (According to previous work done in our 
lab, these two reference compounds showed more than 80% cell viability at 
the concentration of 200µM in the MTT assay). The cells were treated with 
100µM of the test compounds along with 80nM PMA for 24h. The 
conditioned medium from the cell culture was collected and the secretion of 
MMP-9 (band corresponded to the MW of 92 kDa) was analyzed. As shown in 
Figure 9, a significant change in band intensity compared to the control (which 
was treated with DMSO instead of testing compounds) was only detected for 
compound 17q and 17r. Therefore, only 17q and 17r could significantly 
reduce the secretion of MMP-9 in the MDA-MB-231 cell line at the 
concentration of 100µM. Interestingly, TPI and 7DX did not suppress the 
secretion of MMP-9. Therefore, albeit literature reported that over-expression 
of TP could stimulate the MMP-9 secretion61-63, indeed it might be TP itself 
instead of its enzymatic activity that caused such effects. (Similar cases were 
found in reumatoid arthritis86 as described in the introduction.) Therefore, 
suppression of MMP-9 secretion by 17q and 17r could not be attributed to 
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their corresponding TP inhibitory activity. It might be caused by other unclear 
mechanisms, and one possible explanation could be such compounds might 





Figure 9. Gelatine zymography screening of TPI, 7DX and selected 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones at the 
concentrations of 100µM. 
Further concentraion dependent studies (Figure 10) as well as densitometric 
analysis of the band intensity for the corresponding concentrations (100µM, 
50µM, 25µM, and 10µM) of 17q and 17r (Figure 11) showed that their 
suppressive effects on the MMP-9 secretion were concentration dependent. 
Both compounds could still exhibit above 70% inhibition of the MMP-9 
secretion at the concentration of 50µM. In particular, 17r was even able to 
show above 40% suppression of MMP-9 secretion at the concentration of 
25µM. However, such inhibitory activity against the secretion of MMP-9 
would disappear as the concentration dropped down to 10µM thus 17r still 






        Control  TPI   7DX    15h     15j     15l 





Figure 10. Concentration dependent studies for 17q and 17r at the 
concentrations of 100µM, 50µM, 25µM, and 10µM. 
 
 
Figure 11. Densitometric analysis of band intensities of corresponding 
concentrations for 17q and 17r, normalized to respective controls. 
Experiments carried out at least duplicate. 
2.5 Summary 
The selected synthetic strategy of annulating the 1,3,5-triazine ring onto a 
pyrazole scaffold was proven to be quite an efficient way to synthesize the 
pyrazolo[1,5-a][1,3,5]triazines as designed. The two series of 2,4-diones and 
2-thioxo-4-ones were synthesized with ease and all the final target compounds 
were prepared in generally good yields. The hypothesis that 10a might possess 
TP inhibitory activity comparable to 7DX was not supported by the 
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However, it was found that many substituted 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones were more active 
than 7DX. Therefore, the isosteric replacement of the oxygen atom with a 
sulfur atom at position 2 of the pyrazolo[1,5-a][1,3,5]triazine scaffold was 
found to be essential for the TP inhibitory activity of this type of compounds; 
and proper substitution on position 7 or 8 of this scaffold would enhance the 
inhibitory activity. In particular, the insertion of a phenyl ring at either 
position 7 or 8 was enough to enhance the TP inhibition, especially when the 
aryl group was located at position 8; the inhibitory activity was found to 
increase by a larger extent. Lastly, it was also found that when substituents 
which had a larger hydrophobic constant and more positive Hammett constant 
(ie. more electron withdrawing) were introduced at the para position of the 
attached phenyl ring, the IC50 values would decrease further. This was 
validated by compounds 17q and 17r where their inhibitory activities were 
around 150 times and 800 times more potent than 7DX respectively. Further 
kinetic studies revealed that the inhibition type of most active compounds 
from each library (namely 15l and 17r) was non-competitive, thus different 
from their lead compound 7DX. To explore antiangiogenic potential of this 
type of compounds, a total of 11 compounds with IC50 values less than 10µM 
against TP were then selected for evaluating their suppressive effects on the 
MMP-9 secretion in the MDA-MB-231 cell line by the gelatin zymography 
assay. It was found that only 17q and 17r inhibited the secretion of MMP-9 at 
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the concentration of 100µM, but both became not active once the 
concentration dropped down to 10µM. However, since both reference 
compounds TPI and 7DX were not active, it might be TP itself instead of its 
enzymatic activity that stimulated the MMP-9 secretion in cancer cells, and 
the observed suppressive effects of these two compounds could be due to 










































Since TPI is a competitive inhibitor while KIN59 is a non-competitive 
inhibitor, it is believed that the pyrimidine moiety could be accommodated in 
the substrate binding site while the purine moiety without the 
homophthalimide structure could interact with the enzyme at an allosteric site. 
Therefore, it is hypothesized that compounds consisting of both the pyrimidine 
moiety and the purine moiety without the homophthalimide structure would 
give rise to new TP inhibitors. In order to test this hypothesis, a series of 
5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines was generated and 
evaluated against TP for inhibiting activity. 
In the design of these new compounds, choosing the right spacer to link both 
the uracil scaffold and the pyrazolo[1,5-a][1,3,5]triazine scaffold is critical to 
ensure that inhibitory activity against the enzyme is retained. Since Yano et al. 
has reported that S-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethyl) 
thiourea hydrochloride (Figure 12) inhibited TP at an IC50 value of 0.35µM109, 
this proposal hypothesized that a methylthio moiety at position 6 of the uracil 
ring may be able to allow the uracil ring in these new compounds to interact 
appropriately with the enzyme. This prompted the use of the methylthio 
moiety as a flexible linker to connect the pyrazolo[1,5-a][1,3,5]traizine and 
uracil scaffolds together. Therefore, the  target compounds were finally 
decided to be 2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio) 












































Figure 12. Design of the linker. 
3.1 Chemistry  
According to the dissection analysis of target compounds, it was found that 
they could be dissected into the uracil scaffold and the 
pyrazolo[1,5-a][1,3,5]triazine scaffold in three ways as shown in the following 































A B C  
Figure 13. Dissection analysis of  
5-chlorouracil linked pyrazolo[1,5-a][1,3,5]triazines. 
Since a lot of 1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones were 
already synthesized for testing the first hypothesis, it would be convenient to 
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adopt plan B as the method for preparing target compounds in this chapter. 
Therefore, the corresponding retrosynthesis plan was devised in which the 
designed target compounds would be generated through coupling reactions 
using 5-chloro-6-chloromethyluracil and 































Figure 14. Retrosynthesis of 
5-chlorouracil linked pyrazolo[1,5-a][1,3,5]triazines. 
The key intermediate 5-chloro-6-chloromethyluracil (22) was prepared via a 
four-step reaction (Scheme 19). In the first step, 6-methyluracil (18) was 
oxidized to uracil-6-carbaldehyde (19) in the presence of selenium oxide. This 
reaction was first reported by Zee-Chen et al.178; and during the synthesis it 
was found that the reaction was completed within 3h instead of the reported 6h. 
However, the yield obtained (35%) was lower than the reported yield (58%), 
probably due to the inefficient extraction of the products from the cake of 
selenium that was formed. In the second step, uracil-6-carbaldehyde (19) was 
reduced with sodium borohydride to generate 6-hydroxymethyluracil (20) A 
yield of 79% was obtained which was close to the result reported by Kalman 
et al.179 (88%) for the same reaction condition. In the third step, the hydroxyl 
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group was subsequently replaced by chlorine via refluxing 20 in an excess of 
neat thionyl chloride to obtain 6-chloromethyluracil (21). A high yield of 95% 
was obtained which was similar to the yield (93%) reported by Robert et al.180. 
Due to the high reactivity of the 6-chloro group in protic solvents, 21 was 
subjected to nuclear chlorination at C-5 of the uracil ring, without futher 
purification, to generate the key intermediate 22. It has been reported that 
N-chlorosuccinimide181 and sulfuryl chloride182 were both suitable reagents for 
nuclear chlorination. In this case, sulfuryl chloride was chosen because higher 
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Scheme 19. Synthesis of 5-chloro-6-chloromethyluracil. Reagents and 
conditions: (a) SeO2, AcOH, reflux, yield 35%; (b) NaBH4, MeOH/H2O, 0°C, 
yield 79%; (c) SOCl2, reflux, yield 95%; (d) SO2Cl2, AcOH, yield 68%. 
Target compounds 23 and 24 were then generated via coupling reactions, in 
refluxing methanol, (Scheme 20) between 5-chloro-6-chloromethyluracil (22) 
and previously synthesized 
1,3-dihydropyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones (15 and 17). This 
coupling reaction has not been reported previously. The presence of sodium 
ethoxide was necessary for this type of reactions since it was needed to 
generate highly nucleophilic anions through abstracting the acidic proton on 
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the pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones. The anionic forms of 
pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones would then react with 
5-chloro-6-chloromethyluracil via a nucleophilic attack to generate the target 
compounds in good yields (Yields 60%-92% for 23a-m, yields 40%-96% for 


























































































































17r  R=4-pentafluorosulfur-phenyl  
 
Scheme 20. Synthesis of 2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-yl 
methylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-ones. Reagents and conditions: 








































Mechanism 8. Synthesis of target compounds. 














Cpd R Yield (%) Cpd R Yield (%) 






23b Me 79 23i  84 
23c 
 






67 23k OMe  88 





85 23m  89 
23g Br
 



















Cpd R Yield (%) Cpd R Yield (%) 
24a Cl 59 24j Br  93 
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24e CH3 59 24n OMe  
80 
24f CN 56 24o OEt
 
94 
24g  84 24p NO2  
89 








None of these target compounds has been reported previously, and all of them 
were systematically characterized by melting points and spectroscopic 
techniques (1H and 13C NMR). In addition, the purity of the compounds was 
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determined by reverse-phase HPLC and was found to be in the range of 95% 
and 100% pure. These purified compounds were used in the bioassay that 
determined the inhibitory activity against TP. 
3.2 Thymidine phosphorylase inhibitory activity 
TP inhibitory activity of the synthesized target compounds was evaluated by 
the same continuous UV spectrophotometric enzyme assay183 as described 
previously. Initially, two compounds (23m and 24g) were tested, and it was 
found that they possessed IC50 values of 13.0µM and 9.7µM respectively. 
Therefore, they were more potent than their corresponding compounds (15m, 
IC50 = 46.2µM and 17g, IC50 = 26.3µM) in the 
1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones series. Other 
analogues were subsequently synthesized and evaluated against TP. Based on 
the results of the in vitro TP bioassay, these compounds (23a-m, 24a-r) 
exhibited TP inhibitory activity with IC50 values ranging from 67.8µM to 
0.36µM (Table 12 and Table 13). TPI was used as the reference compound for 
comparison, its IC50 value under the same evaluating condition was 2.7nM, 
which was consistent with the value reported by Grierson et al. 184(2.5nM). 
From the data, the idea of combining both the uracil scaffold and the 
pyrazolo[1,5-a][1,3,5]triazine scaffold with the methylthio spacer has 
produced new compounds that retained TP inhibitory activity. On closer 
examination of the biological data with the structures of the test compounds, 


































IC50 = 13.0±4.4μMIC50 = 46.2±1.8μM
































Cpd R IC50a(µM) Cpd R IC50a(µM) 
23a H 67.8±4.4 23h 
 
2.1±0.4 
23b Me 55.5±6.8 23i  9.8±2.0 
23c 
 
51.2±6.1 23j  1.5±0.4 
23d 
 
31.0±0.5 23k  11.8±1.9 
23e  22.6±1.9 23l  10.0±1.3 
23f  10.3±2.2 23m  13.0±4.4 
23g  6.2±1.6 TPI  0.0027±0.0001 






























Cpd R IC50a(µM) Cpd R IC50a(µM) 
24a Cl 49.8±1.5 24j Br  1.2±0.3 






24c I 30.8±2.2 24l  7.3±0.6 
24d COOEt 47.2±9.5 24m 
 
1.8±0.1 
24e CH3 35.3±5.4 24n OMe  
21.3±2.1 
24f CN 38.8±5.7 24o OEt
 
12.0±1.0 
24g  9.7±2.4 24p NO2  
3.5±0.3 




24i  2.8±0.6 24r 
SF5  
0.36±0.10 
TPI  0.0027±0.0001    






Compound 23a is the first compound in the library that linked 5-chlororacil to 
pyrazolo[1,5-a][1,3,5]triazine via a methylthio spacer, and it was not 
considered active against TP based on its IC50 value. However, the IC50 values 
improved when 23a was substituted with different groups at positions 7 and 8.  
In particular, it was found that the TP inhibitory activity could be enhanced via 
inserting a phenyl ring at either position 7 or 8. For instance, based on a 
comparison between compounds 23a & 23m, 23b & 23i, 23c & 23j and 23d 
& 23h, the results showed that the inclusion of a phenyl ring had improved the 
TP inhibition by 5.2, 5.7, 34.1 and 14.8 times respectively. A similar phenyl 
effect was also observed for compounds 23a & 24g, 24a & 24i, 24b & 24j and 
24e & 24l. The changes in TP inhibition in these cases were 7.0, 17.8, 33.3 
and 4.8 times respectively. Therefore, it is very clear from the results that the 
presence of the phenyl ring is important for the inhibitory activity of this type 
of compounds, and it seems to suggest that there is a potential hydrophobic 
interaction site close to positions 7 and 8.  
In addition to the requirement of a phenyl ring, the substituents on the para 
position of this phenyl ring also appeared to be an important contributory 
factor to the inhibitory activity. For compounds with a phenyl ring at position 
7, the fact that inhibitory activity of 23i < 23j suggested that increasing the 
hydrophobicity of substituents on the phenyl ring would improve the potency. 
This is consistent with the Craig plot where the methyl group and the 
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tert-butyl group are known to possess similar electron donating properties 
while the hydrophobicity of methyl group < tert-butyl group (Figure 7). The 
same trend was also observed for compounds with substituents located in the 
top right hand quadrant of the Craig plot (+σ, +π): Potency of 23e < 23f < 23g 
< 23h while their corresponding substituents, which were fluoro, chloro, 
bromo, trifluoromethyl respectively, showed an increase in hydrophobicity 
(Figure 7). However, the fact that 23e was less potent than 23m indicated that 
the electron withdrawing property of the substituent might reduce the 
inhibitory activity.  
For compounds with a phenyl ring at position 8, it was also found that the 
inhibitory activity would be improved while increasing the hydrophobicity of 
substituents on the phenyl ring based on the result that potency of methoxy 
substituted compound 24n < ethoxy substituted compound 24o < methyl 
substituted compound 24l < tert-butyl substituted compound 24m and potency 
of fluoro substituted compound 24h < chloro substituted compound 24i < 
bromo substituted compound 24j as well as trifluoromethyl substituted 
compound 24k. However, different from compounds with a phenyl ring at 
position 7, the fact that compound 24m with the more hydrophobic tert-butyl 
group was less potent than bromo substituted compound 24j and 
trifluoromethyl substituted compound 24k suggested that the electron donating 
property of the substituent might reduce the inhibitory activity. This 
conclusion was also supported by the fact that methoxy substituted compound 
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24n was less potent than non-substituted compound 24g, and fluoro 
substituted compound 24h was less potent than nitro substituted compound 
24p. Therefore, for compounds with a phenyl ring at position 8, electron 
withdrawing and hydrophobic substituents on the para position of this phenyl 
ring were preferred. Further synthesized compound 24q and 24r with more 
electron withdrawing and hydrophobic iodo group and pentafluorosulfur group 
showed better activity with IC50 values as low as 0.61µM and 0.36µM 
respectively. The Ki value of the most potent compound in this series 24r was 
also calculated as 0.44µM. 
In summary, the results of the in vitro enzyme assay have provided evidence 
to support the hypothesis that by using TPI and KIN59 as leads, the designed 
target compounds consisting of both pyrimidine and purine moieties linked via 
a methylthio spacer would exhibit TP inhibitory activity. 
3.3 Enzyme inhibition kinetics studies 
With the identification of 23j and 24r as the most active compounds in 
relative libraries, it was of interest to determine whether 23j and 24r would 
interact with TP in any way that would be different from TPI and KIN59. 
Further investigation was thus carried out to determine the enzyme inhibition 
kinetics of 23j and 24r using four different concentrations of the substrate 
thymidine.104   
Four different concentrations of 23j (0, 0.4µM, 1µM, 2µM) and 24r (0, 0.1µM, 
0.5µM, and 2µM) were chosen for performing the enzyme inhibition kinetic 
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study. For 23j, it was evident from the Lineweaver-Burk plot that the lines 
generated at different concentrations had different gradients and they 
converged at a point neither on the y axis nor on the x axis (Figure 15a). This 
observation pointed to the fact that 23j exhibited mixed-type inhibition 
kinetics on TP with respect to thymidine being the substrate. This was further 
supported by the fact that the Vmax values decreased from 8µM /min to 3.5µM 
/min, while the Km values increased from 692µM to 1368µM as the inhibitor 
concentration increased from 0 to 2µM. (Km and Vmax values are calculated 
from the Eadie-Hofstee plots) This behaviour of the change in Vmax and Km 
values of the enzyme is typical of an inhibitor that exhibits mixed inhibition 
kinetics. For 24r, a similar Lineweaver-Burk plot was generated which 
demonstrated that 24r was also a mixed-type inhibitor of TP (Figure 15b). In 
this case, the Vmax values decreased from 8.9µM /min to 5.9µM /min while the 
Km values increased from 770µM to 2829µM as the inhibitor concentration 
increased from 0 to 2µM. 
In summary, different from TPI and KIN59, both 23j and 24r were found to 
be mixed-type inhibitors, and it was possible that they might interact with TP 











Figure 15. Lineweaver-Burk plots of thymidine phosphorylase inhibition by 
compound 23j (a) and 24r (b) prepared at different concentrations. All data 
















































3.4 Antiangiogenic potential studies 
3.4.1 Cytotoxic studies of selected TP inhibitors against MDA-MB-231 
A total of 15 compounds in this series with IC50 values less than 10µM against 
TP were selected for further biological investigation. Their effect on MMP-9 
secretion in breast cancer cell line MDA-MB-231 was studied using the 
gelatin zymography assay. The ability to inhibit MMP-9 secretion is an 
indication of their antiangiogenic potential. Again as in chapter two, cytotoxic 
effect of these compounds against the MDA-MB-231 cell line was evaluated 
first using the MTT assay. This is to ensure that the concentration used in the 
following gelatin zymography assay would not cause severe antiproliferative 
effect. All selected compounds were screened at the concentration of 100µM. 
As shown in the Table 14, all selected compounds, exhibited cell viability 
above 50% at the concentration of 100µM. Therefore, from these observations, 
these selected compounds could be considered not to cause severe 
antiproliferative effect at the concentration of 100µM. Therefore 100µM was 







































































24r H SF5  
67±6 
aValues are mean, n=3. 
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3.4.2 Inhibition of MMP-9 secretion in MDA-MB-231 by selected TP 
inhibitors 
In the gelatin zymography assay, an initial screen at 100µM was carried out 
for all fifteen selected compounds. It was found that a total of 7 compounds in 
this series, namely 23g, 23h, 23j, 24i, 24j, 24m and 24r, had significantly 
reduced the secretion of MMP-9 in the MDA-MB-231 cell line at the 
concentration of 100µM (Figure 16). Compared with the screening result for 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones, it was found that 
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-a][1
,3,5]triazin-4(3H)-ones were more active. Therefore, it was suggested that the 
co-existence of a uracil scaffold together with a pyrazolo[1,5-a][1,3,5]triazine 
scaffold might be better than possessing a pyrazolo[1,5-a][1,3,5]triazine 





Figure 16. Gelatine zymography screening of selected 
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio) 






    Control  23g  23h   23i    23j   23l   24g  24h  24i 
     Control  24j   24q   24k    24l   24m  24r   24p 
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Selected compounds from 23 and 24 were further analyzed, using more 
quantitative approach. Concentration dependent studies (Figure 17) as well as 
densitometric analysis of the band intensity for the corresponding 
concentrations (100µM, 50µM, 25µM, and 10µM) of 23g, 23h and 23j 
(Figure 18) were conducted. The results revealed that all three compounds 
could still exhibit more than 80% inhibition of the MMP-9 secretion at the 
concentration of 50µM. In particular, 23j was even able to show above 50% 
suppression of MMP-9 secretion at the concentration of 25µM. However, like 
previously described 17q and 17r, such inhibitory activity against the 
secretion of MMP-9 disappeared as the concentration dropped down to 10µM 









Figure 17. Concentration dependent studies for 23g, 23h and 23j at the 
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Figure 18. Densitometric analysis of band intensities of corresponding 
concentrations for 23g, 23h and 23j, normalized to respective controls. 
Experiments carried out at least duplicate. 
 
For 24i, 24j, 24m and 24r, concentration dependent studies (Figure 19) as 
well as the densitometric analysis (Figure 20) revealed that all these 
compounds were still able to inhibit more than 40% secretion of MMP-9 even 
at the concentration as low as 25µM. However, such suppressive effects again 
disappeared once the concentration dropped down to 10µM, and they also 










































Figure 19. Concentration dependent studies for 24i, 24j, 24m and 24r at 
the concentrations of 100µM, 50µM, 25µM, and 10µM. 
 
 
Figure 20. Densitometric analysis of band intensities of corresponding 
concentrations for 24i, 24j, 24m and 24r, normalized to respective controls. 
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Control  100  50   25   10   100   50   25   10 
                    24r                 
Control   100    50     25     10    
                24i                 




The designed synthetic scheme was successful in linking 22 to 15 and 17 thus 
generating a total of 31 compounds (23a-m, 24a-r) that, with appropriate 
substituents, exhibited different extent of inhibition against TP. It was found 
that the insertion of a phenyl ring at position 7 or 8 of the 
pyrazolo[1,5-a][1,3,5]triazine scaffold could significantly improve the 
inhibitory activity. Moreover, the nature of the substituents on the phenyl ring 
also affected the potency. In particular, for the phenyl ring located at position 
7, substituents which had a larger hydrophobic constant and more negative 
Hammett constant would be better while for the phenyl ring located at position 
8, substituents which had a larger hydrophobic constant and more positive 
Hammett constant were preferred. The most active compound 24r 
demonstrated an IC50 value as low as 0.36µM.  Therefore, the hypothesis that 
compounds consisting of both the pyrimidine moiety and the purine moiety 
would also possess TP inhibitory activity was proven to be true. Further 
kinetic studies revealed that the most active compounds (namely 23j and 24r) 
from each library exhibited mixed-type of enzyme inhibition kinetics thus 
suggesting the possibility of their binding at two sites on the enzyme. The 
flexible methylthio linker was found to be able to retain interaction of the 
target compounds with TP at both sites. To explore antiangiogenic potential of 
this type of compounds, a total of 15 compounds with IC50 values less than 
10µM against TP were subsequently subjected to the gelatin zymography 
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assay. It was found that 7 out of 15 selected compounds exhibited suppressive 
effect on MMP-9 secretion at the screening concentration of 100µM, but the 
inhibition diminished significantly once the concentration dropped down to 
10µM. Compared with the screening results of selected 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones, the 
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-a][1
,3,5]triazin-4(3H)-ones series turned out to be more active indicating the 









































This project has focused on developing new TP inhibitors based on the 
pyrazolo[1,5-a][1,3,5]triazine scaffold. The reason for the selection of this 
analogue of purine as a template to develop new TP inhibitors was derived 
from literature reviews on previous works. It was found from these reviews 
that currently the most potent TP inhibitors are restricted to the pyrimidine 
scaffold. Albeit there are some purine based inhibitors such as 7DX and 
KIN59, their potency against TP is still weak thus there is room for further 
improvement. In this study, two hypotheses were identified. The first 
hypothesis was that fused bicyclic pyrazolo[1,5-a][1,3,5]triazines  might  
possess TP inhibitory activity, and the second one was that compounds 
consisting of a pyrimidine moiety together with a purine moiety without the 
homophthalimide structure would also inhibit TP 
To test the first hypothesis, a total of 59 fused bicyclic 
pyrazolo[1,5-a][1,3,5]triazines were successfully synthesized. The chosen 
synthetic approach derived from retrosynthesis was proven to be an efficient 
way to achieve synthetic goals. The target compounds were synthesized 
through reacting substituted 3-amino pyrazoles with either ethoxycarbonyl 
isocyanate or ethoxycarbonyl isothiocyanate. To test the second hypothesis, a 
total of 31 5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines, designed as 
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-a][1
,3,5]triazin-4(3H)-ones in this study, were synthesized. The newly developed 
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coupling reaction using 5-chloro-6-chloromethyluracil and the corresponding 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones as starting materials 
was also demonstrated as an efficient method to generate the target 
compounds. 
Based on the results of the enzyme tests, the first hypothesis was proven to be 
partially true. In particular, it was found that non-substituted 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-dione was obviously weaker 
than 7DX, indicating that the pyrazolo[1,5-a][1,3,5]triazine scaffold itself was 
not superior to the deazapurine scaffold with respect to the inhibitory activity 
against TP. However, many substituted 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones showed TP 
inhibitory activity. SAR studies (Figure 21) revealed that potency of the 
pyrazolo[1,5-a][1,3,5]triazine scaffold could be enhanced through proper 
structural modifications. These modifications included isosteric replacement 
of the oxygen atom at position 2 with a sulfur atom as well as attaching an aryl 
substituent to position 8. The best compound 17r (Figure 22) exhibited an IC50 
value as low as 40nM. Therefore, it is much more potent than the lead 
































17r IC50 = 40nM  
Figure 22. The most potent compound in the 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one series. 
The second hypothesis was proven to be true as the results of enzyme tests 
showed that target compounds exhibited TP inhibitory activity. In particular, it 
was found that analogues with aryl substituents at either position 7 or position 
8 were more potent than others. SAR studies (Figure 23) were subsequently 
conducted. For the aryl substituent attached to position 7, a hydrophobic and 
electron donating group located at the para position of the phenyl ring was 
preferred. For the aryl substituent attached to position 8, a hydrophobic and 
electron withdrawing substituent located at the para position of the phenyl 
ring was better. The most potent compound in this series was compound 24r 
An aryl substituent with a 
hydrophobic and electron donating 
group on the para position of the 
phenyl ring is preferred. 
An aryl substituent with a hydrophobic 
and electron withdrawing group on the 
para position of the phenyl ring is 
preferred. 
 




(Figure 24) which showed an IC50 value of 0.36µM. In addition, it was found 
that the SAR of 5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines was 
similar to the SAR of fused bicyclic pyrazolo[1,5-a][1,3,5]triazines, which 
suggested that the pyrazolo[1,5-a][1,3,5]triazine scaffold in these two types of 




























24r IC50 = 0.36μM  
Figure 24. The most potent compound in the 
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio) 
pyrazolo[1,5-a][1,3,5]triazin-4(3H)-ones. 
Enzyme inhibition kinetic studies revealed that the most potent compound 
among fused bicyclic pyrazolo[1,5-a][1,3,5]triazines (17r) was a 
An aryl substituent with a 
hydrophobic and electron donating 
group on the para position of the 
phenyl ring is preferred. 
An aryl substituent with a hydrophobic 
and electron withdrawing group on the 





non-competitive inhibitor, which suggested that its binding site should be an 
allosteric site. This finding indicated that these fused bicyclic 
pyrazolo[1,5-a][1,3,5]triazines might not interact with the substrate binding 
site of TP, thus explained the observation that the 2,4-dione series was less 
active than the 2-thioxo-4-one series. Besides, the most potent compounds 
among 5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines (24r) was found 
to be a mixed type inhibitor in the enzyme kinetic studies. Therefore, it might 
interact with TP at both the substrate binding site and the allosteric site.  
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-a] 
[1,3,5]triazin-4(3H)-ones were generated from the corresponding 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones, thus it was of 
interest to do a comparison between these two series of TP inhibitors to 
investigate the effect of introducing a uracil ring on TP inhibitory activity .   
As the SAR of 5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines was 
similar to the SAR of fused bicyclic pyrazolo[1,5-a][1,3,5]triazines, TP 
inhibitory activity of 5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines 
should be predominated by the interaction between the 
pyrazolo[1,5-a][1,3,5]triazine scaffold and the allosteric site. When 
5-chlorouracil was chemically coupled to the pyrazolo[1,5-a][1,3,5]triazine 
scaffold, the 5-chlorouracil moiety would be expected to affect the binding 
affinity of the pyrazolo[1,5-a][1,3,5]triazine scaffold at the allosteric site. On 
the other hand, the presence of the 5-chlorouracil moiety would provide 
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binding possibility at the substrate binding site. Therefore, the resultant 
biological effect of introducing the 5-chlorouracil moiety would depend on the 
cooperativity between this moiety and the pyrazolo[1,5-a][1,3,5]triazine 
scaffold at the allosteric site, as well as the interaction of 5-chlorouracil at the 
substrate binding site. If the compromise in binding could be compensated by 
the increase of one more binding site, the inhibitory activity would increase 
upon linking with the 5-chlorouracil moiety. If such a compromise could not 
be compensated by the increase of one more binding site, the inhibitory 
activity would decrease upon linking with the 5-chlorouracil moiety.  
Based on the results of comparison (Table 15), it was found that for most 
fused bicyclic compounds with substituents at position 7 (15), linked with 
5-chlorouracil could improve their potency against TP. Therefore, for these 
7-substituted pyrazolo[1,5-a][1,3,5]triazines, the effect of one more binding 
site overcame the effect of less binding affinity at the allosteric site. However, 
for fused bicyclic compounds with substituents at position 8 (17), the results 
of comparison did not follow a trend. In this case, it was found that half 
compounds became less active upon linked with 5-chlorouracil. Close 
examination revealed that seven of the most potent compounds in this library 
with IC50 values around or less than 1µM got their activity decreased after 
coupling. Therefore, for these more potent pyrazolo[1,5-a][1,3,5]triazines, the  
compromise in the interaction between the pyrazolo[1,5-a][1,3,5]triazine 
127 
 
scaffold and the allosteric site could not be compensated by one more binding 
site. 
Table 15. Comparison between two series of TP inhibitors. 
Comparison Relative activitya Comparison Relative activity 
15a vs 23a 1.0 17c vs 24c 0.7  
15b vs 23b 1.4  17e vs 24e 2.5  
15c vs 23c 0.6  17g vs 24g 2.7  
15d vs 23d 1.1  17h vs 24h 1.3  
15e vs 23e 1.8  17i vs 24i 0.2  
15f vs 23f 3.3  17j vs 24j 0.5  
15g vs 23g 5.6  17k vs 24k 0.2 
15h vs 23h 4.7 17l vs 24l 0.2  
15i vs 23i 2.0  17m vs 24m 3.1  
15j vs 23j 4.4  17n vs 24n 1.9  
15k vs 23k 2.4  17o vs 24o 1.3  
15l vs 23l 0.6  17p vs 24p 0.2  
15m vs 23m 3.6  17q vs 24q 0.3  
17a vs 24a 0.6  
  
17r vs 24r 0.1  
17b vs 24b 1.1    
a The relative TP inhibitory activity was calculated by taking the ratio of the 
IC50 value of the pyrazolo[1,5-a][1,3,5]triazine to the IC50 value of the 
corresponding 5-chlorouracil coupled compound (eg. IC50 value ratio of 15a to 





As TP has been associated with angiogenesis process, extra efforts have been 
made to explore the antiangiogenic potential of 26 TP inhibitors with IC50 
values less than 10µM. The potential is related to the suppressive effect on the 
secretion of angiogenic factor MMP-9 in TP over-expressed breast cancer cell 
line MDA-MB-231. Results of the gelatin zymography assay showed that 6 
compounds evidently suppressed the secretion of MMP-9 at the concentration 
as low as 25µM thus they were proven to possess antiangiogenic potential. 
However, as TPI and 7DX were found not to inhibit MMP-9 secretion, it was 
hypothesized that up-regulating effect of over expressed TP on MMP-9 
secretion might be attributed to TP itself instead of its enzymatic activity. 
Therefore, the observed suppressive effects caused by these compounds could 
be due to some mechanisms other than inhibiting TP. The 
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-a][1
,3,5]triazin-4(3H)-one series was found to be more active than the 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one series, indicating that 
an extra uracil ring could improve this type of suppressive effects. 
In summay, all listed objectives were accomplished and the goal of developing 
potent non-pyrimidine based TP inhibitors was fulfilled by the discovery of 
compound 17r and 24r, which increased the structural diversity of potent TP 
inhibitors. In addition, kinetic studies revealed that these two compounds 
could interact with an allosteric site of TP thus their inhibitory activity would 
not be completely overcome by the accumulation of substrates. This could be 
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recognized as their potential advantage over traditional competitive TP 
inhibitors in therapeutic applications. Moreover, potent inhibitors in this study 
were also proved to possess antiangiogenic potential which might promote 
their further development into therapeutic agents. 
4.2 Future work 
In this project, some purine analogues have been developed into TP inhibitors, 
and kinetic studies proved them to be allosteric inhibitors thus they might 
possess some advantages over competitive inhibitors. However, they are still 
comparatively weaker than TPI with regard to IC50 values determined from 
the enzyme test. Therefore, one direction in the future for this project to 
extend is the study to develop more potent inhibitors via further structural 
modifications on the pyrazolo[1,5-a][1,3,5]triazine scaffold.  Most 
modifications done in this project were carried out at either position 7 or  
position 8 of the pyrazolo[1,5-a][1,3,5]triazine scaffold. Based on the SAR 
study, it would be good for the inhibitory activity if there are aryl substituents 
at both position 7 and 8. In addition, as kinetic studies revealed that 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones might interact with 
TP at a site different from the substrate binding site, there is no need to 
maintain the S=C-NH-C=O structure which was initially designed for 
mimicking the homophthalimide structure and interacting with the substrate 
binding site. The reactive sulfur atom at position 2 of the 
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pyrazolo[1,5-a][1,3,5]triazine thus could be utilized to connect with other 
substituents such as some aliphatic chains or monocyclic groups. These 
proposed target compounds (Figure 25) could be synthesized via coupling 









R1: Hydrophobic and electro-donating groups (eg. halogens)
R2: Hydrophobic and electro-withdrawing groups (eg. halogens)
R3: Flexible side chains (eg. aliphatic chains);
     Monocyclic groups (eg. aromatic rings, heterocyclic rings)
R1
 
Figure 25. Proposed new TP inhibitors. 
The most potent compound in the 
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-a][1
,3,5]triazin-4(3H)-ones series (24r) was found to be a mixed-type inhibitor, 
and it was hypothesized that 24r could interact with TP at two different sites: 
the thymidine binding site and an allosteric site. Therefore, it is of interest to 
perform a docking study of 24r using the crystal structure of TP (PDB ID: 
1UOU) to elucidate how the bulky pyrazolo[1,5-a][1,3,5]triazine system at the 




Since both the electronic property and the hydrophobic property of the 
substituent on the phenyl ring would affect the inhibitory activity, a QSAR 
study could be performed using the electronic property (σ values) and the 
hydrophobic property (π values or cLogP values) as major descriptors. This 
would be helpful to elucidate which property is more important to the 
inhibitory activity. 
The angiogensis process involved the digestion of intercellular matrix as well 
as the migration of endothelial cells. Some compounds in this study have 
already been found to suppress the secretion of the angiogenic factor MMP-9, 
which could digest the intercellular matrix. Therefore, it is of interest to 
subsequently investigate whether these compounds could also inhibit the 
migration of endothelia cells at the same time. Relevant cell based assays such 
as the Boyden chamber assay and wound healing assay could be performed 
using the HUVEC cell line to evaluate the effects of these compounds on the 
migration of endothelia cells. In addition, as these compounds are expected to 
be developed into therapeutic agents that exhibit antiangiogenic property, it is 
also necessary to investigate their potential cytotoxic effects against normal 
human cells by MTT assay to confirm their safety towards patients. 
As mentioned in the introduction, it has been proposed that inhibiting TP can 
enhance the bioavailability of some nucleoside therapeutic agents such as TFT. 
Therefore, formulations consisting of most potent TP inhibitors developed in 
this project together with TFT may possess good therapeutic value in cancer 
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treatment. A preliminary study about antiproliferative activity of these 
proposed formulations could be carried out through performing MTT assay so 
as to evaluate their potential therapeutic value in the cancer treatment. 
It was found that xanthine, the substrate of xanthine oxidase, was structurally 
similar to 1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin -2-thioxo-4-ones. 
Therefore, it was necessary to evaluate the inhibitory activity of  
1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-2-thioxo -4-ones against 













































All starting materials were obtained from commercial suppliers and used 
without further purification. Melting points were determined on a Gallenkamp 
melting point apparatus without correction. NMR spectra were recorded, on a 
Bruker DPX-300 spectrometer, in DMSO-d6 and using TMS as the internal 
standard. Chemical shifts (δ) were reported in parts per million downfield 
from the internal standard. The signals were quoted as s (singlet), d (doublet), t 
(triplet), m (multiplet). TLC was developed on aluminum-supported 
pre-coated silica gel plates (Merck, 60 F254). Column chromatography was 
conducted on silica gel (230-400 mesh). ESI-MS was recorded on a Finnigan 
MAT LC-MS. HPLC analysis was carried out for all target compounds used in 
biological assays, using  a Hewlett-Packard series 1050 HPLC system  
equipped with a HP-1050 quaternary pump, a degasser, diode array detector, a 
HP-1100 autosampler and a LiChrosorb reversed phase C18 (5 µm) column 
(4.6×250 mm).  All the samples were prepared by dissolving them in 
methanol. The analysis was performed at 30°C with a suitable mobile phase at 
a flow rate of 1 ml/min, and the ultraviolet detection was made at wavelength 
254 nm. The separations were carried out using gradient elution. The initial 
mobile phase consisting of water with 0.1% acetic acid and acetonitrile with 
0.1% acetic acid (95:5) was eluted for one minute. This was gradually changed 
to 0:100 within six minutes and remained at 0:100 for another one minute. The 
mobile phase was then gradually changed back to the starting composition 
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within six minutes and maintained for one more minute. The injection volume 
was 5 µL. The purity of all target compounds was found to be more than 95 % 
which was satisfactory for bioassay. 
5.1.1 Preparation and characterization of intermediates 
General procedure for the preparation of aryl substituted acetonitriles (2) 
To 8mmol of the correspondingly substituted benzylbromide in 40ml of 
ethanol was added 2ml of 6M potassium cyanide solution. The reaction 
mixture was refluxed for 1 hour. On cooling, the mixture was concentrated by 
rotary evaporation under vacuum to remove the ethanol. The residue was 
washed with deionized water and recrystallized from ethanol/water to give the 
product. 
(4-Iodophenyl)acetonitrile (2a) Yield 56%. Mp: 50-52˚C (lit169: 56-58˚C). 
1HNMR (DMSO-d6): δ 4.02 (s, 2H, CH2), 7.17 (d, J = 8.4Hz, 2H, CH), 7.76 (d, 
J = 8.4Hz, 2H, CH). 
(4-Pentafluorosulfurphenyl)acetonitrile (2b) Yield 69%. Mp: 53-54˚C. 
1HNMR (DMSO-d6): δ 4.21 (s, 2H, CH2), 7.60 (d, J = 8.4Hz, 2H, CH), 7.95 (d, 







General procedure for the preparation of 3-dimethylamino-2-aryl 
substituted-acrylonitriles (3) To 3mmol of the corresponding aryl substituted 
acetonitrile dissolved in 5ml of anhydrous DMF was added 4.5mmol of 
dimethoxymethyl dimethylamine. The reaction mixture was refluxed for 5 
hours. On cooling, the mixture was poured into 50ml of cold water. The 
precipitate that formed was filtered to give the product. 
3-Dimethylamino-2-(4-iodophenyl)acrylonitrile (3a) Yield 80%. Mp: 
91-92˚C. 1HNMR (DMSO-d6): δ 3.20 (s, 6H, CH3), 7.13 (d, J = 8.8Hz, 2H, 
CH), 7.50 (s, 1H, CH), 7.60 (d, J = 8.8Hz, 2H, CH). 
3-Dimethylamino-2-(4-pentafluorosulfurphenyl)acrylonitrile (3b) Yield 
85%. Mp: 144-145˚C. 1HNMR (DMSO-d6): δ 3.25 (s, 6H, CH3), 7.48 (d, J = 
8.8Hz, 2H, CH), 7.71 (s, 1H, CH), 7.76 (d, J = 8.8Hz, 2H, CH). 
General procedure for the preparation of 4-aryl 
substituted-1H-pyrazol-3-ylamines (4) To 5mmol of the corresponding 
3-dimethylamino-2-aryl substituted acrylonitriles in 80ml of ethanol was 
added 13ml of 80%wt hydrazine water solution (200mmol). The reaction 
mixture was refluxed for 8 hours. On cooling, the reaction mixture was 
concentrated by rotary evaporation under vacuum. The residue was extracted 
with ethyl acetate (20ml× 2) and purified by column chromatography 
(HEX:EA (1:1) was first used to remove impurities followed by flashing out 




4-(4-Iodophenyl)-1H-pyrazol-3-ylamine (4a) Yield 29%. Mp: 168-170˚C. 
1HNMR (DMSO-d6): δ 4.63 (s, 1H, CH), 5.19 (s, broad, 1H, NH), 7.33 (d, J = 
6.4Hz, 2H, CH), 7.64 (d, J = 8.4Hz, 2H, CH), 7.77 (s, 1H, NH), 11.79 (s, 1H, 
NH). 
4-(4-Pentafluorosulfurphenyl)-1H-pyrazol-3-ylamine (4b) Yield 19% as 
black oil. 1HNMR (DMSO-d6): δ 5.05 (s, 2H, NH2), 7.70 (d, J = 8.4Hz, 2H, 
CH), 7.79 (d, J = 8.4Hz, 2H, CH), 7.81 (s, 1H, CH), 11.83 (s, broad, 1H, NH). 
3-Oxo-3-phenylpropionitrile (6) To 1.99g of 2-bromo-1-phenyl-ethanone 
(10mmol) dissolved in 6ml of ethanol was added 6ml of 5M potassium 
cyanide solution. The reaction mixture was stirred at 50˚C for 1 hour and then 
poured into 50ml of water. The pH was adjusted to 3 with 2M HCl, the 
precipitate that formed was filtered and recrystallized from ethanol/water to 
give 1.1g product. Yield 76%. Mp: 77-78˚C (lit172: 80˚C). 1HNMR (DMSO-d6): 
δ 4.76 (s, 2H, CH2), 7.57 (t, J = 7.2Hz, 2H, CH), 7.71 (t, J = 7.2Hz, 1H, CH), 
7.95 (d, J = 7.2Hz, 2H, CH).  
5-Phenyl-1H-pyrazol-3-ylamine (7) To 1.45g of 
3-oxo-3-phenyl-propionitrile (10mmol) in 25ml of ethanol was added 6.4ml of 
80%wt hydrazine water solution (100mmol). The reaction mixture was 
refluxed for 1 hour. On cooling, the precipitate that came out was filtered. The 
filtrate was then concentrated by rotary evaporation under vacuum to remove 
the ethanol. The residue was extracted with ethyl acetate (20ml×2) and 
purified by column chromatography (HEX:EA (1:1) was first used to remove 
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impurities followed by CHCl3:MeOH (3:1) to flash out the product) to give 
0.25g product. Yield 16%. Mp: 122-123˚C (lit185: 126-127˚C). 1HNMR 
(DMSO-d6): δ 4.77 (s, 2H, NH2), 5.76 (s, 1H, CH), 7.25 (t, J = 7.2Hz, 1H, 
CH), 7.37 (t, J = 7.2Hz, 2H, CH), 7.64 (d, J = 7.2Hz, 2H, CH), 11.75 (s, 1H, 
NH). 
General procedure for the preparation of 
N-ethoxycarbonyl-N’-(pyrazol-3-yl) ureas (9, 12) To a fine suspension of 
1mmol of the corresponding amine in 3ml of anhydrous DMF was added 
1mmol of ethoxycarbonyl isocyanate. After stirring the mixture for 12 hours at 
room temperature, 30ml of cold water was added. The precipitated product 
was filtered, washed with cold water and recrystallized from acetonitrile. 
N-ethoxycarbonyl-N’-(pyrazol-3-yl) urea (9a) To a solution of 83mg 
(1mmol) 3-aminopyrazole in 2ml anhydrous DMF was added 115mg (1 mmol) 
ethoxycarbonyl isocyanate. After stirring for 1 hour at room temperature, the 
reaction mixture was poured into 15 times volume cold water and extracted 
with EA. The organic layer was collected and dried by molecular sieve. Then 
solvent was evaporated, and residue was purified by column chromatography 
(Hex: EA, 1:1 to MeOH: CHCl3, 1:3) to give 81mg product as white crystals, 
yield 41%. Mp: 158-160˚C. (lit168: 162˚C). 1HNMR (DMSO-d6): δ 1.24 (t, J = 
7.0Hz, 3H, CH3), 4.18 (q, J = 7.2 Hz, 2H, CH2), 7.62 (s, 1H, CH), 10.02 (s, 1H, 




N-ethoxycarbonyl-N’-(5-methyl-pyrazol-3-yl) urea (9b) Yield 53%. 
Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.0Hz, 3H, CH3), 4.17 (q, J = 
7.0 Hz, 2H, CH2), 6.17 (s, 1H, CH), 9.91 (s, 1H, NH), 10.33 (s, 1H, NH), 
12.03 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-tert-butyl-pyrazol-3-yl) urea (9c) Yield 91%. Mp: 
181-182˚C. 1HNMR (DMSO-d6): δ 1.20-1.27 (m, 12H, CH3), 4.17 (q, J = 
7.2Hz, 2H, CH2), 6.17 (s, 1H, CH), 11.22 (s, 1H, NH), 11.94 (s, 1H, NH), 
12.48 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-trifluoromethyl-pyrazol-3-yl) urea (9d) Yield 
79%. Mp: 163-164˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 
4.20 (q, J = 7.2Hz, 2H, CH2), 6.57 (s, 1H, CH), 10.36 (s, 1H, NH), 10.71 (s, 
1H, NH), 13.37 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-fluorophenyl)-pyrazol-3-yl) urea (9e) Yield 
70%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 4.19 
(q, J = 7.2Hz, 2H, CH2), 6.78 (s, 1H, CH), 7.30 (t, J = 8.4Hz, 2H, CH), 
7.73-7.83 (m, 2H, CH), 10.06 (s, 1H, NH), 10.43 (s, 1H, NH), 12.89 (s, 1H, 
NH). 
N-ethoxycarbonyl-N’-(5-(4-chlorophenyl)-pyrazol-3-yl) urea (9f) Yield 
72%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 3H, CH3), 4.19 
(q, J = 7.2Hz, 2H, CH2), 6.82 (s, 1H, CH), 7.52 (d, J = 8.4Hz, 2H, CH), 7.75 




N-ethoxycarbonyl-N’-(5-(4-bromophenyl)-pyrazol-3-yl) urea (9g) Yield 
69%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 4.19 
(q, J = 7.2Hz, 2H, CH2), 6.83 (s, 1H, CH), 7.67 (q, J = 8.4Hz, 4H, CH), 10.07 
(s, 1H, NH), 10.44 (s, 1H, NH), 12.98 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-trifluoromethylphenyl)-pyrazol-3-yl) urea (9h) 
Yield 58%. Mp: 298-299˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, 
CH3), 4.19 (q, J = 7.2Hz, 2H, CH2), 6.94 (s, 1H, CH), 7.82 (d, J = 8.4Hz, 2H, 
CH), 7.96 (d, J = 8.4Hz, 2H, CH), 10.11 (s, 1H, NH), 10.46 (s, 1H, NH), 13.16 
(s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-methylphenyl)-pyrazol-3-yl) urea (9i) Yield 
83%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 2.33 
(s, 3H, CH3), 4.19 (q, J = 7.2Hz, 2H, CH2), 6.74 (s, 1H, CH), 7.26 (d, J = 
8.4Hz, 2H, CH), 7.61 (d, J = 8.4Hz, 2H, CH), 10.04 (s, 1H, NH), 10.41 (s, 1H, 
NH), 12.81 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-tert-butylphenyl)-pyrazol-3-yl) urea (9j) Yield 
86%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 1.30 
(s, 9H, CH3), 4.19 (q, J = 7.2Hz, 2H, CH2), 6.74 (s, 1H, CH), 7.46 (d, J = 
8.4Hz, 2H, CH), 7.64 (d, J = 8.4Hz, 2H, CH), 10.05 (s, 1H, NH), 10.42 (s, 1H, 
NH), 12.83 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-methoxyphenyl)-pyrazol-3-yl) urea (9k) Yield 
68%. Mp: 297-299˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.4Hz, 3H, CH3), 
3.79 (s, 3H, CH3), 4.19 (q, J = 7.4Hz, 2H, CH2), 6.69 (s, 1H, CH), 7.01 (d, J = 
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8.8Hz, 2H, CH), 7.65 (d, J = 8.8Hz, 2H, CH), 10.03 (s, 1H, NH), 10.41 (s, 1H, 
NH), 12.73 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-ethoxyphenyl)-pyrazol-3-yl) urea (9l) Yield 
94%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 1.34 
(t, J = 7.2Hz, 3H, CH3), 4.06 (q, J = 7.2Hz, 2H, CH2), 4.19 (q, J = 7.2Hz, 2H, 
CH2), 6.68 (s, 1H, CH), 6.99 (d, J = 8.8Hz, 2H, CH), 7.63 (d, J = 8.8Hz, 2H, 
CH), 10.03 (s, 1H, NH), 10.41 (s, 1H, NH), 12.73 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-phenyl-pyrazol-3-yl) urea (9m) Yield 58%. 
Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 4.19 (q, J = 
7.2Hz, 2H, CH2), 6.79 (s, 1H, CH), 7.35 (t, J = 7.2Hz, 1H, CH), 7.45 (t, J = 
7.6Hz, 2H, CH), 7.72 (d, J = 7.2Hz, 2H, CH), 10.06 (s, 1H, NH), 10.43 (s, 1H, 
NH), 12.9 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-chloro-pyrazol-3-yl) urea (12a) Yield 47%. Mp: 
155-156˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.0Hz, 3H, CH3), 4.18 (q, J = 
7.1 Hz, 2H, CH2), 7.95 (s, 1H, CH), 9.36 (s, 1H, NH), 10.40 (s, 1H, NH), 
12.93 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-bromo-pyrazol-3-yl) urea (12b) Yield 72%. Mp: 
158-160˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 3H, CH3), 4.18 (q, J = 
7.1 Hz, 2H, CH2), 7.96 (s, 1H, CH), 9.36 (s, 1H, NH), 10.39 (s, 1H, NH), 
13.00 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-iodo-pyrazol-3-yl) urea (12c) Yield 76%. Mp: 
166-167˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.0Hz, 3H, CH3), 4.18 (q, J = 
142 
 
7.1 Hz, 2H, CH2), 7.88 (s, 1H, CH), 9.33 (s, 1H, NH), 10.38 (s, 1H, NH), 
12.99 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4- carboxylic acid ethyl ester -pyrazol-3-yl) urea 
(12d) Yield 85%. Mp: 197-198˚C. 1HNMR (DMSO-d6): δ 1.19-1.36 (m, 6H, 
CH3), 4.13-4.31 (m, 4H, CH2), 7.73 (s, 1H, CH), 10.92 (s, 1H, NH), 11.42 (s, 
1H, NH), 13.10 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-carbonitrile-pyrazol-3-yl) urea (12f) Yield 48%. 
Mp: 176˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.0Hz, 3H, CH3), 4.20 (q, J = 
7.0Hz, 2H, CH2), 8.51 (s, 1H, CH), 9.86 (s, 1H, NH), 10.55 (s, 1H, NH), 13.48 
(s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-phenyl-pyrazol-3-yl) urea (12g) Yield 47%. Mp: 
156-157˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 3H, CH3), 4.18 (q, J = 
7.2Hz, 2H, CH2), 7.21 (t, J = 7.6Hz, 1H, CH), 7.34 (t, J = 7.6Hz, 2H, CH), 
7.47 (d, J = 7.6Hz, 2H, CH), 8.05 (s, 1H, CH), 9.37 (s, 1H, NH), 10.29 (s, 1H, 
NH), 12.82 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-fluorophenyl)-pyrazol-3-yl) urea (12h) Yield 
55%. Mp: 165-166˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 3H, CH3), 
4.17 (q, J = 7.2Hz, 2H, CH2), 7.18 (t, J = 8.4Hz, 2H, CH), 7.45-7.53 (m, 2H, 
CH), 8.04 (s, 1H, CH), 9.36 (s, 1H, NH), 10.29 (s, 1H, NH), 12.82 (s, 1H, 
NH). 
N-ethoxycarbonyl-N’-(4-(4-chlorophenyl)-pyrazol-3-yl) urea (12i) Yield 
57%. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 3H, CH3), 4.18 (q, J = 7.2Hz, 
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2H, CH2), 7.40 (d, J = 8.8Hz, 2H, CH), 7.48 (d, J = 8.8Hz, 2H, CH), 8.09 (s, 
1H, CH), 9.39 (s, 1H, NH), 10.30 (s, 1H, NH), 12.87 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-bromophenyl)-pyrazol-3-yl) urea (12j) Yield 
46%. Mp: 175-177˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 3H, CH3), 
4.18 (q, J = 7.2Hz, 2H, CH2), 7.42 (d, J = 8.4Hz, 2H, CH), 7.53 (d, J = 8.4Hz, 
2H, CH), 8.09 (s, 1H, CH), 9.39 (s, 1H, NH), 10.29 (s, 1H, NH), 12.87 (s, 1H, 
NH). 
N-ethoxycarbonyl-N’-(4-(4-trifluoromethylphenyl)-pyrazol-3-yl) urea 
(12k) Yield 50%. Mp: 176-177˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 
3H, CH3), 4.18 (q, J = 7.2Hz, 2H, CH2), 7.68 (s, 4H, CH), 8.19 (s, 1H, CH), 
9.46 (s, 1H, NH), 10.31 (s, 1H, NH), 12.97 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-methylphenyl)-pyrazol-3-yl) urea (12l) Yield 
76%. Mp: 159-160˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 3H, CH3), 
2.28 (s, 3H, CH3), 4.17 (q, J = 7.2Hz, 2H, CH2), 7.15 (d, J = 8.0Hz, 2H, CH), 
7.34 (d, J = 8.0Hz, 2H, CH), 7.99 (s, 1H, CH), 9.34 (s, 1H, NH), 10.28 (s, 1H, 
NH), 12.77 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-tert-butylphenyl)-pyrazol-3-yl) urea (12m) 
Yield 75%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 
1.3 (s, 9H, CH3), 4.19 (q, J = 7.2Hz, 2H, CH2), 6.74 (s, 1H, CH), 7.46 (d, J = 
8.4Hz, 2H, CH), 7.64 (d, J = 8.4Hz, 2H, CH), 10.06 (s, 1H, NH), 10.42 (s, 1H, 
NH), 12.83(s, 1H, NH). 
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N-ethoxycarbonyl-N’-(4-(4-methoxyphenyl)-pyrazol-3-yl) urea (12n) Yield 
40%. Mp: 156-157˚C. 1HNMR (DMSO-d6): δ 1.24 (t, J = 7.2Hz, 3H, CH3), 
3.75 (s, 3H, CH3), 4.17 (q, J = 7.2Hz, 2H, CH2), 6.92 (d, J = 8.4Hz, 2H, CH), 
7.38 (d, J = 8.4Hz, 2H, CH), 7.95 (s, 1H, CH), 9.31 (s, 1H, NH), 10.28 (s, 1H, 
NH), 12.73(s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-ethoxyphenyl)-pyrazol-3-yl) urea (12o) Yield 
75%. Mp: 296-298˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.2Hz, 3H, CH3), 
1.34 (t, J = 7.2Hz, 3H, CH3), 4.06 (q, J = 7.2Hz, 2H, CH2), 4.19 (q, J = 7.2Hz, 
2H, CH2), 6.68 (s, 1H, CH), 6.99 (d, J = 8.4Hz, 2H, CH), 7.63 (d, J = 8.4Hz, 
2H, CH), 10.03 (s, 1H, NH), 10.41 (s, 1H, NH), 12.72 (s, 1H, NH). 
General method for preparation of 
N-ethoxycarbonyl-N’-(pyrazol-3-yl)thioureas (14, 16)  To a fine 
suspension of 1mmol of the corresponding amine in 3ml of anhydrous DMF 
was added 1mmol of ethoxycarbonyl isothiocyanate. After stirring the mixture 
for 1 hour at room temperature, 30ml of cold water was added. The 
precipitated product was filtered, washed with cold water and recrystallized 
from ethanol. 
N-ethoxycarbonyl-N’-(pyrazol-3-yl)thiourea (14a) To a solution of 835mg 
(10mmol) 3-aminopyrazole in 15ml anhydrous DMF was added 1.31g (10 
mmol) ethoxycarbonyl isothiocyanate. After stirring for 1h at room 
temperature, the reaction mixture was poured into 15 times volume cold water. 
The precipitate was filtered, purified by column chromatography (Hex: EA, 
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4:1 to 2:1), and recrystallized from EtOH/H2O to give 425mg product as white 
crystals, yield 20%. Mp: 156-157˚C. (lit168: 163˚C). 1HNMR (DMSO-d6): δ 
1.26 (t, J = 6.9Hz, 3H, CH3), 4.22 (q, J = 7.1 Hz, 2H, CH2), 7.00 (s, 1H, CH), 
7.69 (s, 1H, CH), 11.29 (s, 1H, NH), 12.02 (s, 1H, NH), 12.70 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-methyl-pyrazol-3-yl)thiourea (14b) Yield 89%. 
Mp: 157˚C. 1HNMR (DMSO-d6): δ 1.25 (t, J = 7.0Hz, 3H, CH3), 2.22 (s, 3H, 
CH3), 4.20 (q, J = 7.0 Hz, 2H, CH2), 6.78 (s, 1H, CH), 11.24 (s, 1H, NH), 
11.94 (s, 1H, NH), 12.37 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-tert-butyl-pyrazol-3-yl)thiourea (14c) Yield 86%. 
Mp: 162-163˚C. 1HNMR (DMSO-d6): δ 1.22-1.31 (m, 12H, CH3), 4.22 (q, J = 
7.2Hz, 2H, CH2), 6.80 (s, 1H, CH), 11.22 (s, 1H, NH), 11.94 (s, 1H, NH), 
12.48 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-trifluoromethyl-pyrazol-3-yl)thiourea (14d) Yield 
90%. Mp: 146-147˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.2Hz, 3H, CH3), 
4.23 (q, J = 7.2Hz, 2H, CH2), 6.99 (s, 1H, CH), 11.66 (s, 1H, NH), 11.78 (s, 
1H, NH), 13.83 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-fluorophenyl)-pyrazol-3-yl)thiourea (14e) 
Yield 98%. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.2Hz, 3H, CH3), 4.23 (q, J = 
7.2Hz, 2H, CH2), 7.25-7.42 (m, 3H, CH), 7.72-7.86 (m, 2H, CH), 11.37 (s, 1H, 
NH), 12.03 (s, 1H, NH), 13.22 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-chlorophenyl)-pyrazol-3-yl)thiourea (14f) 
Yield 96%. 1HNMR (DMSO-d6): δ 1.27 (t, J = 6.9Hz, 3H, CH3), 4.23 (q, J = 
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6.9Hz, 2H, CH2), 7.42 (s, 1H, CH), 7.54 (d, J = 8.4Hz, 2H, CH), 7.76 (d, J = 
8.4Hz, 2H, CH), 11.39 (s, 1H, NH), 12.04 (s, 1H, NH), 13.29 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-bromophenyl)-pyrazol-3-yl)thiourea (14g) 
Yield 90%. Mp: 283-284˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 6.9Hz, 3H, 
CH3), 4.23 (q, J = 6.9Hz, 2H, CH2), 7.43 (s, 1H, CH), 7.60-7.77 (m, 4H, CH), 
11.38 (s, 1H, NH), 12.04 (s, 1H, NH), 13.30 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-trifluoromethylphenyl)-pyrazol-3-yl)thiourea 
(14h) Yield 95%. Mp: 276-278˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.2Hz, 
3H, CH3), 4.24 (q, J = 7.2Hz, 2H, CH2), 7.54 (s, 1H, CH), 7.84 (d, J = 8.4Hz, 
2H, CH), 7.97 (d, J = 8.4Hz, 2H, CH), 11.41 (s, 1H, NH), 12.07 (s, 1H, NH), 
13.48 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-methylphenyl)-pyrazol-3-yl)thiourea (14i) 
Yield 86%. Mp: 272-273˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.2Hz, 3H, 
CH3), 2.33 (s, 3H, CH3), 4.23 (q, J = 7.2Hz, 2H, CH2), 7.28 (d, J = 8.4Hz, 2H, 
CH), 7.35 (d, J = 2Hz, 1H, CH), 7.62 (d, J = 8.4Hz, 2H, CH), 11.34 (s, 1H, 
NH), 12.02 (s, 1H, NH), 13.13 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-tert-butylphenyl)-pyrazol-3-yl)thiourea (14j) 
Yield 93%. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.2Hz, 3H, CH3), 1.30 (s, 9H, 
CH3), 4.23 (q, J = 7.2Hz, 2H, CH2), 7.35 (d, J = 2Hz, 1H, CH), 7.48 (d, J = 
8.4Hz, 2H, CH), 7.65 (d, J = 8.4Hz, 2H, CH), 11.35 (s, 1H, NH), 12.03 (s, 1H, 




Yield 96%. 1HNMR (DMSO-d6): δ 1.27 (t, J = 6.9Hz, 3H, CH3), 3.80 (s, 3H, 
CH3), 4.23 (q, J = 6.9Hz, 2H, CH2), 7.03 (d, J = 8.7Hz, 2H, CH), 7.29 (s, 1H, 
CH), 7.66 (d, J = 8.7Hz, 2H, CH), 11.34 (s, 1H, NH), 12.01 (s, 1H, NH), 13.05 
(s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-(4-ethoxyphenyl)-pyrazol-3-yl)thiourea (14l) 
Yield 92%. Mp: 282-283˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.2Hz, 3H, 
CH3), 1.33 (t, J = 7.2Hz, 3H, CH3), 4.06 (q, J = 7.2Hz, 2H, CH2), 4.22 (q, J = 
7.2Hz, 2H, CH2), 7.00 (d, J = 8.8Hz, 2H, CH), 7.28 (s, 1H, CH), 7.63 (d, J = 
8.8Hz, 2H, CH), 11.34 (s, 1H, NH), 12.00 (s, 1H, NH), 13.03 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(5-phenyl-pyrazol-3-yl)thiourea (14m) Yield 82%. 
Mp: 272-274˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.0Hz, 3H, CH3), 4.23 (q, 
J = 7.0 Hz, 2H, CH2), 7.33-7.52 (m, 4H, CH), 7.73 (d, J = 7.5, 2H, CH), 11.38 
(s, 1H, NH), 12.04 (s, 1H, NH), 13.23 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-chloro-pyrazol-3-yl)thiourea (16a) Yield 64%. Mp: 
188-190˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.2Hz, 3H, CH3), 4.22 (q, J = 
7.1 Hz, 2H, CH2), 7.99 (s, 1H, CH), 10.96 (s, 1H, NH), 11.45 (s, 1H, NH), 
13.06 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-bromo-pyrazol-3-yl)thiourea (16b) Yield 87%. 
Mp: 187-189˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.0Hz, 3H, CH3), 4.22 (q, 
J = 7.1 Hz, 2H, CH2), 8.00 (s, 1H, CH), 10.95 (s, 1H, NH), 11.44 (s, 1H, NH), 
13.13 (s, 1H, NH). 
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N-ethoxycarbonyl-N’-(4-iodo-pyrazol-3-yl)thiourea (16c) Yield 76%. Mp: 
172-173˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.0Hz, 3H, CH3), 4.22 (q, J = 
7.0 Hz, 2H, CH2), 7.93 (s, 1H, CH), 10.94 (s, 1H, NH), 11.41 (s, 1H, NH), 
13.11 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4- carboxylic acid ethyl ester 
-pyrazol-3-yl)thiourea (16d) Yield 85%. Mp: 201-202˚C. 1HNMR (CDCl3): 
δ 1.30-1.51 (m, 6H, CH3), 4.33-4.54 (m, 4H, CH2), 7.88 (s, 1H, CH), 8.48 (s, 
1H, NH), 13.10 (s, 1H, NH), 13.26 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-carbonitrile-pyrazol-3-yl)thiourea (16f) Yield 
73%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.0Hz, 3H, CH3), 4.23 
(q, J = 7.0 Hz, 2H, CH2), 8.57 (s, 1H, CH), 11.21 (s, 1H, NH), 11.58 (s, 1H, 
NH), 13.65 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-phenyl-pyrazol-3-yl)thiourea (16g) Yield 84%. 
Mp: 191-192˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.2Hz, 3H, CH3), 4.21 (q, 
J = 7.0 Hz, 2H, CH2), 7.20 (t, J =7.5, 1H, CH), 7.33 (t, J = 7.6, 2H, CH), 7.48 
(d, J = 7.8, 2H, CH), 8.12 (s, 1H, CH), 11.08 (s, 1H, NH), 11.35 (s, 1H, NH), 
12.94 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-fluorophenyl)-pyrazol-3-yl)thiourea (16h) 
Yield 93%. Mp: 198-199˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 6.9Hz, 3H, 
CH3), 4.21 (q, J = 6.9 Hz, 2H, CH2), 7.18 (t, J = 8.9, 2H, CH), 7.43-7.55 (m, 





Yield 92%. Mp: 206-207˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.2Hz, 3H, 
CH3), 4.22 (q, J = 7.2Hz, 2H, CH2), 7.39 (d, J = 8.4Hz, 2H, CH), 7.49 (d, J = 
8.4Hz, 2H, CH), 8.15 (s, 1H, CH), 11.08 (s, 1H, NH), 11.33 (s, 1H, NH), 
12.98 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-bromophenyl)-pyrazol-3-yl)thiourea (16j) 
Yield 91%. Mp: 209-210˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 6.9Hz, 3H, 
CH3), 4.22 (q, J = 6.9Hz, 2H, CH2), 7.43 (d, J = 8.4Hz, 2H, CH), 7.53 (d, J = 
8.4Hz, 2H, CH), 8.16 (s, 1H, CH), 11.08 (s, 1H, NH), 11.34 (s, 1H, NH), 
12.99 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-trifluoromethylphenyl)-pyrazol-3-yl)thiourea 
(16k) Yield 91%. Mp: 208-209˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.2Hz, 
3H, CH3), 4.22 (q, J = 7.2Hz, 2H, CH2), 7.69 (s, 4H, CH), 8.27 (s, 1H, CH), 
11.14 (s, 1H, NH), 11.35 (s, 1H, NH), 13.08 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-methylphenyl)-pyrazol-3-yl)thiourea (16l) 
Yield 87%. Mp: 192-193˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.2Hz, 3H, 
CH3), 2.28 (s, 3H, CH3), 4.21 (q, J = 7.2Hz, 2H, CH2), 7.14 (d, J = 8.4Hz, 2H, 
CH), 7.36 (d, J = 8.4Hz, 2H, CH), 8.05 (s, 1H, CH), 11.06 (s, 1H, NH), 11.33 
(s, 1H, NH), 12.89 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-tert-butylphenyl)-pyrazol-3-yl)thiourea (16m) 
Yield 88%. Mp: 277-278˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.0Hz, 3H, 
CH3), 1.30 (s, 9H, CH3), 4.23 (q, J = 7.0Hz, 2H, CH2), 7.35 (s, 1H, CH), 7.48 
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(d, J = 8.0Hz, 2H, CH), 7.65 (d, J = 8.5Hz, 2H, CH), 11.35 (s, 1H, NH), 12.04 
(s, 1H, NH), 13.15 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-methoxyphenyl)-pyrazol-3-yl)thiourea (16n) 
Yield 93%. Mp: 193-194˚C. 1HNMR (DMSO-d6): δ 1.26 (t, J = 7.0Hz, 3H, 
CH3), 3.74 (s, 3H, CH3), 4.21 (q, J = 7.0Hz, 2H, CH2), 6.91 (d, J = 8.5Hz, 2H, 
CH), 7.40 (d, J = 8.5Hz, 2H, CH), 8.02 (s, 1H, CH), 11.04 (s, 1H, NH), 11.33 
(s, 1H, NH), 12.84 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-ethoxyphenyl)-pyrazol-3-yl)thiourea (16o) 
Yield 89%. Mp: 282-283˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.2Hz, 3H, 
CH3), 1.34 (t, J = 7.2Hz, 3H, CH3), 4.07 (q, J = 7.2Hz, 2H, CH2), 4.23 (q, J = 
7.2Hz, 2H, CH2), 7.01 (d, J = 8.8Hz, 2H, CH), 7.28 (d, J = 2Hz, 1H, CH),7.64 
(d, J = 8.8Hz, 2H, CH), 11.33 (s, 1H, NH), 12.01 (s, 1H, NH), 13.04 (s, 1H, 
NH). 
N-ethoxycarbonyl-N’-(4-(4-nitrophenyl)-pyrazol-3-yl)thiourea (16p) Yield 
95%. Mp: 223˚C. 1HNMR (DMSO-d6): δ 1.28 (t, J = 7.2Hz, 3H, CH3), 4.23 (q, 
J = 7.2Hz, 2H, CH2), 7.75 (d, J = 8.8Hz, 2H, CH), 8.20 (d, J = 8.8Hz, 2H, CH), 
8.38 (s, 1H, CH), 11.19 (s, 1H, NH), 11.38 (s, 1H, NH), 13.18 (s, 1H, NH). 
N-ethoxycarbonyl-N’-(4-(4-iodophenyl)-pyrazol-3-yl)thiourea (16q) Yield 
69%. Mp: >300˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J = 7.2Hz, 3H, CH3), 4.22 
(q, J = 7.2Hz, 2H, CH2), 7.29 (d, J = 8.4Hz, 2H, CH), 7.69 (d, J = 8.4Hz, 2H, 





thiourea (16r) Yield 68%. Mp: 179-180˚C. 1HNMR (DMSO-d6): δ 1.27 (t, J 
= 7.2Hz, 3H, CH3), 4.23 (q, J = 7.2Hz, 2H, CH2), 7.68 (d, J = 8.8Hz, 2H, CH), 
7.86 (d, J = 8.8Hz, 2H, CH), 8.30 (s, 1H, CH), 11.16 (s, 1H, NH), 11.38 (s, 1H, 
NH), 13.12 (s, 1H, NH). 
Uracil-6-carbaldehyde (19) 7.57g (60mmol) 6-Methyluracil and 7.99g 
(70mmol) selenium oxide were refluxed in 90ml of AcOH for 3 hours. The 
reaction mixture was filtered and extracted with 2×15ml boiled AcOH.  
Filtrate was evaporated and residue was recrystallised from 70ml water to give 
2.57g product as yellow crystals, an additional 0.35g product was obtained 
from concentrated the mother liquid, yield 35%. Mp: 272-274˚C. (lit178: 
273-275˚C). 1HNMR (DMSO-d6): δ 6.28 (s, 1H, CH), 9.56 (s, 1H, CHO), 
11.12 (s, 1H, NH), 11.40 (s, 1H, NH). 
6-Hydroxymethyluracil (20) To 1.4g (10mmol) uracil-6-carbaldehyde 
dissolved in 20ml MeOH and 10ml H2O, stirred on an ice bath, 0.75g 
(20mmol) NaBH4 in 10ml H2O was added gradually portion-wise until 
completion. After 1 hour, pH of the reaction mixture was adjust to 2 with 10% 
HCl and cooled. Pale yellow crystals were filtered and dried to give 1.12g 
product, yield 79%. Mp: 254˚C. (lit186: 254˚C). 1HNMR (DMSO-d6): δ 4.15 (s, 




6-Chloromethyluracil (21) Neat thionyl chloride 5ml (69mmol) was slowly 
added to 6-hydroxymethyluracil 0.66g (4.65mmol), stirred at room 
temperature until a homogeneous brown suspension was obtained, and heated 
at reflux for 2 hours. The solvent was evaporated in vacuo to give 0.71g 
off-white/pale brown solid, which was used directly for subsequent nuclear 
chlorination without further purification, due to its instability in protic solvents, 
yield 95%. Mp: 246-248˚C. (lit180: 249-251˚C). 1HNMR (DMSO-d6): δ 4.38 
(s, 2H, CH2), 5.67 (s, 1H, CH), 11.13 (s, 2H, NH). 
5-Chloro-6-chloromethyluracil (22) To 6-chloromethyluracil 1g (6.23mmol) 
in 6ml AcOH, 0.75ml (9.31mmol) sulfuryl chloride was added dropwise, and 
stirred at room temperature for 6 hours. Reaction was quenched with twice the 
volume of cold H2O, white crystalline solid which precipitated out was filtered 
and dried to give 0.83g product, yield 68%. Mp: 223-224˚C. (lit182: 225˚C). 
1HNMR (DMSO-d6): δ 4.47 (s, 2H, CH2), 11.56 (s, 1H, NH), 11.70 (s, 1H, 
NH). 
5.1.2 Preparation and characterization of target compounds 
General procedure for the preparation of 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-diones (10, 13) 1mmol of the 
corresponding N-ethoxycarbonyl-N’-(pyrazol-3-yl) urea was refluxed in a 
mixture of 4ml of ethanol and 0.76ml of 21%wt EtONa (2mmol) ethanol 
solution for 0.5 hours. The precipitate that formed was collected by filtration, 
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then dissolved in water and acidified with HCI until pH 4. The precipitate 
formed was filtered and recrystallized from methanol/water. 
1,3-Dihydro-pyrazolo[1,5-a][1,3,5]triazin-2,4-dione (10a) Yield 64%. 
Mp: >300˚C. ESI-MS 150.5 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 
5.79 (d, J = 1.8Hz 1H, CH), 7.88 (d, J = 1.5Hz, 1H, CH), 11.58 (s, 1H, NH), 
11.88 (s, 1H, NH). 13CNMR (DMSO-d6): δ 89.6, 141.8, 145.4, 146.3, 149.4. 
1,3-Dihydro-7-methylpyrazolo[1,5-a][1,3,5]triazin-2,4-dione (10b) Yield 
55%. Mp: >300˚C. ESI-MS 165.0 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 2.19 (s, 3H, CH3), 5.65 (s, 1H, CH), 11.49 (s, 1H, NH), 11.78 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 14.9, 90.0, 141.9, 145.1, 149.5, 155.8. 
1,3-Dihydro-7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-2,4-dione (10c) Yield 
41%. Mp: 258-259˚C. ESI-MS 207.1 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 1.25 (s, 9H, CH3), 5.74 (s, 1H, CH), 11.45 (s, 1H, NH), 11.81 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 29. 5, 32.4, 85.7, 140.7, 144.2, 148.3, 166.6. 
1,3-Dihydro-7-trifluoromethylpyrazolo[1,5-a][1,3,5]triazin-2,4-dione (10d) 
1mmol of N-ethoxycarbonyl-N’-(5-trifluoromethyl-pyrazol-3-yl) urea was 
refluxed in a mixture of 4ml of ethanol and 0.76ml of 21%wt EtONa (2mmol) 
ethanol solution for 0.5 hours. The precipitate that formed was collected by 
filtration, then dissolved in 20ml of water and acidified with HCI until pH 4. 
The resulting solution was extracted by ethyl acetate (20ml×3) and the 
organic phase was rotary evaporated under vacuum to dryness to yield 0.16g 
product. Yield 73%. Mp: 228-230˚C. ESI-MS 218.9 m/z (M-1). Purity: >99%. 
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1HNMR (DMSO-d6): δ 6.21 (s, 1H, CH), 12.02 (s, broad, 2H, NH). 13CNMR 
(DMSO-d6): δ 86. 3, 116.5, 119.2, 121.9, 124.6, 142.5, 143.8, 144.8, 145.2, 
145.6, 146.0, 148.1.  
1,3-Dihydro-7-(4-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione (10e) 
Yield 80%. Mp: >300˚C. ESI-MS 245.0 m/z (M-1). Purity: 97%. 1HNMR 
(DMSO-d6): δ 6.31 (s, 1H, CH), 7.30 (t, J = 6.6Hz, 2H, CH), 7.98 (dd, J = 
6.6Hz, JH-F = 4.2Hz, 2H, CH), 11.63 (s, 1H, NH), 12.03 (s, 1H, NH).13CNMR 
(DMSO-d6): δ 86.02, 115.9, 128.3, 141.9, 144.3, 148.4, 154.3, 161.6, 164.0. 
1,3-Dihydro-7-(4-chlorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione (10f) 
Yield 64%. Mp: 296-298˚C. ESI-MS 261.2, 263.2 m/z (M-1). Purity: 96%. 
1HNMR (DMSO-d6): δ 6.33 (s, 1H, CH), 7.53 (d, J = 8.8Hz, 2H, CH), 7.95 (d, 
J = 8.8Hz, 2H, CH), 11.64 (s, 1H, NH), 12.04 (s, 1H, NH). 13CNMR 
(DMSO-d6): δ 86.0, 127.8, 128.8, 130.4, 133.9, 141.9, 144.2, 148.3, 154.0. 
1,3-Dihydro-7-(4-bromophenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(10g) Yield 58%. Mp: >300˚C. ESI-MS 305.2, 307.2 m/z (M-1). Purity: 98%. 
1HNMR (DMSO-d6): δ 6.33 (s, 1H, CH), 7.53 (d, J = 8.8Hz, 2H, CH), 7.95 (d, 
J = 8.8Hz, 2H, CH), 11.64 (s, 1H, NH), 12.04 (s, 1H, NH). 13CNMR 
(DMSO-d6): δ 86.0, 122.6, 128.1, 130.8, 131.7, 141.9, 144.1, 148.3, 154.0. 
1,3-Dihydro-7-(4-trifluoromethylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-
dione (10h) Yield 91%. Mp: >300˚C. ESI-MS 295.2 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 6.43 (s, 1H, CH), 7.83 (d, J = 8.4Hz, 2H, CH), 8.16 (d, 
J = 8.4Hz, 2H, CH), 11.70 (s, 1H, NH), 12.09 (s, 1H, NH). 13CNMR 
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(DMSO-d6): δ 86.4, 122.7, 125.4, 125.6, 125.7, 126.8, 128.1, 128.8, 129.1, 
129.4, 129.7, 135.5, 142.1, 144.1, 148.3, 153.6.  
1,3-Dihydro-7-(4-methylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(10i) Yield 83%. Mp: >300˚C. ESI-MS 241.3 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 2.35 (s, 3H, CH3), 6.26 (s, 1H, CH), 7.28 (d, J = 8.0Hz, 
2H, CH), 7.80 (d, J = 8.0Hz, 2H, CH), 11.59 (s, 1H, NH), 11.98 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 20.9, 85.8, 126.0, 128.8, 129.4, 138.9, 141.7, 144.2, 
148.4, 155.2. 
1,3-Dihydro-7-(4-tert-butyl-phenyl)-pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(10j) Yield 85%. Mp: >300˚C. ESI-MS 283.3 m/z (M-1). Purity: 95%. 
1HNMR (DMSO-d6): δ 1.31 (s, 9H, CH3), 6.26 (s, 1H, CH), 7.49 (d, J = 8.8Hz, 
2H, CH), 7.84 (d, J = 8.8Hz, 2H, CH), 11.60 (s, 1H, NH), 11.99 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 30.9, 34.4, 85.8, 125.5, 125.8, 128.7, 141.6, 144.2, 
148.3, 151.9, 155.0. 
1,3-Dihydro-7-(4-methoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(10k) Yield 78%. Mp: 260-262˚C. ESI-MS 257.2 m/z (M-1). Purity: 95%. 
1HNMR (DMSO-d6): δ 3.81 (s, 3H, CH3), 6.22 (s, 1H, CH), 7.02 (d, J = 8.8Hz, 
2H, CH), 7.85 (d, J = 8.8Hz, 2H, CH), 11.56 (s, 1H, NH), 11.96 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 55.1, 85.5, 114.1, 124.0, 127.5, 141.6, 144.1, 148.3, 
154.9, 160.1. 
1,3-Dihydro-7-(4-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione (10l) 
Yield 55%. Mp: >300˚C. ESI-MS 271.1 m/z (M-1). Purity: 95%. 1HNMR 
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(DMSO-d6): δ 1.35 (t, J = 6.8Hz, 3H, CH3), 4.08 (q, J = 6.8Hz, 2H, CH2), 
6.22 (s, 1H, CH), 7.00 (d, J = 8.8Hz, 2H, CH), 7.84 (d, J = 8.8Hz, 2H, CH), 
11.57 (s, 1H, NH), 11.97 (s, 1H, NH). 13CNMR (DMSO-d6): δ 15.1, 63.6, 
86.1, 115.1, 124.4, 128.1, 142.1, 144.7, 148.9, 155.6, 159.9. 
1,3-Dihydro-7-phenylpyrazolo[1,5-a][1,3,5]triazin-2,4-dione (10m) Yield 
89%. Mp: >300˚C. (lit130: 295-297˚C). ESI-MS 227.0 m/z (M-1). Purity: 99%. 
1HNMR (DMSO-d6): δ 6.31 (s, 1H, CH), 7.39-7.53 (m, 3H, CH), 7.93 (d, J = 
6.8Hz, CH, 2H), 11.63 (s, 1H, NH), 12.02 (s, 1H, NH). 13CNMR (DMSO-d6): 
δ 86.0, 126.1, 128.8, 129.3, 131.5, 141.8, 144.2, 148.3, 155.1. 
1,3-Dihydro-8-chloropyrazolo[1,5-a][1,3,5]triazin-2,4-dione (13a) Yield 
53%. Mp: 299-300˚C. ESI-MS 185.0, 186.9 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 7.94 (s, 1H, CH), 11.72 (s, 1H, NH), 12.33 (s, 1H, 
NH).13CNMR (DMSO-d6): δ 91.2, 138.4, 144.4, 144.8, 149.4. 
1,3-Dihydro-8-bromopyrazolo[1,5-a][1,3,5]triazin-2,4-dione (13b) Yield 
66%. Mp: >300˚C. ESI-MS 228.9, 230.9 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 7.91 (s, 1H, CH), 11.72 (s, 1H, NH), 12.25 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 75.1, 140.0, 144.8, 146.2, 149.5. 
1,3-Dihydro-8-iodopyrazolo[1,5-a][1,3,5]triazin-2,4-dione (13c) Yield 61%. 
Mp: 292-294˚C. ESI-MS 276.9 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): 
δ 7.82 (s, 1H, CH), 11.67 (s, 1H, NH), 12.01 (s, 1H, NH). 13CNMR 
(DMSO-d6): δ 142.1, 143.6, 148.5, 149.1. 
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1,3-Dihydro-8- carboxylic acid ethyl ester 
-pyrazolo[1,5-a][1,3,5]triazin-2,4-dione (13d) Yield 54%. Mp: 232-233˚C. 
ESI-MS 223.0 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 1.27 (t, J = 
6.9Hz, 3H, CH3), 4.26 (q, J = 6.9Hz, 2H, CH2), 8.08 (s, 1H, CH), 11.73 (s, 1H, 
NH), 11.95 (s, 1H, NH). 13CNMR (DMSO-d6): δ 15.4, 61.0, 98.1, 144.0, 
144.9, 145.5, 149.4, 162.0 . 
1,3-Dihydro-8-methylpyrazolo[1,5-a][1,3,5]triazin-2,4-dione (13e) Yield 
51%. Mp: >300˚C. ESI-MS 164.5 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 1.96 (s, 3H, CH3), 7.65 (s, 1H, CH), 11.47 (s, 1H, NH), 11.81 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 6.52, 97.1, 137.2, 144.2, 146.5, 148.6. 
1,3-Dihydro-8-carbonitrilepyrazolo[1,5-a][1,3,5]triazin-2,4-dione (13f) 
Yield 75%. Mp: >300˚C. ESI-MS 176.0 m/z (M-1). Purity: 96%. 1HNMR 
(DMSO-d6): δ 8.26 (s, 1H, CH), 12.01(s, 1H, NH), 12.97 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 75.8, 112.9, 144.6, 146.7, 146.8, 149.2. 
1,3-Dihydro-8-phenylpyrazolo[1,5-a][1,3,5]triazin-2,4-dione (13g) Yield 
54%. Mp: 268-269˚C. ESI-MS 227.0 m/z (M-1). Purity: 100%. 1HNMR 
(DMSO-d6): δ 7.3 (t, J = 7.2Hz, 1H, CH), 7.42(t, J = 7.2Hz, 2H, CH), 7.53 (d, 
J = 7.2Hz, 2H, CH), 8.13 (s, 1H, CH), 11.7 (s, 1H, NH), 11.88 (s, broad, 1H, 
NH). 13CNMR (DMSO-d6): δ 104.3, 126.6, 127.1, 128.6, 129.6, 136.2, 144.1, 
144.5, 148.8. 
1,3-Dihydro-8-(4-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(13h) Yield 79%. Mp: 280-282˚C. ESI-MS 245.0 m/z (M-1). Purity: >99%. 
158 
 
1HNMR (DMSO-d6): δ 7.24 (t, J = 6.6Hz, 2H, CH), 7.55 (dd, J = 6.6Hz, JH-F = 
4.2Hz, 2H, CH), 8.10 (s, 1H, CH), 11.7 (s, 1H, NH), 11.92 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 103.5, 115.3, 115.5, 126.0, 129.2, 129.3, 136.2, 144.2, 
144.5, 148.8, 159.8, 162.3.   
1,3-Dihydro-8-(4-chlorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione (13i) 
Yield 57%. Mp: 296-297˚C. ESI-MS 261.3, 263.1 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 7.45 (d, J = 8.4Hz, 2H, CH), 7.55 (d, J = 8.4Hz, 2H, 
CH), 8.14 (s, 1H, CH), 11.75 (s, 1H, NH), 11.95 (s, 1H, NH). 13CNMR 
(DMSO-d6): δ 103.2, 128.5, 128.6, 128.9, 131.1, 136.5, 144.1, 144.4, 148.8. 
1,3-Dihydro-8-(4-bromophenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(13j) Yield 49%. Mp: 278-280˚C. ESI-MS 306.9 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ7.49 (d, J = 8.8Hz, 2H, CH), 7.59 (d, J = 8.8Hz, 2H, 
CH), 8.14 (s, 1H, CH), 11.71 (s, 1H, NH), 11.93 (s, 1H, NH). 13CNMR 
(DMSO-d6): δ 103.2, 119.6, 128.9, 129.1, 131.4, 136.5, 144.1, 144.3, 148.8. 
1,3-Dihydro-8-(4-trifluoromethylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-
dione (13k) Yield 77%. Mp: 288-289˚C. ESI-MS 295.3 m/z (M-1). 
Purity: >99%. 1HNMR (DMSO-d6): δ 7.61-8.13 (m, 4H, CH), 8.23 (s, 1H, 
CH), 11.74 (s, 1H, NH), 12.05 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 
103.0, 122.9, 125.3, 125.3, 125.3, 125.4, 125.6, 126.5, 126.8, 127.5, 134.0, 
137.4, 144.1, 144.3 148.9.  
1,3-Dihydro-8-(4-methylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(13l) Yield 87%. Mp: 289-290˚C. ESI-MS 241.3 m/z (M-1). Purity: 98%. 
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1HNMR (DMSO-d6): δ 2.32 (s, 3H, CH3), 7.21 (d, J = 8.0Hz, 2H, CH), 7.41 (d, 
J = 8.0Hz, 2H, CH), 8.09 (s, 1H, CH), 11.69 (s, 1H, NH), 11.81 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 20.7, 104.3, 126.6, 126.9, 129.1, 135.8, 135.9, 144.1, 
144.5, 148.8. 
1,3-Dihydro-8-(4-tert-butylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(13m) Yield 74%. Mp: >300˚C. ESI-MS 283.0 m/z (M-1). Purity: 96%. 
1HNMR (DMSO-d6): δ 1.31 (s, 9H, CH3), 6.25 (s, 1H, CH), 7.48 (d, J = 8.4Hz, 
2H, CH), 7.84 (d, J = 8.4Hz, 2H, CH), 11.59 (s, 1H, NH), 11.98 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 30.9, 34.4, 85.8, 125.5, 125.8, 128.7, 141.6, 144.2, 
148.3, 151.9, 155.0. 
1,3-Dihydro-8-(4-methoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(13n) Yield 75%. Mp: 264-266˚C. ESI-MS 257.3 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 3.78 (s, 3H, CH3), 6.97 (d, J = 8.4Hz, 2H, CH), 7.44 (d, 
J = 8.4Hz, 2H, CH), 8.06 (s, 1H, CH), 11.66 (s, 1H, NH), 11.81 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 55.1, 104.2, 114.1, 121.9, 128.5, 135.5, 144.2, 144.6, 
148.8, 158.1. 
1,3-Dihydro-8-(4-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2,4-dione 
(13o) Yield 92%. Mp: 298-300˚C. ESI-MS 271.1 m/z (M-1). Purity: 95%. 
1HNMR (DMSO-d6): δ 1.34 (t, J = 6.4Hz, 3H, CH3), 4.07 (q, J = 6.4Hz, 2H, 
CH2), 6.21 (s, 1H, CH), 6.99 (d, J = 7.6Hz, 2H, CH), 7.82 (d, J = 7.6Hz, 2H, 
CH), 11.56 (s, 1H, NH), 11.96 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 
14.6, 63.2, 85.7, 114.7, 123.9, 127.6, 141.7, 144.3, 148.4, 155.2, 159.5. 
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General method for preparation of 
1,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones (15, 17) 1mmol 
of the corresponding N-ethoxycarbonyl-N’-(pyrazol-3-yl)thiourea was 
refluxed in a mixture of 4ml of ethanol and 0.76ml of 21%wt EtONa (2mmol) 
ethanol solution for 0.5 hours. Precipitate that came out was collected by 
filtration, then dissolved in water and acidified with HCI until pH 4. 
Precipitate that formed was filtered and recrystallized from methanol/water. 
1,3-Dihydro-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (15a) Yield 54%. 
Mp: 284-286˚C. ESI-MS 167.0 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): 
δ 5.90 (d, J = 1.5Hz, 1H, CH), 7.88 (d, J = 1.5Hz, 1H, CH), 12.72 (s, 1H, NH), 
13.46(s, 1H, NH). 13CNMR (DMSO-d6): δ 90.5, 141.5, 142.6, 146.6, 174.0. 
1,3-Dihydro-7-methylpyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (15b) 
Yield 79%. Mp: 281-282˚C. ESI-MS 181.0 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 2.23 (s, 3H, CH3), 5.77 (s, 1H, CH), 12.61 (s, 1H, NH), 13.33 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 15.0, 90.7, 141.8, 142.3, 155.8, 173.9. 
1,3-Dihydro-7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (15c) 
Yield 56%. Mp: 258-260˚C. ESI-MS 223.3 m/z (M-1). Purity: 96%. 1HNMR 
(DMSO-d6): δ 1.26 (s, 9H, CH3), 5.85 (s, 1H, CH), 12.62 (s, 1H, NH), 13.41 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 29. 5, 32.5, 86.5, 140.5, 141.4, 166.9, 172.8. 
1,3-Dihydro-7-trifluoromethylpyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one 
(15d) 1mmol of N-ethoxycarbonyl-N’-(5-trifluoromethyl-pyrazol-3-yl) 
thiourea was refluxed in a mixture of 4ml of ethanol and 0.76ml of 21%wt 
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EtONa (2mmol) ethanol solution for 0.5 hours. The precipitate that formed 
was collected by filtration, then dissolved in 20ml of water and acidified with 
HCI until pH 4. The resulting solution was extracted by ethyl acetate (20ml×
3) and concentrated by rotary evaporation under vacuum. The residue was 
recrystallized from EA/HEX to give 75mg product. Yield 32%. Mp: 
236-237˚C. ESI-MS 234.9 m/z (M-1). Purity: 95%. 1HNMR (DMSO-d6): δ 
6.27 (s, 1H, CH), 13.02 (s, broad, 1H, NH).13CNMR (DMSO-d6): δ 87. 0, 
116.4, 119.1, 121.8, 124.5, 141.0, 142.2, 144.9, 145.3, 145.7, 146.1, 173.6.  
1,3-Dihydro-7-(4-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (15e) Yield 89%. Mp: 286-287˚C. ESI-MS 261.0 m/z (M-1). 
Purity: >99%. 1HNMR (DMSO-d6): δ 6.41 (s, 1H, CH), 7.31 (t, J = 8.7Hz, 2H, 
CH), 8.01 (dd, J = 8.7Hz, JH-F = 5.7Hz, 2H, CH), 12.76 (s, 1H, NH), 13.59 (s, 
broad, 1H, NH). 13CNMR (DMSO-d6): δ 86.7, 115.9, 128.5, 141.4, 141.6, 
154.4, 161.6, 164.1, 173.0. 
1,3-Dihydro-7-(4-chlorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (15f) Yield 80%. Mp: 288-290˚C. ESI-MS 277.0, 279.3 m/z (M-1). Purity: 
98%. 1HNMR (DMSO-d6): δ 6.40 (s, 1H, CH), 7.53 (d, J = 8.4Hz, 2H, CH), 
7.97 (d, J = 8.4Hz, 2H, CH), 12.71 (s, broad, 1H, NH). 13CNMR (DMSO-d6): 
δ 87.9, 129.0, 130.0, 131.2, 135.2, 142.5, 142.8, 155.3, 174.1. 
1,3-Dihydro-7-(4-bromophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (15g) Yield 64%. Mp: 293-294˚C. ESI-MS 320.9, 322.9 m/z (M-1). 
Purity: >99%. 1HNMR (DMSO-d6): δ 6.43 (s, 1H, CH), 7.68 (d, J = 8.4Hz, 2H, 
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CH), 7.91 (d, J = 8.4Hz, 2H, CH), 12.78 (s, 1H, NH), 13.59 (s, broad, 1H, NH). 
13CNMR (DMSO-d6): δ 86.7, 122.8, 128.2, 130.4, 131.8, 141.3, 141.7, 154.2, 
173.0. 
1,3-Dihydro-7-(4-trifluoromethylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2- 
thioxo-4-one (15h) Yield 85%. Mp: 277-278˚C. ESI-MS 311.2 m/z (M-1). 
Purity: 96%. 1HNMR (DMSO-d6): δ 6.53 (s, 1H, CH), 7.84 (d, J = 8.4Hz, 2H, 
CH), 8.19 (d, J = 8.4Hz, 2H, CH), 12.84 (s, 1H, NH), 13.65 (s, 1H, 
NH).13CNMR (DMSO-d6): δ87.1, 120.0, 122.7, 125.4, 125.7, 126.9, 128.1, 
129.0, 129.3, 129.6, 129.9, 135.1, 141.4, 141.8, 153.8, 173.1.  
1,3-Dihydro-7-(4-methylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (15i) Yield 81%. Mp: 295˚C. ESI-MS 257.2 m/z (M-1). Purity: 96%. 
1HNMR (DMSO-d6): δ 2.35 (s, 3H, CH3), 6.34 (s, 1H, CH), 7.27 (d, J = 8.0Hz, 
2H, CH), 7.81 (d, J = 8.0Hz, 2H, CH), 12.73 (s, 1H, NH), 13.53 (s, broad, 1H, 
NH). 13CNMR (DMSO-d6): δ 20.9, 86.5, 126.1, 128.4, 129.4, 139.2, 141.4, 
141.5, 155.4, 173.0.  
1,3-Dihydro-7-(4-tert-butylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-
one (15j) Yield 67%. Mp: 289˚C. ESI-MS 299.1 m/z (M-1). Purity: 98%. 
1HNMR (DMSO-d6): δ 1.31 (s, 9H, CH3), 6.37 (s, 1H, CH), 7.50 (d, J = 8.8Hz, 
2H, CH), 7.87 (d, J = 8.8Hz, 2H, CH), 12.76 (s, 1H, NH), 13.57 (s, broad, 1H, 
NH). 13CNMR (DMSO-d6): δ 30.9, 34.4, 86.5, 125.5, 125.9, 128.4, 141.4, 




one (15k) Yield 58%. Mp: 288˚C. ESI-MS 273.2 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 3.81 (s, 3H, CH3), 6.30 (s, 1H, CH), 7.02 (d, J = 8.4Hz, 
2H, CH), 7.88 (d, J = 8.4Hz, 2H, CH), 12.57 (s, broad, 1H, NH), 13.53 (s, 
broad, 1H, NH). 13CNMR (DMSO-d6): δ 56.3, 87.6, 115.2, 124.9, 128.7, 142.7, 
143.2, 156.3, 161.3, 174.0. 
1,3-Dihydro-7-(4-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (15l) Yield 75%. Mp: 288-290˚C. ESI-MS 287.0 m/z (M-1). Purity: 96%. 
1HNMR (DMSO-d6): δ 1.35 (t, J = 6.8Hz, 3H, CH3), 4.08 (q, J = 6.8Hz, 2H, 
CH2), 6.32 (s, 1H, CH), 7.01 (d, J = 8.8Hz, 2H, CH), 7.86 (d, J = 8.8Hz, 2H, 
CH), 12.72 (s, 1H, NH), 13.52 (s, 1H, NH). 13CNMR (DMSO-d6): δ 14.6, 63.2, 
86.3, 114.6, 123.5, 127.7, 141.4, 155.3, 159.6, 172.9. 
1,3-Dihydro-7-phenylpyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (15m) 
Yield 69%. Mp: 295-296˚C (lit174: 304-305˚C). ESI-MS 243.3 m/z (M-1). 
Purity: 97%. 1HNMR (DMSO-d6): δ 6.41 (s, 1H, CH), 7.37-7.58 (m, 3H, CH), 
7.95 (d, J = 6.6Hz, 2H, CH), 12.78 (s, 1H), 13.58 (s, 1H). 13CNMR 
(DMSO-d6): δ 87.8, 127.3, 129.9, 130.6, 132.3, 142.5, 142.7, 156.4, 174.1. 
1,3-Dihydro-8-chloropyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (17a) 
Yield 45%. Mp: 258-260˚C. ESI-MS m/z 200.9, 203.0 (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 8.02 (s, 1H, CH), 12.80 (s, 1H, NH), 13.79 (s, 1H, 




Yield 56%. Mp: >300˚C. ESI-MS 245.0, 246.9 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 8.00 (s, 1H, CH), 12.78 (s, 1H, NH), 13.70 (s, 1H, 
NH). 13CNMR (DMSO-d6): δ 75.9, 139.9, 142.0, 146.7, 174.9. 
1,3-Dihydro-8-iodopyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (17c)  
Yield 60%. Mp: 199-201˚C. ESI-MS 292.7 m/z (M-1). Purity: 96%. 1HNMR 
(DMSO-d6): δ 7.92 (s, 1H, CH), 12.77 (s, 1H, NH), 13.50 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 42.5, 141.9, 143.1, 151.0, 174.9. 
1,3-Dihydro-8- carboxylic acid ethyl ester 
-pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (17d) Yield 87%. Mp: 
224-226˚C. ESI-MS 239.0 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 
1.29 (t, 3H, CH3, J = 7.0Hz), 4.27 (q, 2H, CH2, J = 7.0Hz), 8.17 (s, 1H, CH), 
13.11 (s, 1H, NH). 13CNMR (DMSO-d6): δ 15.4, 61.3, 98.5, 142.0, 142.9, 
145.8, 161.7, 175.4. 
1,3-Dihydro-8-methylpyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (17e) 
Yield 47%. Mp: 276˚C. ESI-MS 180.6 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 2.04 (s, 3H, CH3), 7.76 (s, 1H, CH), 12.61 (s, 1H, NH), 13.41 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 6.7, 98.4, 137.1, 141.4, 146.9, 172.9. 
1,3-Dihydro-8-carbonitrilepyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one 
(17f) Yield 70%. Mp: >300˚C. ESI-MS 192.0 m/z (M-1). Purity: 97%. 
1HNMR (DMSO-d6): δ 8.33 (s, 1H, CH), 13.04 (s, 1H, NH). 13CNMR 
(DMSO-d6): δ 76.4, 112.6, 141.9, 145.8, 147.2, 175.4. 
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1,3-Dihydro-8-phenylpyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one (17g)  
Yield 60%. Mp: 247-249˚C. (lit175: 251-253˚C). ESI-MS 243.3 m/z (M-1). 
Purity: >99%. 1HNMR (DMSO-d6): δ 7.02 (m, 5H, CH), 8.17 (s, 1H, CH), 
12.80 (s, NH, 1H). 13CNMR (DMSO-d6): δ 106.5, 128.1, 129.2, 129.5, 130.2, 
137.2, 142.6, 146.2, 174.9. 
1,3-Dihydro-8-(4-fluorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (17h) Yield 68%. Mp: >300˚C. ESI-MS 261.3 m/z (M-1). Purity: 98%. 
1HNMR (DMSO-d6): δ 7.25 (t, J = 8.7Hz, 2H, CH), 7.55 (dd, J = 8.7Hz, JH-F = 
5.7Hz, 2H, CH), 8.14 (s, 1H, CH), 12.75 (s, NH, 1H). 13CNMR (DMSO-d6): δ 
105.4, 116.1, 116.4, 126.66, 126.7, 131.3, 131.4, 137.6, 142.6, 146.1, 160.8, 
164.1, 174.9. 
1,3-Dihydro-8-(4-chlorophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (17i) Yield 90%. Mp: 262-263˚C. ESI-MS 276.7, 279.3 m/z (M-1). Purity: 
98%. 1HNMR (DMSO-d6): δ 7.47 (d, J = 8.4Hz, 2H, CH), 7.53 (d, J = 8.4Hz, 
2H, CH), 8.16 (s, 1H, CH), 12.81 (s, 1H, NH).13CNMR (DMSO-d6): δ 104.2, 
128.0, 128.3, 129.9, 131.7, 136.5, 141.4, 144.9, 173.9. 
1,3-Dihydro-8-(4-bromophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (17j) Yield 81%. Mp: 239˚C. ESI-MS 321.1, 322.9 m/z (M-1). 
Purity: >99%. 1HNMR (DMSO-d6): δ7.48 (d, J = 8.4Hz, 2H, CH), 7.60 (d, J = 
8.4Hz, 2H, CH), 8.17 (s, 1H, CH), 12.79 (s, 1H, NH). 13CNMR (DMSO-d6): δ 





thioxo-4-one (17k) Yield 85%. Mp: 256-257˚C. ESI-MS 311.0 m/z (M-1). 
Purity: 97%. 1HNMR (DMSO-d6): δ 7.72-7.79 (m, 4H, CH), 8.24 (s, 1H, CH), 
12.78 (s, 2H, NH). 13CNMR (DMSO-d6): δ 104.0, 120.3, 123.0, 125.2, 125.7, 
126.7, 127.0, 127.3, 127.6, 128.4, 128.7, 133.6, 137.4, 141.5, 144.8, 174.0.  
1,3-Dihydro-8-(4-methylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (17l) Yield 94%. Mp: 241-242˚C. ESI-MS 257.0 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 2.34 (s, 3H, CH3), 7.22 (d, J = 8.4Hz, 2H, CH), 7.40 (d, 
J = 8.4Hz, 2H, CH), 8.12 (s, 1H, CH), 12.77 (s, 1H, NH), 13.37 (s, broad, 1H, 
NH). 13CNMR (DMSO-d6): δ 20.7, 105.3, 126.1, 127.9, 129.0, 135.9, 136.3, 
141.5, 145.0, 173.4. 
1,3-Dihydro-8-(4-tert-butylphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-
one (17m) Yield 94%. Mp: 288-289˚C. ESI-MS 299.1 m/z (M-1). Purity: 96%. 
1HNMR (DMSO-d6): δ 1.31 (s, 9H, CH3), 6.34 (s, 1H, CH), 7.49 (d, J = 8.5Hz, 
2H, CH), 7.86 (d, J = 8.5Hz, 2H, CH), 12.72 (s, 1H, NH), 13.54 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 30.9, 34.4, 86.5, 125.5, 125.0, 128.4, 141.4, 141.5, 
152.1, 155.3, 172.9. 
1,3-Dihydro-8-(4-methoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-
one (17n) Yield 85%. Mp: 227-228˚C. ESI-MS 273.2 m/z (M-1). 
Purity: >99%. 1HNMR (DMSO-d6): δ 3.79 (s, 3H, OCH3), 6.98 (d, J = 8.5Hz, 
2H, CH), 7.45 (d, J = 8.5Hz, 2H, CH), 8.10 (s, 1H, CH), 12.62 (s, 1H, NH). 
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13CNMR (DMSO-d6): δ 55.1, 105.1, 113.8, 121.3, 129.4, 135.8, 141.4, 145.0, 
158.4, 173.6.  
1,3-Dihydro-8-(4-ethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4- 
one (17o) Yield 91%. Mp: 286-287˚C. ESI-MS 287.2 m/z (M-1). Purity: 96%. 
1HNMR (DMSO-d6): δ 1.35 (t, J = 7.2Hz, 3H, CH3), 4.08 (q, J = 7.2Hz, 2H, 
CH2), 6.33 (s, 1H, CH), 7.01 (d, J = 8.8Hz, 2H, CH), 7.86 (d, J = 8.8Hz, 2H, 
CH), 12.72 (s, 1H, NH), 13.52 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 
14.6, 63.1, 86.3, 114.6, 123.5, 127.7, 141.4, 141.4, 155.3, 159.6, 172.9. 
1,3-Dihydro-8-(4-nitrophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one 
(17p) Yield 81%. Mp: 261-263˚C. ESI-MS 288.1 m/z (M-1). Purity: 99%. 
1HNMR (DMSO-d6): δ 7.83 (d, J = 8.4Hz, 2H, CH), 8.25 (d, J = 8.4Hz, 2H, 
CH), 8.32 (s, 1H, CH), 12.89 (s, 1H, NH). 13CNMR (DMSO-d6): δ 103.5, 
123.5, 128.6, 136.4, 137.8, 141.4, 144.7, 145.7, 174.2. 
1,3-Dihydro-8-(4-iodophenyl)pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one 
(17q) Yield 86%. Mp: >300˚C. ESI-MS 321.1, 322.9 m/z (M-1). Purity: 96%. 
1HNMR (DMSO-d6): δ 7.33 (d, J = 7.2Hz, 2H, CH), 7.76 (d, J = 7.2Hz, 2H, 
CH), 8.16 (s, 1H, CH), 12.79 (s, 1H, NH). 13CNMR (DMSO-d6): δ 92.8, 104.3, 
128.7, 130.2, 136.4, 137.1, 141.3, 144.6, 173.8. 
1,3-Dihydro-8-(4-pentafluorosulfurphenyl)-pyrazolo[1,5-a][1,3,5]triazin-2
-thioxo-4-one (17r) Yield 43%. Mp: 268-269˚C. ESI-MS 369.0 m/z (M-1). 
Purity:  1HNMR (DMSO-d6): δ 7.72 (d, J = 8.4Hz, 2H, CH), 7.93 (d, J = 
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8.0Hz, 2H, CH), 8.24 (s, 1H, CH), 12.86 (s, 1H, NH).13CNMR (DMSO-d6): δ 
103.4, 125.7, 128.8, 133.4, 137.5, 141.4, 144.7, 151.0, 174.0. 
General method for preparing 
2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-a
][1,3,5]triazin-4(3H)-ones (23, 24) 0.5mmol 
pyrazolo[1,5-a][1,3,5]triazine-2-thioxo-4(1H,3H)-ones and 0.5mmol 
5-chloro-6-chloromethyluracil were refluxed in a mixture of 4ml 
methanol/ethanol and 0.19ml 21%wt EtONa ethanol solution for 0.5 hours. 
Precipitate was filtered, washed with cold water, recrystallized from 
dmso/water and dried in oven to give products. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-4(3H)-one (23a) Yield 60%. Mp: 268-270˚C. ESI-MS 325.2, 
326.8 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 4.34 (s, 2H, CH2), 
6.37 (d, J = 1.2Hz, 1H, CH), 8.01 (d, J = 1.2Hz, 1H, CH), 11.33 (s, 1H, NH), 
11.64 (s, 1H, NH), 13.00 (s, 1H, NH). 13CNMR (DMSO-d6): δ 30.3, 98.6, 
107.6, 144.5, 146.8, 148.0, 149.0, 150.8, 155.5, 160.7. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-7-methyl-4(3H)-one  (23b) Yield 79%. Mp: >300˚C. 
ESI-MS 339.0, 341.0 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 2.29 
(s, 3H, CH3), 4.32 (s, 2H, CH2), 6.19 (s, 1H, CH), 11.30 (s, 1H, NH), 11.62 (s, 
1H, NH), 12.88 (s, 1H, NH). 13CNMR (DMSO-d6): δ 15.2, 30.3, 98.6, 107.6, 




a][1,3,5]triazin-7-tert-butyl-4(3H)-one  (23c) Yield 63%. Mp: 208-209˚C. 
ESI-MS 381.2, 382.9 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 1.29 
(s, 9H, CH3), 4.29 (s, 2H, CH2), 6.23 (s, 1H, CH), 11.43 (s, 1H, NH), 11.62 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 29.1, 29.7, 32.4, 93.6, 106.1, 144.2, 147.4, 
148.5, 149.6, 155.7, 159.6, 166.6. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin7-trifluoromethyl-4(3H)-one  (23d) Yield 67%. Mp: 
288-289˚C. ESI-MS 393.1, 395.1m/z (M-1). Purity: 96%. 1HNMR 
(DMSO-d6): δ 4.34 (s, 2H, CH2), 6.78 (s, 1H, CH), 11.31 (s, 1H, NH), 11.62 
(s, 1H, NH). 13CNMR (DMSO-d6): δ 29.3, 94.9, 106.6, 116.8, 119.5, 122.2, 
124.8, 143.1, 145.1, 145.4, 145.8, 146.2, 146.7, 149.3, 149.6, 157.0, 159.6. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-7-(4-fluorophenyl)-4(3H)-one (23e) Yield 90%. Mp: 
212-214˚C. ESI-MS 419.0, 421.1 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 4.35 (s, 2H, CH2), 6.86 (s, 1H, CH), 7.32 (t, J = 8.7 Hz, 2H, 
CH), 8.03 (dd, J = 8.7Hz, JH-F = 5.7Hz, 2H, CH), 11.36 (s, 1H, NH), 11.63 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 29.2, 92.1, 105.8, 115.5, 115.7, 128.1, 






ylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (23f) Yield 85%. 
Mp: >300˚C. ESI -MS 434.9, 437.0 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 4.36 (s, 2H, CH2), 6.91 (s, 1H, CH), 7.57 (d, 2H, J = 8.4 Hz, 
CH), 8.00 (d, J = 8.4 Hz, 2H, CH), 11. 35 (s, 1H, NH), 11.64 (s, 1H, NH), 
13.11 (s, 1H, NH). 13CNMR (DMSO-d6): δ 30.4, 95.7, 107.6, 128.9, 130.0, 
131.8, 135.0, 144.5, 148.0, 150.3, 150.8, 155.4, 156.4, 160.7. 
7-(4-Bromophenyl)-2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmeth
ylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (23g) Yield 92%. 
Mp: >300˚C. ESI -MS 479.0, 481.0 m/z (M-1). Purity: 98%. 1HNMR 
(DMSO-d6): δ 4.25 (s, 2H, CH2), 6.61 (s, 1H, CH), 7.62 (d, J = 8.4 Hz, 2H, 
CH), 7.92 (d, J = 8.4 Hz, 2H, CH), 11.59 (s, 2H, NH). 13CNMR (DMSO-d6): δ 
29.1, 91.4, 105.4, 121.8, 127.9, 131.5, 132.0, 147.1, 148.5, 149.5, 150.8, 152.5, 
159.6, 161.4. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-7-(4-trifluoromethylphenyl)-4(3H)-one (23h) Yield 72%. 
Mp: 258-260˚C. ESI-MS 468.9, 471.2 m/z (M-1). Purity: 98%. 1HNMR 
(DMSO-d6): δ 4.37 (s, 2H, CH2), 6.99 (s, 1H, CH), 7.86 (d, J = 8.0Hz, 2H, 
CH), 8.22 (d, J = 8.0Hz, 2H, CH), 11.37 (s, 1H, NH), 11.65 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 29.3, 95.1, 106.5, 122.8, 125.5, 125.8, 125.8, 126.8, 




a][1,3,5]triazin-7-(4-methylphenyl)-4(3H)-one (23i) Yield 84%. Mp: 
268-269˚C. ESI-MS 415.2, 417.3 m/z (M-1). Purity: 98%. 1HNMR 
(DMSO-d6): δ 2.34 (s, 3H, CH3), 4.29 (s, 2H, CH2), 6.65 (s, 1H, CH), 7.27 (d, 
J = 8Hz, 2H, CH), 7.84 (d, J = 8Hz, 2H, CH), 11.48 (s, 1H, NH), 11.62 (s, 
broad, 1H, NH). 13CNMR (DMSO-d6): δ 20.9, 29.2, 92.7, 105.9, 126.0, 126.1, 
129.3, 129.4, 129.6, 138.5, 147.9, 149.7, 149.9, 154.6, 159.7. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-7-(4-tert-butyllphenyl)-4(3H)-one(23j) Yield 74%. Mp: 
252-254˚C. ESI-MS 457.3, 459.3 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 1.32 (s, 9H, CH3), 4.37 (s, 2H, CH2), 6.85 (s, 1H, CH), 7.51 (d, 
J = 8.4Hz, 2H, CH), 7.91 (d, J = 8.4Hz, 2H, CH), 11.37 (s, 1H, NH), 11.66 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 29.2, 30.9, 34.4, 94.5, 106.4, 125.5, 125.9, 
129.0, 143.4, 146.9, 149.0, 149.7, 151.9, 154.9, 155.5, 159.6. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-7-(4-methoxyphenyl)-4(3H)-one (23k) Yield 88%. 
Mp: >300˚C. ESI -MS 431.0, 433.0 m/z (M-1). Purity: 98%. 1HNMR 
(DMSO-d6): δ 3.81 (s, 3H, CH3), 4.24 (s, 2H, CH2), 6.49 (s, 1H, CH), 7.026 
(d, J = 8.7 Hz, 2H, CH), 7.86 (d, J = 8.7 Hz, 2H, CH), 11. 59 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 29.1, 55.1, 90.6, 105.3, 114.0, 125.3, 127.3, 147.6, 




a][1,3,5]triazin-7-(4-ethoxyphenyl)-4(3H)-one (23l) Yield 76%. Mp: >300˚C. 
ESI-MS 445.2, 447.0 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 1.35 
(t, J = 6.8Hz, 3H, CH3), 4.07 (q, J = 6.8Hz, 2H, CH2), 4.20 (s, 2H, CH2), 6.35 
(s, 1H, CH), 6.98 (d, J = 8.8Hz, 2H, CH), 7.86 (d, J = 8.8Hz, 2H, CH), 11.58 
(s, 1H, NH), 11.74 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 14.6, 29.0, 
48.5, 63.0, 88.9, 104.8, 114.3, 125.7, 127.2, 149.4, 149.6, 151.6, 152.6, 158.7, 
159.8, 165.1. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-7-phenyl-4(3H)-one  (23m) Yield 89%. Mp: 156-158˚C. 
ESI-MS 401.0, 403.2 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 4.36 
(s, 2H, CH2), 6.89 (s, 1H, CH), 7.47 (m, 3H, CH), 7.98 (d, J = 7.2 Hz, 2H, 
CH), 11.35 (s, 1H, NH), 11.64 (s, 1H, NH). 13CNMR (DMSO-d6): δ 29.2, 
94.5, 106.4, 126.1, 128.8, 129.3, 131.8, 143.4, 146.9, 149.1, 149.7, 155.4, 
159.6, 161.1. 
8-Chloro-2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyr
azolo[1,5-a][1,3,5]triazin-4(3H)-one (24a) Yield 59%. Mp: 162-164˚C 
ESI-MS 358.8, 360.9 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 4.40 
(s, 2H, CH2), 8.15 (s, 1H, CH), 11.28 (s, 1H, NH), 11.62 (s, 1H, NH), 13.04 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 30.3, 100.0, 107.5, 144.1, 144.8, 144.9, 




zolo[1,5-a][1,3,5]triazin-4(3H)-one (24b) Yield 79%. Mp: 238-240˚C. 
ESI-MS 402.9, 404.9 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 4.41 
(s, 2H, CH2), 8.13 (s, 1H, CH), 11.28 (s, 1H, NH), 11.62 (s, 1H, NH), 13.08 (s, 
1H, NH). 13CNMR (DMSO-d6): δ 30.2, 85.2, 107.4, 144.0, 146.4, 146.6, 
148.0, 150.8, 157.4, 160.8. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-iodo-4(3H) -one (24c) Yield 63%. Mp: >300˚C. ESI -MS 
450.9, 452.9 m/z (M-1). Purity: >99%.  1HNMR (DMSO-d6): δ 4.44 (s, 2H, 
CH2), 8.08 (s, 1H, CH), 11.29 (s, 1H, NH), 11.63 (s, 1H, NH), 13.19 (s, 1H, 
NH). 13CNMR (DMSO-d6): δ 30.1, 53.4, 107.4, 144.1, 148.0, 149.4, 150.5, 
150.8, 157.2, 160.7. 
8-Carboxylic acid ethyl ester–2-(5-chloro-1,3-dihydropyrimidin 
-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (24d) 
Yield 40%. Mp: 266˚C. ESI -MS 396.8, 399.0 m/z (M-1). Purity: >99%. 
1HNMR (DMSO-d6): δ 1.30 (t, J = 6.9Hz, 3H, CH3), 4.26 (q, J = 7.0Hz, 2H, 
CH2), 4.37 (s, 1H, CH2), 8.23, (s,1H, CH), 10.99 (s, 1H, NH), 11.65 (s, 1H, 
NH). 13CNMR (DMSO-d6): δ 15.3, 30.5, 61.1, 103.8, 107.3, 144.2, 146.9, 
148.1, 149.5, 150.4, 160.7, 160.9, 162.4. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-methyl-4(3H)-one (24e) Yield 59%. Mp: >300˚C. ESI-MS 
339.1, 341.1 m/z (M-1). Purity: 95%. 1HNMR (DMSO-d6): δ 2.12 (s, 3H, 
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CH3), 4.37 (s, 2H, CH2), 7.86 (s, 1H, CH), 11.32 (s, 1H, NH), 11.63 (s, 1H, 
NH), 12.78 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 7.1, 29.1,105.5, 106.0, 
144.0, 145.0, 146.2, 147.6, 149.6, 153.9, 159.6. 
8-Carbonitrile-2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthi
o)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (24f) Yield 56%. Mp: >300˚C. 
ESI-MS 350.0, 351.9 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 4.41 
(s, 2H, CH2), 8.38 (s, 1H, CH), 11.33 (s, 1H, NH), 11.60 (s, 1H, NH). 
13CNMR (DMSO-d6): δ 30.3, 81.8, 107.4, 114.0, 145.2, 146.7, 148.1, 150.8, 
153.7, 160.8, 163.8. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-phenyl-4(3H)-one (24g) Yield 84%. Mp: >300˚ C. ESI -MS 
401.1, 403.2 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 4.49 (s, 2H, 
CH2), 7.26 (t, J = 7.5 Hz, 1H, CH), 7.42 (t, J = 7.5 Hz, 2H, CH), 8.01 (d, J = 
7.5 Hz, 2H, CH), 8.54 (s, 1H, CH), 11.36 (s, 1H, NH), 11.68 (s, 1H, NH), 
11.68 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 29.4, 105.5, 107.3, 125.3, 
125.5, 128.5, 132.2, 141.8, 145.8, 147.5, 148.6, 149.7, 159.7, 161.9. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-fluorophenyl)-4(3H)-one (24h) Yield 90%. Mp: 
288-289˚C. ESI-MS 418.9, 421.0 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 4.43 (s, 2H, CH2), 7.23 (t, J = 8.7Hz, 2H, CH), 8.02 (dd, J = 
8.7Hz, JH-F = 5.7Hz, 2H, CH), 8.47 (s, 1H, CH), 11.39 (s, 1H, NH), 11.66 (s, 
1H, NH), 13.17 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 29.4, 105.8, 
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108.0, 115.2, 115.5, 127.3, 127.9, 142.8, 144.4, 144.9, 145.1, 147.5, 149.6, 
158.0, 158.9, 159.6, 162.1. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-chlorophenyl)-4(3H)-one (24i) Yield 83%. Mp: >300˚C. 
ESI-MS 435.2, 437.2 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 4.39 
(s, 2H, CH2), 7.41 (d, J = 8.4Hz, 2H, CH), 7.99 (d, J = 8.4Hz, 2H, CH), 8.40 (s, 
1H, CH), 11.40 (s, 1H, NH), 11.64 (s, 1H, NH). 13CNMR (DMSO-d6): δ 29.5, 
105.7, 107.0, 127.0, 128.6, 130.0, 130.8, 142.4, 145.4, 146.1, 148.0, 149.7, 
159.7, 160.2. 
8-(4-Bromophenyl)-2-(5-chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmeth
ylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (24j) Yield 93%. 
Mp: >300˚C. ESI -MS 479.0, 481.0 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 4.39 (s, 2H, CH2), 7.56 (d, J = 8.4Hz, 2H, CH), 7.95 (d, J = 
8.7Hz, 2H, CH), 8.42 (s, 1H, CH), 11.43 (s, 1H, NH), 11.64 (s, 1H, NH), 
13.18 (s, 1H, NH). 13CNMR (DMSO-d6): δ 29.4, 105.6, 107.1, 118.4, 127.3, 
131.1, 131.4, 142.3, 145.3, 145.8, 147.8, 149.6, 159.6, 160.0. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-trifluoromethylphenyl)-4(3H)-one (24k) Yield 96%. 
Mp: >300˚C. ESI-MS 469.2, 471.2 m/z (M-1). Purity: 98%. 1HNMR 
(DMSO-d6): δ 4.48 (s, 2H, CH2), 7.76 (d, J = 8.4Hz, 2H, CH), 8.22 (d, J = 
8.4Hz, 2H, CH), 8.63 (s, 1H, CH), 11.37 (s, 1H, NH), 11.68 (s, 1H, NH). 
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13CNMR (DMSO-d6): δ 29.5, 106.1, 108.2, 123.0, 125.4, 125.5, 125.7, 126.0, 
126.3, 126.7, 128.4, 135.4, 143.6, 143.8, 144.9, 146.9, 149.6, 159.5. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-methylphenyl)-4(3H)-one (24l) Yield 72%. 
Mp: >300˚C. ESI-MS 415.2, 417.2 m/z (M-1). Purity: 97%. 1HNMR 
(DMSO-d6): δ 2.31 (s, 3H, CH3), 4.47 (s, 2H, CH2), 7.22 (d, J = 4.4Hz, 2H, 
CH), 7.88 (d, J = 4.4Hz, 2H, CH), 8.47 (s, 1H, CH), 11.37 (s, 1H, NH), 11.66 
(s, 1H, NH), 13.03 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 20.7, 29.3, 
106.0, 109.8, 125.6, 128.1, 129.2, 135.4, 143.4, 143.7, 144.1, 147.0, 149.7, 
155.8, 159.5. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-tert-butylphenyl)-4(3H)-one (24m) Yield 93%. Mp: 
264-266˚C. ESI-MS 457.1, 459.1 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 1.32 (s, 9H, CH3), 4.29 (s, 2H, CH2), 6.67 (s, 1H, CH), 7.49 (d, 
J = 8.5Hz, 2H, CH), 7.88 (d, J = 8.0Hz, 2H, CH), 11.50 (s, 1H, NH), 11.61 (s, 
1H, NH), 13.04 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 29.3, 31.0, 34.4, 
93.6, 106.3, 125.5, 125.9, 129.3, 144.6, 147.5, 149.5, 149.7, 151.8, 155.1, 
156.7, 159.7. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-methoxyphenyl)-4(3H)-one (24n) Yield 80%. Mp: 
292-294˚C. ESI-MS 431.0, 433.0 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 3.77 (s, 3H, OCH3), 4.39 (s, 2H, CH2), 6.96 (d, J = 8.5Hz, 2H, 
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CH), 7.90 (d, J = 8.5Hz, 2H, CH), 8.33 (s, 1H, CH), 11.45 (s, 1H, NH), 11.63 
(s, 1H, NH), 13.11 (s, broad, 1H, NH). 13CNMR (DMSO-d6): δ 29.4, 55.0, 
105.6, 108.1, 114.1, 124.3, 126.7, 142.1, 144.5, 146.4, 148.1, 149.7, 157.5, 
159.4, 159.7. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-ethoxyphenyl)-4(3H)-one (24o) Yield 94%. 
Mp: >300˚C. ESI-MS 445.3, 447.3 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 1.35 (t, J = 7.2Hz, 3H, CH3), 4.07 (q, J = 7.2Hz, 2H, CH2), 
4.19 (s, 2H, CH2), 6.33 (s, 1H, CH), 6.98 (d, J = 8.8Hz, 2H, CH), 7.86 (d, J = 
8.8Hz, 2H, CH), 11.58 (s, 1H, NH), 11.76 (s, 1H, NH). 13CNMR (DMSO-d6): 
δ 14.6, 29.1, 63.1, 88.7, 104.8, 114.4, 125.8, 127.3, 149.5, 149.9, 150.1, 151.8, 
152.5, 158.7, 159.9, 165.1. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-nitrophenyl)-4(3H)-one (24p) Yield 89%. Mp: >300˚C. 
ESI-MS 445.9, 448.2 m/z (M-1). Purity: 99%. 1HNMR (DMSO-d6): δ 4.47 (s, 
2H, CH2), 8.19-8.36 (m, 4H, CH), 8.64 (s, 1H, CH), 11.40 (s, 1H, NH), 11.68 
(s, 1H, NH). 13CNMR (DMSO-d6): δ 29.7, 106.2, 107.9, 124.0, 126.0, 138.3, 
143.6, 143.8, 145.0, 145.4, 146.8, 149.6, 149.7, 159.5. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-iodophenyl)-4(3H)-one (24q) Yield 67%. Mp: >300˚C. 
ESI-MS 527.1, 529.1 m/z (M-1). Purity: >99%. 1HNMR (DMSO-d6): δ 4.27 
(s, 2H, CH2), 7.68 (d, J = 8.4Hz, 2H, CH), 7.81 (d, J = 8.4Hz, 2H, CH), 8.23 (s, 
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1H, CH), 11.57 (s, broad, 2H, NH). 13CNMR (DMSO-d6): δ 29.4, 48.5, 91.0, 
105.7, 107.4, 127.5, 131.2, 137.2, 142.5, 145.1, 145.4, 147.6, 149.6, 159.6. 
2-(5-Chloro-1,3-dihydropyrimidin-2,4-dioxo-6-ylmethylthio)pyrazolo[1,5-
a][1,3,5]triazin-8-(4-pentafluorosulfurphenyl)-4(3H)-one (24r) Yield 89%. 
Mp: >300˚C. ESI-MS 527.2, 529.2 m/z (M-1). Purity: >99%. 1HNMR 
(DMSO-d6): δ 4.30 (s, 2H, CH2), 7.84 (d, J = 8.8Hz, 2H, CH), 8.19 (d, J = 
8.8Hz, 2H, CH), 8.33 (s, 1H, CH), 11.50 (s, broad, 1H, NH), 11.61 (s, 1H, 
NH). 13CNMR (DMSO-d6): δ 29.5, 103.3, 105.1, 124.6, 125.86, 125.91, 
125.94, 137.4, 140.8, 148.3, 148.8, 148.9, 149.1, 149.2, 149.5, 159.7, 167.3. 
5.2 Biological tests 
5.2.1 Evaluation of inhibitory activity against thymidine phosphorylase 
Enzyme and substrate were obtained from Sigma-Aldrich, and the activity 
assay was performed at room temperature in a Hitachi U -1900 
spectrophotometer at a detection wavelength of 290nm. This method is based 
on the manufacturer instruction, which was a classical method described by 
Krenitsky183. 
For all compounds, inhibition rate at a certain concentration was obtained by 
the following procedure:  
To 780µl phosphate buffer (pH 7.4) in the 1.5ml absorption cuvette was 
subsequently added 10µl TP solution (1.5U/ml in pH 7.0 phosphate buffer), 
10µl compound solution in DMSO (for blank, add in 10µl DMSO), and 200µl 
Thymidine solution (5mM in pH 7.4 phosphate buffer). After gentle shaking 
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by inversion of the cuvette, the absorption values at 4min, 8min, 12min, 16min, 
20 min were recorded successively. These absorption values were plotted 
against time, and linear regression was performed to obtain the slope of the 
line plotted, which was equaled to the velocity of enzyme catalyzed reaction. 
Then the inhibition rate at this concentration could be calculated using the 
following formula:  
Inhibition rate= velocity  without  the  inhibitor  – velocity  with  the  inhibitorvelocity  without  the  inhibitor × 100% 
 
For IC50 value determination, inhibition rates of at least 7 different 
concentrations that span over the estimated IC50 value were determined in the 
same way and plotted against logarithmic concentrations using OriginPro 8 
SR0 v8.0724 (B724). IC50 value was determined as the concentration of the 
inhibitor that caused 50% inhibition. Results were means of three experiments. 
5.2.2 Thymidine phosphorylase inhibition kinetic studies 
To investigate the inhibitory effect of compounds against TP at varying 
thymidine concentrations, velocities of the enzyme catalyzed reactions at 
different concentrations of thymidine (100µM, 250µM, 500µM and 1000µM) 
were determined using the same procedure as described previously. 
Compounds were used at four concentrations that span over their IC50 values. 
Lineweaver-Burk plots of TP inhibition by these compounds were then 
generated using Microsoft Office Excel 2007 based on data obtained from 
triplicate experiments to determine their inhibition types. 
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5.2.3 MTT assay 
The cell line used in this assay was human breast cancer line MDA-MB-231 
which expresses TP. Cell line was maintained in RPMI 1640 supplemented 
with L-glutamine (2mM), 1%penicillin/streptomycin and 10% fetal bovine 
serum (Hyclone Laboratories) at 37 ˚C in a humidified atmosphere containing 
5% CO2. The cell line was passaged every 3 days after previous treatment with 
1×trypsin/EDTA. 
Compound stock solutions were prepared by dissolving compounds in DMSO 
at a concentration of 20mM. MTT solution was prepared in 5mg/ml in 
phosphate buffer, filtered via 0.2µm membrane filter, kept at 4˚C and 
protected from light. 
MTT assay was carried out on 96-well plates. To each well in a 96-well plate, 
5000 cells were seeded by adding 100µl cell suspension. The plates were 
incubated at 37˚C for 24 hours in 5% CO2 to allow the cells to adhere to the 
surface. The medium of the plates was then replaced with 200µl of medium 
containing testing compounds. Six wells containing fresh medium only served 
as blank; three wells containing medium with DMSO served as vehicle 
controls. After an incubation period of 72 hours, 50µl/well MTT working 
solution (1mg/ml) was added and the plates were incubated for another 4 
hours. At the end of incubation, supernatant in each well was carefully 
aspirated and 150µl of DMSO was added to each well to solubilise the MTT 
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formazan. Plates were shaked at 200rpm for 10 minutes and read at 570nm 
using Tecan GENios Microplate Reader. 






__  ×100% 
Inhibition rate = 100%- cell viability 
5.2.4 Gelatine zymography 
Gelatine zymography was preformed according to reported procedures with 
slight modifications (Liotta and Stetler-Stevenson 1990)187. MDA-MB-231 
cells were seeded onto six-well plates in RPMI with 10% FBS, and allowed to 
propagate to 80% confluence. The cells were then maintained in serum-free 
medium for at least 24hours prior to designated treatments with compounds 
and PMA (80 nM). Following 24 hours incubation of cells with compounds 
and PMA, conditioned medium was collected and centrifuged at 8000g for 8 
minutes at 4 ºC to remove cells and debris. Quantify the protein content of 
conditioned medium using the protein assay kit. Loading samples containing 
equal amount of protein were then prepared by diluting corresponding 
conditioned medium with PBS. This resulting sample was mixed with 
3×loading buffer and subjected to electrophoresis on a 7.5% SDS-PAGE gel 
containing 0.1% (w/v) gelatine using 1×Tris-Glycin SDS Running buffer at 
100 V for 90-120 minutes. Following electrophoresis, the gels were washed in 
renaturing buffer (2.5% Triton X-100) for 30 minutes twice to remove SDS 
and then equilibrated for 30 minutes in 1×zymogram developing buffer 
(50mM tris, 10mM CaCl2, 0.15M NaCl, pH-7.5). The gels were subsequently 
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incubated in fresh 
developing buffer at 37 °C for 24 hours to allow gelatine digestion. The 
gelatinolytic activity of MMPs was visualized by staining the gels with 1% 
coomassie blue R-250 in 50% methanol, 10% acetic acid, 40% water (v/v) and 
destained with 50% methanol, 10% acetic acid, 40% water (v/v) until clear 
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